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ABSTRACT 
 
Intellectual property rights (IPRs) play an important role in creating 
incentives for innovations. To strengthen and harmonise global standards of IPRs, 
the WTO members established the international agreement on Trade Related 
Aspects of Intellectual Property Rights (TRIPS) and provided flexibilities for 
governments to safeguard social benefits of their countries. Compulsory licensing 
(CL) is one of the flexibilities under TRIPS that enables a government authority to 
use the licenses of patented medicines without patent-holders’ permission. However, 
policy makers in many countries are reluctant to use CL to promote access to 
essential medicines. One explanation is that most countries are worried about the 
potential implications of using the policy, and they are uncertain about which 
implementation strategies might help avoid negative consequences. 
The aim of this PhD thesis is to propose a framework to aid decision-making 
and implementation of drug policy, focusing on CL under the condition of public 
non-commercial use and government use of license. This framework is designed to 
be used as a tool for policy makers in the Thai Ministry of Public Health, suggesting 
a list of policy elements to help them consider related elements for policy action in 
making a decision and implementing CL policy in order to minimise negative 
consequences of the CL. Mixed methods were employed to develop the framework. 
This study began by developing a preliminary framework based on generic elements 
of CL policy suggested by inter-governmental organisations. The preliminary 
framework was strengthened by incorporating lessons learnt from experiences of the 
former government of Thailand. The implications of CL policy decisions on certain 
drugs were evaluated in terms of lifetime cost savings compared across different 
drug types.  This allowed the identification of key factors to be included in criteria 
for drug selection. In addition, the performance of the Thai government in policy 
implementation was evaluated in order to prioritise areas for improvement. Finally, 
the contents of the preliminary framework were assessed in terms of applicability to 
the Thai context. Any additional elements derived from experiences of the former 
government were used to strengthen the framework.  
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The findings of this study suggest key elements, which should be included in 
the framework to aid decision-making and implementation of drug policy, focusing 
on CL policy. 32 elements were identified to be included in the framework. This 
study also suggests strategies for the decision-making process. Three additional 
factors are suggested to be incorporated in the drug selection criteria, in order to help 
policy makers to select the drugs that potentially create the greatest benefits from CL 
implementation. In addition, this study suggests strategies for the implementation 
process. The findings help prioritise four implementation areas, which should 
receive more attention within current CL implementation. This study closes with 
policy recommendations for the Thai government about the current and future use of 
CL policy to improve its performance, and also for other countries having the 
similar context to learn from the Thai experiences.  
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Chapter 1: Introduction 
 
Intellectual property rights (IPRs) are a legal agreement, which 
acknowledges exclusive rights to creations of the mind.  According to intellectual 
property law, innovators are granted exclusive rights to protect their intangible 
assets. The aim is to create incentives for innovations in research and development 
(R&D) [1]. Patents are a form of IPR approved by a sovereign state.  They give 
exclusive rights to an innovator for a limited time period, in exchange for the public 
disclosure of the innovation. The exclusive right is granted to a patent owner to 
prevent others from exploiting, producing, selling, or distributing the patented 
invention without permission from the patent owner. The degree of exclusive rights 
and the practice for granting patents differ between countries according to domestic 
laws and international agreements [2].   
The international agreement on Trade Related Aspects of Intellectual 
Property Rights (TRIPS) was established by World Trade Organization (WTO) 
members in 1995 as the most comprehensive multilateral agreement on IPRs [3]. For 
a variety of industrial sectors, such as computer software, pharmaceutical and 
agricultural innovations, strengthened and harmonised global IPR standards are 
necessary to internationally warrant innovations. TRIPS obligatorily require member 
countries to recognise patent protection in almost all fields of technology, and the 
agreement states that patent protection must be offered to innovative inventions for 
at least 20 years and covered for both products and production processes [4].  
 IPRs and patent protection play an important role in the development of 
pioneering technology and the global economy. The benefits of patenting are 
recognised as an instrument to promote innovative knowledge and technological 
advancement, which are essential factors for economic growth [5]. Patenting is used 
to promote global economic growth by transferring know-how and expertise from 
developed countries to less developed ones through international trade and foreign 
direct investment (FDI). One study found that the strength of IPR protection in low 
and middle income countries (LMICs) seemed to have a considerable effect on the 
extent of direct investment, particularly in high-technology industries from 
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American, Japanese and German firms, although the size of the effects differed from 
industry to industry [6].   
Patenting in pharmaceutical products is more complicated than other pioneer 
products. Being a high-technology industry, pharmaceutical manufacturing requires 
a substantial investment in the product development process. Evidence shows that 
annual expenditures for pharmaceutical R&D of new drug approvals during 1994 
and 2000 ranged between US$ 400 million and US$ 1 billion [7, 8]. However, only 
11% of investments were successful in developing a high quality, safe and 
efficacious product for treatment in people [9]. As a result, prices of pharmaceutical 
products seem to be relatively higher than other technologies. Patenting enables 
pharmaceutical firms to sell a patent drug at a monopoly price in order to 
compensate their R&D costs, thereby providing industrial incentives for 
pharmaceutical innovation [10].      
 However, the private interests of profit and cost-covering need to be assessed 
in the context of public health interests. As outlined above, offering IPRs and patents 
is an incentive for R&D, but can also result in monopoly prices that are sometimes 
beyond the ability to pay of patients and governments in poor countries. Evidence 
shows that in the late 1990s, despite the rising death and morbidity rates of 
HIV/AIDS, prices of patented antiretroviral drugs (ARVs) increased by 200-300% 
[11, 12]. Therefore, at that time, there was concern that private incentives needed to 
be balanced with ethical issues of patients’ access to patented medicines [13]. 
The 1995 TRIPS agreement provided flexibilities that allowed governments 
to safeguard social benefits for their countries [14]. Compulsory licensing (CL) is 
one of the flexibilities under TRIPS that enables a government authority to use 
licenses of patented products, including medicines, without patent-holder permission 
[15]. A number of conditions were formulated for governments to make exceptions to 
patent owners’ rights, including  “national emergencies”, “other circumstances of 
extreme urgency”, “public non-commercial use” (or “government use”), or “anti-
competition” [16]. In addition, countries are permitted to determine the grounds upon 
which licenses are granted, as well as what constitutes a national emergency and 
circumstances of extreme urgency [17]. 
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It has been acknowledged that the costs of treatment with patented medicines 
are unaffordable to some governments, especially in LMICs. Sometimes the purchase 
of expensive, patented medicines could threaten the sustainability of government-
provided health services. In order to address this problem, some countries have 
decided to apply the CL policy to manufacture or import cheaper generic medicines. 
However, policy makers in many countries are reluctant to use CL to promote access 
to essential medicines. Beall et al. found that only few LMICs made use of this CL 
policy between 1995 and 2010, and the trend of documented CL episodes declined 
during the fifteen-year period [18]. Possible explanations for the decline in use of 
CL is that most countries are worried about potential political and economic 
retaliations [19, 20]. Based on my best knowledge, there is no concrete framework, 
which suggests strategic approaches to optimise benefits and minimise cost when the 
policy is implemented.  
In this PhD thesis, I will address this topic through focusing on the case of 
Thai CLs. The former Minister of Public Health, Dr. Mongkol Na Songkla, decided 
to implement CL policy in the condition of “public non-commercial use or 
government use of license” in order to promote access to essential drugs for Thai 
people. The former government aimed to issue CL policy for seven medicines, 
including two ARV drugs for treatment of HIV/AIDS (efavirenz and LPV/r), one 
drug for treatment of cardiovascular disease (clopidogrel), and four drugs for 
treatment of cancer (letrozole, docetaxel, erlotinib and imatinib). However, only five 
drugs (efavirenz, LPV/r, clopidogrel, letrozole, and docetaxel) have been 
implemented under CL policy in Thailand. During the CL implementation period, 
there were a number of unanticipated events in the Thai CL for the said drugs. 
Policy insights derived and lessons learnt from experiences of the former 
government could be of value for developing a framework. The framework suggests 
key elements to be considered for decision-making and implementation of drug 
policy, focusing on CL policy, in order to optimise the benefits and minimise 
negative consequences of the policy. 
 
1.1 Thesis aims and objectives 
The aim of this PhD thesis is to develop a framework for decision making and 
implementation of drug policy, focusing on CL policy under the condition of public non-
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commercial use or government use of a license. The framework is designed to be used as 
a tool for policy makers in the Thai Ministry of Public Health by providing a list of policy 
elements that could help optimise benefits of the policy. It is a descriptive framework 
that seeks to be comprehensive in encompassing all elements of concern in CL policy. 
The framework does not provide an analytical explanation or rationale for decision 
making and implementation.  The policy elements include:  
• Activities and supportive instruments required to implement the policy,  
• Actors required to participate in the policy process,  
• Contextual factors required to support the policy implementation,  
• And other implementation strategies to improve policy performance and 
implications. 
In this study, I propose a framework to aid decision-making and 
implementation of drug policy, focusing on CL policy based on experiences of the 
former government of Thailand. This study began with the development of a 
preliminary framework based on generic recommendations from literature published 
by intergovernmental organisations. It was strengthened by an investigation of the 
experiences of the former government, in terms of implications of the decisions to issue 
CL on different drug types, and the implementation of the policy during 2007 to 2014. 
Finally, the applicability of the framework was assessed through qualitative approaches. 
The four study objectives are as follows: 
Objective 1: To develop a preliminary framework to aid decision making 
and implementation of drug policy, focusing on CL policy. 
Objective 2: To estimate life time treatment cost savings due to 
implementation of CL for five drugs against HIV/AIDS, stroke and cancer.  
Objective 3:  To analyse the performance of the Thai government in 
implementation of CL policy in terms of drug procurement, drug substitution at 
health care facilities, and drug access among patients. 
Objective 4: To assess the applicability of the framework in Thailand. 
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1.2 Outline of the thesis 
This thesis is organised into nine chapters. Chapter Two gives background to 
CL policy. A literature review was conducted to explore situations leading to the use 
of CL policy and implications of such CL use in LMICs. Chapter Three provides 
background information on Thailand in terms of the health care system and political 
issues surrounding CL policy. Chapter Four gives an overview of the research 
methodology for each objective.    
In Chapter Five, a framework was initially developed by analysing policy 
elements that affect CL policy decision and implementation. The framework was 
classified into four stages, including agenda setting, policy formulation, policy 
implementation and policy monitoring. The first two steps belong to the decision-
making process, while the others belong to the implementation process. I conducted 
a literature review to identify policy elements that should be included in each stage 
of the CL policy process. All identified elements were retrieved from generic 
recommendations of intergovernmental organisations such as the WTO and WHO. 
In the next chapters, the preliminary framework was strengthened through 
investigation of the experiences of the former Thai government when implementing 
the policy.        
In chapter six, the implications of CL policy implementation for the five 
drugs were estimated in monetary terms. The implications were analysed in terms of 
benefits from a reduction in lifetime treatment costs among patients receiving the 
five drugs under CL policy. The comparative benefits across different drug types 
were used to identify key elements, which should be incorporated in the drug 
selection criteria in order to gain the highest benefits from CL implementation. The 
findings could be used to help develop drug selection criteria to be included in the 
framework of CL policy. 
In chapter seven, the performance of CL policy implementation was 
evaluated to identify key elements, which should be considered by policymakers and 
authorised agencies for improving the policy performance. In this study, the CL 
policy performance is classified into three sections: drug procurement, generic drug 
substitution for its patented versions, and drug access improvements. Achievements 
of policy implementation in each section were analysed. If there was any failure to 
such achievement, the costs from defective performance or unanticipated results 
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were analysed in monetary terms. The findings could be used to help prioritise areas, 
which should receive more attention within current CL implementation, and develop 
implementation strategies to be included in the framework of CL policy. 
In addition to the quantitative approaches used in the previous chapters, in 
Chapter Eight, the contents of the framework were assessed by qualitative 
approaches, in order to determine whether it is applicable to the Thai context. This 
was done by using qualitative data obtained from interview, observation, and 
literature published by Thai actors. Experiences of implementation of the Thai CL 
policy were investigated in order to identify key elements that affected the CL 
decision-making process and implementation in Thailand and analysed to see 
whether they are consistent with those in the preliminary framework. Any additional 
elements derived from experiences and insights of CL in Thailand were used to 
strengthen the framework. Chapter Nine is the conclusion. All elements identified 
from previous chapters were discussed, and interactions across different elements 
were analysed, in order to develop strategies to optimise the benefits and minimise 
negative consequences of implementing CL policy.  
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Chapter 2: Background to compulsory licensing 
policy 
 
The inequality between high-income countries (HICs) and low and middle-
income countries (LMICs) in access to medicines is an important issue. The UN’s 
Millennium Development Goal 8 mentions the gap in access to medicines as “Prices 
of essential medicines remain high and availability low, making them unaffordable to 
large segments of populations in developing countries” [21]. Although the inequality 
may origin from the difference in ability to pay for drugs and health care services, 
patent protection of trade interests plays a major role in hindering drug access in 
LMICs [22, 23]. The WHO has developed a framework in order to guide and 
coordinate collective action in line with millennium development goal on access to 
essential medicines. One of the important elements in the framework is CL policy.  
The aim of this chapter is to provide background information on CL policy. 
The background information is classified into four sections: (1) the WHO 
framework for collective action on improving drug access; (2) the establishment of 
CL policy, this section provides a history of CL policy established as a remedial 
flexibility in the TRIPS agreement. The main information was obtained from 
literature of inter-governmental organisation; (3) the utilisation of CL by LMICs, 
this section provides broad experiences of CL implementations in LMICs. The main 
information was obtained from literature of non-governmental organisation; (4) 
implications of CL in LMICs, this section provides results from a systematic review 
for empirical evidence on the positive and negative implications of CL policy. The 
details of each section are provided below.  
 
2.1 The WHO framework for collective actions to improve drug access 
The framework for collective action was initiated in line with the millennium 
development goals. The framework has been adopted by WHO and its partners to 
improve access to essential drugs. Four factors have been proposed: (1) rational 
selection and use of essential medicines, (2) sustainable financing, (3) reliable health 
and supply system, and (4) affordable prices, which could be considered as an 
alternative to promote drug access [23]. For the affordable prices, the issue can be 
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pursued through many mechanisms and the TRIPS flexibilities is one of the 
effective measures to safeguard public health and promote access to medicines. The 
framework suggests countries should incorporate provisions for TRIPS compatible 
safeguards such as compulsory licensing and parallel import in to national 
legislation [23].  
Regarding the measures mentioned above, parallel import (PI) is imports of a 
patented drugs from a nation in which it is already marketed into another nation 
without the permission of the patent holder. Prices of drug are often different across 
countries, even it produced by the same manufacturer. The differences in price may 
be because of local conditions of drug market, such as differences in national IP 
laws, or national income levels, as well as the degree of drug competition among 
producers [24]. Therefore, the health care costs could be significantly saved by 
importing the same drugs from a country where the drugs have a lower price. In 
addition, voluntary licensing (VL) is where a patent owner offers its licence to a 
third party (regularly a generic producer) to produce, distribute and sale the patented 
drug. The use of patent is only permitted if the proposed patent user obtains 
authorization from the patented owner on reasonable commercial terms. This 
requirement may, however, be waived by the WTO Member through compulsory 
licensing (CL). CL is thus a remedy for a variety of condition, including 
anticompetitive practices; in the case of a national emergency or other circumstances 
of extreme urgency; and in the case of government use of license for public non-
commercial purposes including uses necessary to address public health issues [24]. 
Therefore, CL is an effective measure recognised by inter-governmental sectors to 
promote access to essential medicines, and the next section focuses only on the CL 
measure. 
 
2.2 Establishment of compulsory licensing (CL) policy 
 
The TRIPS agreement has been in force since 1995, and a number of LMICs 
has applied the CL policy to safeguard public health benefits. [18]. The Agreement 
sets minimum standards for many forms of intellectual property (IP) regulation as 
applied to all of the WTO Members. The main aim of the agreement is to strengthen 
and harmonise certain aspects of intellectual property protection at the global level. 
However, due to public health concerns, TRIPS also includes provisions, which 
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allow a degree of flexibility for the WTO members to safeguard the social benefits 
of access to medicine. However, LMICs have been reluctant to use these flexibilities 
because they are unsure of how these would be interpreted, and how far their rights 
to use them would be respected [24]. 
In 2001, therefore, the Doha Declaration on the TRIPS Agreement and 
Public Health affirms and clarifies the right of WTO Members to make full use of 
the flexibilities of the TRIPS Agreement to protect their public health and improve 
access to essential medicines [25]. This intended to settle a compromising solution 
between the principal of public interests in access to essential medicines and the 
terms of the TRIPS agreement [26]. CL has been affirmed as a solution under the 
TRIPS flexibilities when the patent protection hinders drug access [23]. In order to 
take advantage of this CL, patent users must provide notice and pay a royalty to the 
patent owner. The “reasonable royalty fee” should be paid based on both the 
particular circumstances of each case, and the economic value of the CL [27]. The 
practice to determine a reasonable or adequate remuneration is greatly varied, and 
there is no single accepted method. The Doha Declaration reiterated that countries 
have "the freedom to determine the grounds upon which such licences are granted" 
[25]. 
The IPRs is a tool to increase competitive power of the IP owner’s country 
over its IP user’s countries. Any actions of the IP users, which seem to infringe IPRs 
are countered with a strong reaction by the IP owner’s country  ]28 [ . The USA is an 
example, which obviously shows its standpoint on the IPRs issue of pharmaceutical 
technologies. The Special 301 program of the United States Trade Representative 
(USTR) is required to yearly publish a list of countries, which “deny adequate and 
effective protection of intellectual property” or “deny fair and equitable market 
access for U.S. firms that rely on intellectual property.” That includes the use of CL 
policy. These requirements resulted in the USTR’s creation of a “Watch List (WL)”, 
“Priority Watch List (PWL)” and “Priority Foreign Country (PFC)” which serve as 
warning mechanisms to countries perceived as out of compliance with USTR’s 
preferences on IP policy. Any country placed on the list could face political or 
economic sanctions under the Section 301 program ]28[ .  
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2.3 History of CL policy in low and middle-income countries (LMICs) 
 
According to Beall et al, CL episodes from 11 LMICs have been adopted 
between 1995 and 2010. These were in three continents across the world: South 
America (Brazil and Ecuador), Africa (Egypt, Zimbabwe, Mozambique, Zambia, 
Ghana, and Rwanda), and Asia (Malaysia, Indonesia, Thailand and India) [18]. In 
this section, I explored the CL history by focusing on the 11 countries. Thailand is 
however not included as this chapter, as it is the focus of the remaining parts of the 
thesis. The findings are visualised in the timeline in figure 2.1. 
 
 
Abbreviation:      ARVs: Anti-retroviral drugs; CL: Compulsory licensing; EFV: efavirenz;  
LPV/r: Lopinavir and ritonavir combination; TRIPS: Trade Related Aspects of  
Intellectual Property Rights; WTO: World Health Organization;   
 
Figure 2. 1 Timeline of CL across the world 
 
Zimbabwe granted CL policy for ARV drugs in 2002. Zimbabwe struggled 
with the burden of HIV/AIDS. During the early 2000s, each day 564 adults and 
children became infected with HIV, and the total number of people who lived with 
HIV/AIDS was between 1.5 and 2.0 million [29]. In May 24th, 2002, P.A. 
Chinamasa, the Zimbabwean Minister of Justice, made the general notice titled 
“Declaration of Period of Emergency (HIV/AIDS) Notice 2002” for a six-month-
period. This notice enabled the State or an individual authorised by the Minister to 
produce any patented medicine, including ARVs, and to import any generic drugs to 
the country [30]. In 2003, the emergency period was extended until 31st December 
2008. With the assistance of Indian generic drug firms, a Zimbabwean generic drug 
company produced generic combivir (AZT/3TC) with at least 50% (US$15 per 
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month) lower price than the patented drug (US$30 per month) [31]. The evidence 
about the royalty rate has not been found 
Egypt is an interesting case as it used CL on Viagra®. In October 2002, two 
months after this drug was approved to be launched into Egypt, the Health Ministry 
was politically requested by local manufacturers to issue a CL for Viagra®. The 
generic drug was sold at one-twentieth of the Pfizer’s Viagra® price [32]. However, 
an argument was raised on the doubtful decision of the Egyptian government about 
whether this legislation intended to increase access because of public interest [33]. 
An argument was raised that the public benefit appeared questionable. First, this 
drug treats erectile dysfunction, which is a health problem, but far from the life-
threatening diseases. Second, the Chairman of the Health Committee in Egypt’s 
upper house of Parliament at the time was also the Chairman of a large generic drug 
manufacturer. Third, the CL decision did not comply with TRIPS because it refused 
to attempt early compliance with regular processes of the agreement when it had the 
opportunity to do so. Fourth, the company seeking the CL may have little interest in 
enhancing access to the drug for poor people in Egypt [34]. After the CL was 
granted, Egypt got negative reactions from the patent owner and the Pharmaceutical 
Research and Manufacturers Association of American (PhRMA) in terms of 
disincentive of investment in Egypt’s pharmaceutical sector. In addition, Egypt was 
placed on the “Priority Watch List/ PWL” by the United States Trade Representative 
(USTR) [33, 35, 36]. However, among economic sanctions, FDI in Egypt has still 
increased since 2002 as this growth of investment was dominated by other sections 
(petroleum industries) [33]. The evidence about the royalty rate and CL period in 
Egypt has not been found.   
Mozambique granted CL policy for ARV drugs in April 2004. Mozambique 
was ranked as one of the highest nations for HIV epidemic. There were 1.4 million 
people living with HIV/AIDS in 2004 and 500 people becoming infected every day 
[37]. On April, 5 2004, Salvador Namburete, the Mozambican Deputy Minister of 
Industry and Trade decided to issue the CL to a local company Pharco Mozambique 
Ltd for producing the triple compound of lamivudine, stavudine and nevirapine. 
Royalties were set at 2% of the total sales [38]. The rationale was made on national 
emergency grounds, because the international patent holders failed to make the 
drugs affordable to the majority of the Mozambican people. Moreover, the three 
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different international owners failed to reach an agreement to produce the drug 
combination [39]. The triple compound drug was produced with the names of 
PHARCOVIR 30® and PHARCOVIR 40® by local generic drug manufacturers.  
Zambia granted CL policy for ARV drugs in September 2004. Zambia met 
the top ten countries in Africa having the high rates of morbidity and mortality from 
HIV/AIDS. The Ministry of Health estimated that, at the end of 2004, one million 
adults and children were living with HIV/AIDS [40]. On 21 September 2004, 
Dipack K Patel, the Zambian Minister of Commerce Trade and Industry issued CL 
on the triple fixed-dose combination of lamivudine, stavudine and nevirapine to a 
local company Pharco Ltd with royalties set at  2.5% of the total sales [41]. The 
application was made based on maintaining and securing sufficient supplies and 
services essential to the wellbeing of the community. The triple fixed-dose 
combination was produced with the names of NORMAVIR 30® and NORMAVIR 
40® [42, 43]. 
Malaysia granted the policy for ARV drugs at the same time as Zambia. In 
Malaysia, the number of HIV/AIDS cases continued to grow from 38,044 cases in 
2000 to 58,012 by 2003. As of September 2004, an aggregate total of 61,486 HIV-
infected individuals of whom 8,955 people had AIDS and 7,083 had died, had been 
reported to Malaysia’s Ministry of Health [44]. In September 2004, the Malaysian 
Minister of Domestic Trade and Consumer Affairs issued a CL to import ARVs, 
including didanosine, zidovudine and lamivudine and zidovudine combination 
(Combivir®) from the India maker, Cipla [45]. Under the CL, Cipla was allowed to 
export and sell the drugs to the Malaysian government under fixed ceiling prices for 
two years [46]. Malaysia set a royalty rate of 4% of the total sales [41]. According to 
the Malaysian Ministry of Health, the average cost of health care treatment for 
HIV/AIDS patients decreased 81% after the availability of generic drugs. The 
expected number of HIV/AIDS patients who could access to the drug in public 
hospitals and clinics improved from 1,500 to 4,000 patients by using CL, and that 
encouraged the Ministry of Health to step up the achievement to cover 10,000 
patients [47]. Moreover, due to the generic versions available, the patent owners 
significantly dropped their own prices in the market [47]. 
A month later, in October 2004 Indonesia granted CL policy for ARV drugs. 
Because, as of January 2004, only 1,300 patients received the treatment compared to 
 28 
 
a total of 15,000 patients in need of ART [48]. Therefore, the government aimed to 
provide ARVs for 5,000 patients in 2004 and 10,000 patients in 2005. The subsidy 
of US$240 per person per year for 4,000 patients was not enough for the price of a 
triple ARV regimen (zidovudine, lamivudine and nevirapine) at US$564 per person 
per year. In October 2004, Indonesia issued CL to produce generic versions of 
lamivudine and nevirapine. The generic versions were produced by a local firm, PT 
Kimia Farma [49]. Royalties were set at  0.5% of total sales [41]. Regarding 
implementation of CL, the Indonesian government estimated that in 2006 about 
5,000 HIV/AIDS patients from the total of 10,000 patients in the country received 
ARV treatment under the CL policy. While only 3.5% of patients had access to 
ARV in 2003, this has increased to 40% in 2005 [49]. 
Ghana granted CL policy for ARV drugs in October 2005. In the case of 
Ghana, 90,000 AIDS cases had been reported, and 400,000 people living with 
HIV/AIDS was estimated in 2004 [50].  On 26 October 2005, Major Courage E.K. 
Quashigah, the Ghanaian Minister of Health, notified an emergency and issuance of 
government used license for HIV/AIDS medicines. Ghana declared an emergency 
situation with regards to HIV/AIDS. It was declared that the ARV medicines would 
be issued to treat HIV/AIDS patients without any commercial interest and for 
government use only [51]. The use of CL aimed to import Indian generic ARVs. It 
was expected that the Ghanaian budget for ARVs would be reduced from US$ 495 
to US$ 235 for one-year treatment per patient (approximately 50% reduction) [31]. 
Brazil granted CL policy for ARV drugs in Aril 2007. Brazil is widely 
known as a leading country making an impressive battle to overcome the HIV/AIDS 
problem. However, its attempt was aggressively undermined by the TRIPS 
agreement. After Brazil passed its revisited national patent law to protect drug 
patent, the price of ARVs increased by patent protection beyond patient affordability 
[52]. On November 13, 1996, the president of Brazil, Jose Sarney, pronounced the 
big challenge by proposing Brazilians’ universal and free access to ARVs through 
the National Health System [53]. The model to promote ARVs access included price 
negotiation with patent owners; and in the case of failure, the CL policy would be 
taken into consideration. By threatening to use CL policy, Brazil preserved high 
power to negotiate with transnational drugs companies and mostly achieved the best 
price of drugs to pursue its universal access to ARVs [54]. On April 25, 2007, the 
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Minister of Health, Jose Gomes Temporao, endorsed Decree 866 to notify CL on 
Efavirenz (Stocrin®) for public interest purposes for a period of five years [55], with 
a remuneration to the patent holder of 1.5% of the drug sale [56]. The use of CL by 
Indian generic drug companies reduced the total price per day by 50%. It was 
expected to save US$30 million in 2007 and US$237 million during 2007 to 2012 
(when the patent of efavirenz expired) [57].   
Rwanda granted CL policy for ARV drugs in July 2007, as the last country, 
which has issued a CL policy in Africa. By the end of 2007, 150,000 people lived 
with HIV/AIDS and the adult HIV prevalence was 2.8%. In July 2007, Rwanda 
declared the need to use CL over two years for public health interests. Apo-TriAvir® 
(a combination of 300 mg Zidovudine, 150 mg Lamivudine and 200 mg Nevirapine) 
was expected to be imported in 260,000 packs from Apotex, Inc, a drug company in 
Canada. However, according to the Canadian Patent Act, Apotex had to initially seek 
a voluntary license from the patent owner, but the request was refused by the 
transnational drug company. Apotex then produced an application under the Canadian 
Access to Medicines Regime (CAMR) to export generic version of Apo-TriAvir® to 
Rwanda. CAMR paid a royalty rate of 4% of the value of the contract for the supply 
of the product [58]. In September 2008, Apotex exported 7 million doses of Apo-
TriAvir to Rwanda under the Canadian regime [59]. 
Ecuador granted CL policy for ARV drugs in October 2009. In Ecuador in 
2008, 26,000 people lived with HIV and 1,200 people had died from AIDS [60]. Due 
to the price of drugs, only an estimated 42% of Ecuadorians requiring ARVs were 
receiving treatment [61]. In October 2009, the Ecuadorian President, Rafael Correa, 
signed a decree issuing CL for an ARV drug, lopinavir and ritonavir combination 
(LPV/r). He said that “This is our vision of intellectual property.  It’s not a 
mechanism to enrich the pharmaceutical or agrochemical companies.  It’s a 
mechanism for development for the people.” License requests are considered on a 
case-by-case basis, depending on their importance to the public interest, including the 
benefits of reducing costs and increasing access [62]. This decree gave authority to 
the Indian pharmaceutical industry, Cipla Ltd, to produce the generic version of 
LPV/r, which was patented by Abbott Laboratories. CL was issued on the ground of 
public interest. The royalty rate was 4% of the finished product sale [63]. According 
to its HIV prevalence, the use of CL reduced the national budget by around US$5.2 
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million per year because generics were available to the government at US$800, while 
the original drugs cost US$ 1,000 annually per person [64].   
India granted its first CL policy in March 2012. Although CL has been done 
predominantly for HIV/AIDS drugs, India granted CLs on anticancer drugs. In 
India, a national survey showed that out of pocket spending expenditure on drugs 
accounted for about 68% of healthcare spending, which is double that in OECD 
countries (32.8%) in 2009 [65]. India granted a CL on an anticancer drug for renal 
and hepatic carcinoma treatment, sorafenib (Nexavar®), on 12 March 2012 [66]. 
Natco paid a 6% royalty to Bayer [66]. In granting the CL, the Controller of Patents 
explicitly declared three criteria that led to the granting of CLs under Indian patent 
law. First, the reasonable needs of the public had not been met (only 2% of patients 
in need received Nexavar®). Second, Nexavar® was available at a price of US$ 
5,610 for a one-month supply, which was considered unaffordable. Third, according 
to the requirement by the country, Nexavar had not manufactured or granted licence 
to any local manufacture in India [67]. According to the criteria, a licence was 
granted to Natco, an Indian generic company with the right to sell sorafenib at 97% 
less than the price of the patent drug [66].  
In summary, the treatment by patented medicines is costly and unaffordable to 
some governments, especially in LMICs. Often newer medicines are still under patent 
protection and their prices are higher, compared to older and generic versions. 
Sometimes the purchase of expensive patented medicines could threaten the 
sustainability of government-provided health services. In order to address this 
problem, LMICs decided to apply the TRIPS Agreement to manufacture or import 
cheaper generic medicines. According to the information mentioned above, positive 
implications of CL policy were highlighted in terms of considerable cost savings to 
the budget, while negative sides were political retaliations by the patent owners. 
However, the policy processes and implications may vary case by case. The next 
section explores the implications of CL policy. 
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2.4 Implications of compulsory licensing: a systematic literature 
review  
 This section is a systematic literature review that provides empirical 
evidence concerning the implications of CL policy. While there is a substantial 
literature on implications of CL policy, most are in an editorial form. This section 
focuses on original articles using concrete evidence to analyse CL implications. The 
objective of the literature review was to determine the implications of CL on health, 
economic and political aspects. The implications referred to positive and negative 
consequences.   
2.4.1 Review methods: 12 databases were searched to cover both published 
and grey literature. The published journal articles from the area of public health 
were obtained from Embase (via Ovid Embase Classic and Embase), PubMed, 
Cochrane library, and Global Health (via Ovid Global Health). Articles in the areas 
of economics and business were retrieved from HEED (via Wiley Online Library), 
Econlit (via Ovid), and Business sources premier (via EBSCO). Articles in the areas 
of politics and social sciences were obtained from IBSS (via Proquest), Social policy 
and practice (via Ovid), Scopus (via sciverse), and Web of Sciences (via web of 
knowledge).  
The search strategies used controlled vocabulary terms, whenever available, 
and relevant free text terms, including “compulsory licensing” or “non-voluntary 
license” or “government use license” in different combinations. According to the 
first use of CL in 2001, the search period was from 2001 to 12 March 2013. The 
papers were included in the analysis if they met the eligibility criteria shown in 
Table 2.1. For data analysis, I categorised information into five sections: publication 
year, authors, countries of the study, methods of evaluation, and findings of the 
study. In the findings, I separated the implications found in each study into positive, 
negative and no causal relationship.  
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Table 2. 1 Eligibility criteria of the systematic review 
 
Eligibility criteria Details 
1. Type of 
studies 
Original studies that addressed the implications of CL policy. 
Although some studies used CL as a side issue for their analysis, I 
considered the results indicating the implication of CL policy. All 
the statuses of publication (such as Unpublished, In press, or 
Published) were included. Review articles and editorial papers were 
excluded from the analysis. 
2. Types of 
intervention 
Studies related to the use of CL for public non-commercial use to 
increase access to health technologies. Papers that did not address 
the intervention characteristics (such as the use of CL for other 
technologies, or the use of other public policies to increase access to 
drugs) were excluded. 
3. Types of 
outcome 
measure 
The outcome of interest was implications of CL policy on health, 
economic, and social aspects. The studies, which analysed policy 
process were not considered.   
 
 
2.4.2 Results: The search strategy gave 1,256 references. After excluding 
763 duplicates, 486 papers were screened. 424 references were excluded based on 
title and abstract because they were not relevant to CL; for example, articles about 
other kinds of license policies (i.e. driver license, professional licenses) or articles 
about the use of CL in other technologies besides health (i.e. software and 
education). Full-text reviews were completed for 62 articles. A total of 52 articles 
were excluded; 43 review or editorial articles, three policy analysis studies, and six 
assessed implications of other alternative policies in promoting drug access. Ten 
studies were included in the analysis (Figure 2.2). 
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Figure 2. 2 Literature review flowchart 
 
 
2.4.3 Description of results: Six areas of impacts of CL policy were 
identified from the ten studies. (1) Three articles indicated impacts of public health 
benefits created by the government issuing CL policy [68-70]; (2) two articles 
indicated impacts of economic retaliation by government representing patent owners 
(e.g. USTR) [70, 71]; (3) two articles indicated impact on drug market in terms of 
patented price reduction by patented industries [72, 73]; (4) three articles indicated 
impacts in terms of market competition created by generic drug industries [74-76]; 
(5) one articles indicated impacts created by patented drug industries on the delay of 
new drug launches [71]; and (6) one article indicated impacts created by patented 
industries on drug innovations [77]. Included articles are summarised in Table 2.2. 
 
Table 2. 2 Summary of included articles 
 
Year Authors Country Method of evaluation Result 
1. impacts of public health benefits created by the government issuing CL policy 
2008  Over, M [68] Thailand Epidemic & 
Economic model 
simulation 
Positive impact on the decrease in the 
national HIV/AIDS treatment budget. 
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Year Authors Country Method of evaluation Result 
2011  Mohara, A [69] Thailand Markov model 
simulation 
Positive impact on the annual national 
health budget.  
2011  Yamabhai, I [70] 
 
Thailand Human capital 
approach 
Positive impacts on patients’ productivity 
and treatment costs. 
2. impacts of economic retaliation by governments representing patent owners (e.g. USTR) 
2011  Yamabhai, I [70] 
 
Thailand Trend analysis  
 
No causal relationship found between CL 
and foreign direct investment  
2013 Yamabhai, I [71] Multi-
countries 
Econometrics 
model   
Insignificant effect of CL on foreign direct 
investment. 
3. impact on drug markets in terms of patented price reduction by patented industries 
2007  Nunn, A [72] Brazil Trend analysis  
 
Positive impact on patented price reduction 
by CL. 
2011  Meiners, C [73] Brazil Econometrics model   Positive impact on market price reduction 
by CL and generic competitions.   
4. impacts in terms of market competition created by generic drug industries 
2003  Chaudhuri, S [74] India Microeconomic 
model  
Positive impact on consumer welfare 
resulting from the entry of generic firms in 
the market under CL.  
2009  Flynn, S [75] Not 
specific 
Theoretical 
analysis 
Positive impact on consumer welfare 
resulting from wealth transferred from 
monopoly firms to the consumer. 
2012  Bond, E [76] Not 
specific 
Theoretical 
analysis 
Positive impact on global welfare when the 
technology gap is significant.  
5. impacts created by patented drug industries on the delay of new drug launches 
2013 Yamabhai, I [71] Thailand Econometrics 
model   
Negative impacts on the speed of new 
product launches. 
6. Impacts created by patented industries on drug innovations 
2002  Chien, C [77] Multi-
countries 
Trend analysis       
 
Insignificant decline in drug innovations of 
patented  companies affected by CL 
 
 
 
A. Effects on public health benefits 
Three studies analysed impacts of CL policy from the government 
perspective. Two articles analysed intermediate outcomes in terms of national health 
budget savings from the availability of generic drugs under CL policy. A study by 
Over (2007) [68] estimated future budget saving for HIV treatment based on the 
assumption of 90% price reduction by CL policy in Thailand. Another study by 
Mohara (2012) [69] predicted the size of the budget decrease due to the difference in 
patent and generic versions of seven medicines according to Thai CL. Although the 
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two studies used different approaches, both concluded that the grant of CL in 
Thailand had led to substantial budget savings. 
A study by Yamabhai (2011) [70] estimated health implications. The study 
analysed treatment costs saved and health benefits gained from receiving seven 
generic medicines under CL policy compared with its alternative treatment being 
used as the standard treatment prior to the grant of CL. The total treatment cost was 
calculated from the summation of drug prices and costs of treatment for each drug. 
This study measured the health benefits in terms of national productivity by using 
the human capital approach. The increase in national productivity was estimated by 
multiplying the Gross Domestic Product (GDP) per capita with the estimated 
Quality Adjusted Life Years (QALYs) gained from the increased drug access. The 
study found that the use of CL created benefits, which far outweighed its cost.    
 
B. Effects on the national economy 
 The drawbacks of CL policy were analysed in the study by Yamabhai (2009) 
[70]. A trend analysis conducted in 2009 comparing before and after CL was issued 
in Thailand.  Because of the reactions from patent industries and the USTR against 
CL policy, Thailand was placed in the Priority Watch List of annual 'Special 301' 
report [78]. The study depicted no evidence to support negative effects from CL 
policy on the changes in investor confidence in not only the stock market 
investments (both local and foreign investors), but also the foreign direct 
investments in Thailand. The author re-analysed again in 2013 by using econometric 
model [71]. The study confirmed that CL does not necessarily discourage foreign 
investors. Instead, market attractiveness (GDP, population number, and international 
trade) and political stability are significant factors in attracting foreign investment. 
C. Effects on market prices of pharmaceutical products   
Studies by Nunn et al. (2007) [72] and Meiners et al. (2011) [73] evaluated 
factors influencing the market price of ARVs in Brazil. CL was a side issue in both 
of these studies. The Nunn study used trend analysis, while Meiners developed an 
econometric model. Both studies found that Brazil achieved significant discounts 
from patented drug firms under the threat of CL policy during the price negotiation 
processes. Moreover, the econometric model indicated that generic drug firms were 
more likely to respond to factors influencing market competition and demand size, 
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while patented drug firms tend to strategically set the drug prices to offset CL threats 
and prices of generic versions available in the market.  
D. Effects on welfare of pharmaceutical product consumers 
A case study in India by Chaudhuri (2003) [74] used a micro-economic 
model to estimate price and expenditure elasticity. In the analysis, counterfactual 
scenarios were assumed that domestic generic drug firms would withdraw from the 
market by the absence of CL policy. The study found that if CL was inhibited, 
consumer welfare would decrease because monopoly patented drug industries would 
dominate the local market. This point was supported by two theoretical studies. 
Flynn (2009) [75] supported that CL policy allowed generic companies to enter into 
the market, and subsequently the market drug prices would decrease, thereby 
transferring wealth from monopoly industries to consumers. Bond (2012) [76] 
extended the view at global level. It was found that CL policy increased LMICs’ 
welfare; nonetheless, such policy was not always favourable if the effect on the 
patent-holder was taken into account. It concluded that CL provided benefits to 
global welfare only when the gap of technology in LMICs and HICs was 
considerable.  
E. Effects on the delay of new drug launches  
An empirical study by Yamabhai (2013) indicates that patent protection 
affected procedure for the launch of new drug products in Thailand. An econometric 
model of Cox proportional hazard model was employed to examine factors, which 
determine the entry of new medicines to the Thai market during 1982-2009. The 
empirical results show that policy related to patent law has a significant and positive 
impact on the rapidity of the launch of new products in Thailand. Most importantly, 
CL is shown to have a significant and adverse effect on the speed of new medicine 
launches. Therefore, the CL caused the delay of new product launches in the Thai 
pharmaceutical market.  
F. Effects on drug innovations 
 Several arguments have been made that the implementation of CL policy 
discourages incentives for drug innovations. However, there was only one original 
study by Chien in 2003 [77], which did a methodological analysis on this issue. The 
observational analysis compared rates of medical innovation before and after CLs in 
global. The finding contradicted the perception that there was no measurable decline 
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in the innovation of license cases under CL. The author postulated that two factors 
were important on patent companies’ decision. This included "predictability" (the 
degree to which a drug firm could predict that a CL would be used to take a patent) 
and "importance" (the relative importance of the markets affected by the license). 
The study concluded that CLs issued on global disease drugs (the drugs that are 
created for rich countries, but are also useful in developing countries; examples of 
these are cancer drugs and AIDS therapeutics) were either unpredictable or did not 
affect important markets at the global level (a wide range of countries which 
included both rich and poor countries), thereby it found no discernible impact on 
such innovations. In contrast, CLs issued on neglected disease drugs were 
predictable and impacted a neglected market for a drug, which would significantly 
discourage R&D incentives. 
 
2.5 Conclusions and gaps of knowledge 
Chapter 2 aimed to set the scene for readers to understand the history and 
implications of CL policy. According to the study of Beall et al. 2012, only few 
LMICs implemented the CL policy, and the trend of documented CL episodes 
declined during 1995 and 2010 [18]. A possible explanation is that most countries 
are concerned about the potential implications, especially political and economic 
implications, resulting from the policy [19,20]. I conducted a systematic literature 
review to retrieve empirical evidence on all potential areas of implications of CL 
policy. According to the systematic review, I found positive and negative 
consequences resulting from CL policy. This suggested there is value in developing 
a framework that suggests a comprehensive set of policy elements throughout the 
CL policy processes and strategies to deal with the potential implications.  
In this PhD thesis, I therefore developed a framework for decision making 
and highlighting implications of drug policy, focusing on CL policy in order to fill 
the gap of knowledge. I addressed this topic by analysing the case of CL policy in 
Thailand. The background of the Thai context is explained in the next chapter. 
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Chapter 3: Background to compulsory licensing in 
Thailand 
 
The aim of this chapter is to provide background information about CL 
policy in Thailand. The information was obtained from literature of stakeholders in 
the public health system such as government, academic, and NGOs in Thailand. This 
chapter classified background information of Thailand into three sections: (1) the 
health system in Thailand, this section helps set a scene for readers to understand the 
context of Thailand; (2) alternative measures for improving access to essential 
medicines in Thailand, this section provides available measures that used by the 
Thai government to improve access to medicines in the country, and CL is one of 
the effective measures; and (3) important events concerning CL policy in Thailand, 
this section provides a history of Thai CL policy from the beginning of the policy 
decision until the policy successfully implemented in the country. The details of 
each section are provided below. 
 
3.1 Health system in Thailand in the context of CL 
Thailand introduced CL in 2006; at that time Thailand was a lower-middle-
income country with GNI per capita of US$2,890 and the total population of 65.9 
million [79]. The public insurance schemes cover 97% of the population. These are 
subdivided into: 1) Civil Service Medical Benefits Scheme (CSMBS) for 
government employees and their dependents; 2) Social Security Scheme (SSS) for 
private business employees; 3) The Universal Coverage Scheme (UC) as the largest 
insurance program for any person who is not covered by the other two schemes [80]. 
The difference across three schemes shows in Table 3.1. 
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Table 3. 1 The difference across the three public health schemes 
 
Schemes CSMBS SSS UC 
Start 1960s 1990s 2001 
Target 
beneficiaries 
Government employee, 
dependents and retirees 
Private sectors 
employees 
Thai citizens without 
the coverage of 
CSMBS nor SSS 
Coverage 8% 14% 78% 
Funding Government budget Tri-parties (Employee, 
Employer, and 
government budget) 
Government budget 
Payment to 
health facilities 
Fee for services Capitation Capitation 
Major problem Constantly raising 
health care cost 
Covering while being 
employed only 
Inadequate budget 
 Sources: Adapted from the Ministry of Public health’s white paper on CL policy [81].  
 
The mission of the Thai ministry of public health (MoPH) is to provide 
universal access to health care, and medications on the National List of Essential 
Medicines (NLEM) are provided free of charge. However, there are different aspects 
across the three schemes. The CSMBS uses the fee-for-service payment by 
allowing the providers to make almost all health care decisions independently. 
Therefore, the CSMBS tends to have more access to expensive products outside of 
the NLEM compared to the two other schemes. On the contrary, the providers under 
the SSS and UC have a disincentive to utilise expensive drugs since their payment 
type is capitation. For utilising drugs outside the NLEM, SSS patients have to make 
a partial payment, while the UC patients have to pay the full price. Therefore, 
patients under the UC scheme have the most severe problem in drug access and the 
Thai government have had to find a strategy to solve it [81].     
  During the last decade, Thailand has faced major health problems from 
HIV/AIDS, heart disease and cancer. Most of the drugs were patented, expensive, 
and inaccessible to the middle class and the poor. Some drugs were included in the 
NLEM but were not fully provided to patients [81, 82]. Due to their prices, which 
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caused unsustainable public finance, only patients who could not tolerate toxicity of 
cheaper alternatives would be eligible to use more effective and less toxic drugs 
[81]. Some were neither included in the NLEM nor covered by the National Health 
Insurance system; therefore, patients had to pay out of their pocket, and many 
patients dropped out of treatment when they could not continue to afford the 
medicines [83]. However, according to the national drug policy, the key imperatives 
of the Thai pharmaceutical policy is that all eligible Thai people must be able to 
access essential drugs; and that the Thai health system is sustainable in the long 
term[84]. The Thai government has tried a number of policies, namely drug patent 
opposition, drug price regulation and negotiation, and TRIPS flexibilities to promote 
drug access. 
3.2 Policies to promote drug access in Thailand 
The Thai government has promulgated measures of patent opposition to 
promote drug access in the national laws. The Patent Act (No. 3) 1999 (B.E. 2542) 
supports patent opposition procedures in order to prevent patent applications for 
medicines that lack novelty (low quality of drug patents) [85]. There are no truly 
worldwide patents of medicines, and a patent from one country does not offer the 
inventor any right in another country. Instead, each country or region grants its own 
geographically limited monopoly for patent protection. The Thai patent office in the 
Department of Intellectual Property, Ministry of Commerce is responsible for 
granting patent protection, and the process complies with minimum international 
standards. However, there is problem called “drug patent evergreening” when brand-
name companies make patent applications for medicines that are just little 
modifications of old medicines. This practice is not looking at any significant 
therapeutic advantage, but rather a company’s commercial advantage. Therefore, a 
measure to help in overcoming problems of drug patent evergreening is needed. The 
patent opposition procedure exists to allow patent offices to examine whether an 
invention possesses novelty and then to prevent the obstacle of drug access due to 
the patent evergreening. [86].    
Thailand has a pre-grant opposition system to allow any party to oppose a 
patent application if the application is made for patent protection to a medicine 
which lacks novelty. The opposition can be made within 90 days after the 
publication date of the application. If the opposition is denied by the Director-
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General of the Department of Intellectual Property, an appeal can be made to the 
Board of Patents. However, if the Board of Patents also rejects the appeal, the party 
can be still eligible to appeal the decision of the Board of Patents to the Central 
Intellectual Property and International Trade Court within 60 days after the Board’s 
decision. If the Court also rejects the appeal, the Intellectual Property and 
International Trade division of the Thai Supreme Court serves as further recourse. 
[87]. In the past, the Thai government has rejected the patent applications due to the 
lack of novelty for Videx® (didanosine /DDI) of Bristol-Myers Squibb (BMS) in 
2004; and Combid/ Combivir® of GlaxoSmithKline (GSK) as the combination of 
lamivudine (3TC) and zidovudine (AZT) in 2006 [88]. 
In addition to patent opposition, pricing policy is another key measure to 
control drug prices and promote drug access. The WHO suggests six main methods 
to control the price of medicines: (1) use of external reference pricing, (2) use of 
health technology assessment, (3) promotion of the use of generic medicines, (4) 
application of cost-plus pricing formulae for pharmaceutical price setting, (5) tax 
exemptions/reductions for pharmaceutical products, and (6) regulation of mark-ups 
in the pharmaceutical supply and distribution chain [89]. In Thailand, the 
government has formally implemented the first three policies. Although the other 
policies have not been implemented yet, concerned actors from academics and 
NGOs have urged the Thai government to put them into action also. The 
implementation details of the pricing policies in Thailand and the evidence of the 
implementation effects are mentioned below.    
The Price of Goods and Services Act 1992 (B.E.2542) reflects the issue 
about price control by enabling the Central Commission on Prices of Goods and 
Services (CCP) to determine purchase prices or distribution prices of controlled 
goods, including medicines. However, the regulation was not successfully 
implemented leading to the variation of drug prices across the country [90], and 
higher prices compared to other countries [91]. In response to the problems, the 
Ministry of Public Health and concerned organizations sought to develop a pricing 
system in the country. In 2015, The Thai government set up a meeting to establish a 
formal working group among relevant stakeholders from public and private sectors 
in order to formulate a system to determine a reasonable price for medicines. The 
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proposed price from the system will be formally approved and regulated by the 
Central Committee on Prices of Goods and Services [92]. 
Regarding price negotiation, the government has appointed the price 
negotiation committee to negotiate the price of medicines with patented industries. 
The committee employs several tools in the process of drug price negotiation, 
including price-volume agreement, international price comparison, and value based 
pricing by using economic evaluation and technology assessment [93]. The price 
negotiation committee has employed these tools to develop pricing strategies and 
succeeded in negotiating prices for many medicines. For example, the committee 
succeeded in negotiating prices of medicines for treatment of hepatitis C by using 
the measures of value based pricing and volume agreement. The committee also 
successfully employed the tools to negotiate the price of Peg Interferon and 
Ribavirin, and achieved 70% reduction from the original prices of the drugs. [94].      
In addition, another effective tool is risk-sharing because the approach helps 
distribute the cost burden between the public payers and the pharmaceutical 
company. The Thai government also used a risk-sharing agreement through a 
performance-based reimbursement scheme. The scheme involves the prices of drugs 
and levels of reimbursement being tied to future performance measures of clinical 
outcomes related to patient quality and quantity of life. The goal is to offset the risks 
among health care payers (such as government or insurance companies) of paying 
huge reimbursement costs for a particular treatment, when there is uncertainty over 
clinical value and health economic value of the treatment [95]. Drug companies can 
implement the risk-sharing agreement through offering the treatment with a 
discounted price, or offering the treatment free of charge within a pre-set timeframe 
[96].  
The MoPH used this risk-sharing approach to promote access to Sunitinib as 
an anti-cancer drug. HITAP conducted a study to assess a value based risk-sharing 
scheme for Sunitinib for the treatment of metastatic RCC (Renal Cell Carcinoma). 
The findings indicated that if the willingness-to-pay threshold was set at 500,000 
THB (3 times of GDP per capita) per QALY gained, the drug industry could 
participate in the risk sharing by offering the treatment free of charge for 16 cycles, 
or offer the treatment free of charge for 14 cycles and give 20% reduction from the 
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original price for the rest of the treatment. In addition, when the willingness-to-pay 
threshold was set at 160,000 THB (1 times of GDP per capita) per QALY gained, 
the drug industry should offer the treatment with 85% discount for 18 cycles. 
However, the negotiation between the committee and the patented drug industry did 
not reach an agreement [96]. Although there was a failure in this attempt, risk 
sharing could be another tool to promote access to essential medicines at affordable 
prices. It has however been suggested that this measure requires an effective 
administration system and strong collaboration between public and private sectors 
[97]. 
Lastly, the Thai government has promulgated measures to promote drug 
access through TRIPS flexibilities. The Patent Act (No. 3) 1999 (B.E. 2542)  reflects 
that the patent protection shall not apply to a number of conditions including the use 
of TRIPS flexibilities [98]. Two main mechanisms to use patent rights by others 
than the patent owner have been clarified. First, non-public uses of patent rights are 
for any individual who wishes to use the patent rights for commercial purposes. This 
mechanism requires the permission from patent holders. Second, public uses of 
patent rights are for any ministry or government department who wish to exercise 
any right for public use by paying a royalty to the patent owner without the 
requirement for prior negotiation on the permission, on the royalty fees, or the term 
of patent. This mechanism contains two categories as follows. 
(1) According to the Thai Patent Act section 52, “during a state of war or 
emergency, the Prime Minister, with the approval of the Cabinet, shall have the 
power to issue an order to exercise any right under any patent necessary for the 
defence and security of the country by paying a fair remuneration to the patent 
owner” [85]. 
(2) According to the Thai Patent Act section 51, “the use for public 
consumption or vital importance to the defence of the country; or for the 
preservation or realization of natural resources or the environment; or to prevent or 
relieve a severe shortage of food, drugs or other consumption items; or for any other 
public service” [85]. The cases of Thai CLs are issued under this category. However, 
after failure in trying other alternative measures mentioned earlier, the Thai 
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government will adopt the CL policy to alleviate the cost barrier of access to 
unaffordable drugs.  
3.3 Issues concerning CL implementation in Thailand  
In the production of pharmaceutical products, drug manufacturers have to 
pass an assessment of standards for pharmaceutical manufacturing according to 
good manufacturing practice (GMP), as well as other standard requirements of the 
Thai FDA. This process involves experts from several agencies, including the Thai 
FDA, the GPO, and the Department of Medical Science (DMSC). These experts 
visit drug-manufacturing facilities of drug companies that would expect to produce 
the drugs under CL policy, in order to check the reliability of the production, 
document and support systems for drug production, and check whether they meet the 
GMP standard. This was to ensure that drug manufacturing will comply with 
standards and build trust and confidence among patients, doctors and medical staff 
in the quality of generic pharmaceutical products [99].  
In addition, in Thailand, the implementation of CL policy is integrated into 
the regular system of drug policy. Before a generic drug is manufactured or 
imported for sale and use, it must be registered and pre-marketing approved by the 
Thai FDA. The generic pharmaceutical products must be endorsed by documented 
evidence showing their therapeutic equivalence to original pharmaceutical products. 
The bioequivalence study is internationally recognised by the WHO as a method that 
proves the therapeutic equivalence of drugs. The following factors are considered: 
the rate and extent of drug absorption into the bloodstream at different time intervals 
after the pharmaceutical products are provided for humans. These are determined by 
measuring drug levels in the blood and duration for which they go into the 
bloodstream among healthy volunteers. This method reveals bioavailability of a 
generic pharmaceutical product compared with an original drug, which is a reference 
product. In addition, the firms have to send samples of generic drugs that they 
produce or import to the DMSC for quality examination, in terms of product 
identification, uniformity of dosage units, dissolution, and impurities, in order to 
ensure that their quality meets the national standard for drug regulation [99].  
The system was implemented by comprehensively assessing not only the 
product quality, but also the manufacturing process as the international standard. For 
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the process of drug approval, the drug suppliers must submit the evidence to the 
Thai FDA as follows: (1) Application form for drug registration; (2) Drug labels and 
medication information leaflet in Thai/English; (3) Certificate of free sale, which 
certifies that the products are allowed to be sold in the producer country; (4) 
Certificate of GMP, which shows that the drug producers have been granted the 
certificate for good manufacturing practice; (5) Documents on quality control for 
drug standards: active and non-active ingredients, production process, details of 
standard control for raw materials and finished drugs, certificate of analysis for raw 
materials and finished drugs, and data about the study of drug stability; (6) 
Published and publicized reference documents showing drug effectiveness and 
safety; and (7) Bioequivalence study report by institutes or laboratories, whereby 
such laboratories have international standard certification [99].  
Once a generic pharmaceutical product is approved as mentioned above, it 
can be imported to the country or manufactured for sale and use in Thailand, and the 
quality of the drugs is then monitored by the government in accordance with the 
annual post-marketing plan. For the inspection of manufacturing procedure, plant 
inspections are performed periodically whether they still meet the GMP standard. 
For the products inspection, the Thai FDA collects product samples and send these 
to the DMSC and other authorised agencies for testing on whether they still keep to 
adequate standards by analyzing for fraudulent characteristics or impurities, which 
have harmful effects to human health. In case of violation, actions like seizure, 
recall, or confiscation will be executed under the authority of the FDA [100]. In 
addition, public health personnel, including doctors, pharmacists, nurses and other 
relevant personnel have to monitor, observe and collect data about undesirable 
symptoms and unsafe effects from the use of health products, including drugs under 
the CL policy. The information and reports are sent to the Health Product Vigilance 
Center (HPVC), the Thai FDA and MOPH for further consideration [100].  
Regarding the capacity of regulatory agencies, the limitation in terms of 
personnel resources and infrastructure is a common issue. In the pre-marketing 
process, there is a long waiting list of drug approval due to limitation in experts 
equipped with the knowledge about pharmaceutical sciences and quality assurance. 
The Thai government has strategic approaches to manage the limitations in order to 
accelerate the procedure of CL drug approval. Because CL drugs were set as the 
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national priority, these drugs were prioritized in the approval process before other 
generic drugs. As a result, the standard procedures for new generic drug registration 
under CL policy were placed in the priority review, which required 70 days for 
approval, while other generic drugs required 110 days. This procedure was assured 
by the Thai FDA and it was fully compliant with the international standard of 
generic drug approval. [101].  
For the capacity of post-marketing inspection, the quality of efavirenz, LPV/r 
and clopidogrel were approved by the Thai FDA, the DMSC and the GPO. 
However, infrastructures of central laboratories were not sufficient to meet the 
national demand of drug inspection. Therefore, the Thai FDA and the DMSC have 
extended the national capacity of inspection through strengthening capacity of local 
laboratories in other regions across the country. In addition, Thailand also lacks the 
capacity to assure the quality of chemotherapy products. To deal with this limitation, 
the Thai government sends anti-cancer drugs including letrozole and docetaxel to 
international laboratories for quality assurance [102]. 
For the drug distribution, budget monies are a key resource for implementing 
the policy to allow the policy objective and goals to be met. As all Thai people are 
covered under the three public health benefit schemes: the UC, the SSS, and the 
CSMBS, the public health budget to provide the essential drugs under national 
policies is disbursed by the three public health scheme agencies, not paid for by 
patients’ out-of-pocket expenses [103]. Therefore, it can be ensured that all eligible 
patients can access the CL drugs. In addition, the GPO and NHSO have established 
the IT system through a Vendor Managed Inventory (VMI) to distribute drugs into 
the public health system. In the system, government hospitals have to inform the 
public health scheme agencies about the number of patients entitled to each scheme 
under their responsibility, and submit an electronic report on administering drug use 
under CL policy to the agencies every quarter before they receive their 
disbursement. The three public health schemes provide the hospitals with funds for 
health services and drugs according to the number of patients, and leave the 
hospitals to manage the budget on their own [103]. This VMI system helps the GPO 
to effectively manage stocks in the warehouse and provide drugs to hospitals. By 
using computer-to-computer communication, the VMI improves the accuracy and 
speed of data transferred in the drug inventory system. The VMI manage drug 
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distributions and is responsible for monitoring the use of CL drugs and making sure 
that the drugs are sufficient to satisfy the requests from users under the three health 
benefit schemes [103]. 
In the step of drug utilisation, under the MOPH’s protocol guidelines, the 
treatment at health care facilities has to comply with the protocol guidelines, and this 
is followed by an assessment and follow-up of the treatment. In health care facilities, 
the hospital directors regularly hold meetings with prescribers, in order to discuss 
specific issues related to their context, to which the main protocol guidelines may 
not be applicable, and develop their own approaches to deal with the issue [103]. In 
practice, the doctors examine patients’ levels of symptoms and empirical medical 
data, and judged appropriate drugs for each patient. They are allowed to make 
changes to use other drugs, which are not included in the MoPH’s protocol 
guidelines.  However, the physicians have to submit a written report with 
attachments, which provide empirical evidence to clarify the reason and need for this 
change to the hospital director. If any doctors who administered a generic drug and 
that the drug has no therapeutic efficiency or has any severe adverse effect, they can 
switch to other generic or patented drugs by submitting a written report to the 
hospital director [103]. 
There are two groups of auditors to monitor rational use of drugs: First, the 
external auditor, which contains authorised government officers from the three 
public health insurance schemes, randomly audits and monitors performance of drug 
utilisation in hospital units whether they comply with the protocol guidelines. 
Second, the internal auditor is authorised local staff of that hospital, who are in 
charge as a hospital committee for regularly considering and assessing drug 
administration in their hospital. The committee consists of health personnel with 
good knowledge of treatment, including doctors, pharmacists, and specialist nurses 
of that hospital [103]. 
3.4 Important events concerning CL policy in Thailand 
There are several events about the use of CL policy in Thailand, which need 
to be highlighted. I summarise important events by starting from the first Thai patent 
act until the successful importation and local production of generic drugs under CL 
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policy. A history of CL policy in Thailand is visualised in figure 3.1, and 
explanations on the figure are summarised in the next section. 
 
Figure 3. 1 Timeline of compulsory licensing (CL) in Thailand 
 
Important events concerning the decision-making processes  
 
In 1979, Thailand introduced Patent Act B.E.2522 as the first legal 
protection for inventions in the country, which granted exclusive rights to only 
production process patents for pharmaceuticals [104]. The system provided the 
opportunity for domestic firms to produce the same product with different 
manufacturing processes. In February 1992, under pressure of HICs, the “Patent Act 
B.E. 2535” was amended from the previous patent law to recognise both 
pharmaceutical products and processes as patentable issues [85]. Since the revised 
patent act, the Thai medicine market has depended heavily on imported 
pharmaceutical products. In the 1990s when the new Patent Act went into effect, the 
proportion of imports rose with accelerating rates. The share of imported drugs in 
the Thai pharmaceutical market increased from 28% in 1990 to 46% in 2001, and it 
progressively increased in the following years [105].  
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In October 2001, the Thai government introduced a Universal Coverage 
(UC) Scheme of health care insurance from general tax revenue, which covered 
approximately 47 million people through public and private hospitals. In October 
2003, the Thai government also established a universal access to ARV drugs [80]. 
Evidence shows the considerable increase in a number of patients receiving the 
ARVs. The enrolment of HIV/AIDS cases from January to December 2003 in the 
early phase revealed 19,551 patients who were recruited in the program. In the rapid 
scaling up phase from January to December 2004, the cumulative number of 
HIV/AIDS patients having access to ARV drugs was 58,133. However, the Thai 
government bared the burden of health expenditure for medical supplies, which 
increased from US$ 1.4 million to US$ 12 million [82]. In addition, Thailand was 
faced with treatment costs of other chronic diseases, and measures to reduce the 
drug prices, therefore, were employed. 
 In April 2005, Thailand established a working group on negotiating 
essential drug prices with patented pharmaceutical firms. The members of the 
working group consisted of representatives from the Ministry of Public health, the 
Ministry of Commerce, and the Secretary-General of the Food and Drug 
Administration. By 2006, the working group claimed that the attempt to negotiate 
the prices of patented drug failed due to lack of cooperation from patent-holders 
[106]. In April 2006, Thailand’s National Health Security Office (NHSO) 
established a subcommittee to issue CL for government use. The subcommittee 
developed criteria for using CL on drugs and medical supplies were as follows:  
(1) “Drugs listed in the NLEM, or necessary in an emergency or a situation 
of extreme urgency, or required to solve important public health problems, or 
needed for prevention and control of outbreaks, epidemics, or pandemics, or 
necessary to save lives.”  
And  
(2) “Drugs priced too high for the government to afford its citizens with 
universal access to essential medicines” [81]. 
 
 There was a political change in Thailand in September 2006. General 
Surayud Chulanont was appointed to be the interim prime minister of Thailand. 
Under the provisional government, several policies were introduced, including CL 
policy for public interests [107]. In November 2006, the Department of Disease 
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Control and the MoPH issue a government use for CL policy on the ARV drug 
efavirenz (Stocrin®). Thailand continued to issue CL on its other health priorities as 
follow. In January 2007, the Thai government further issued CL for an ARV 
combination drug of lopinavir and ritonavir (LPV/r, Kaletra®), and a cardiovascular 
medication, clopidogrel (Plavix®). In January 2008, Thailand came to a decision to 
issue CL for four anti-cancer drugs; docetaxel (Taxotere®), erlotinib (Tarceva®), 
letrozole (Femara®) and imatinib (Glivec®). The royalty fees were paid by generic 
supplier GPO at 0.5% of their total sale values for efavirenz and LPV/r, and at 3% of 
their total sale values for the clopidogrel and cancer drugs to the patent owners [81].  
The Government Pharmaceutical Organisation (GPO) has been designated to 
represent the government to procure the seven CL drugs. The GPO aimed to produce 
three generic drugs, namely efavirenz, LPV/r, clopidogrel. Although knowledge and 
technology may be initially insufficient to develop the drugs, the GPO improves 
their capacity through production technology transferred from India generic drug 
companies. Both ARVs have been successfully transferred the technology. Only 
LPV/r has been produced, while efavirenz has been decided to import because the 
prices of Indian generic drugs are cheaper than the local production. For the 
clopidogrel, the GPO is conducting research and trying to produce it in conjunction 
with bidding to import from qualified generic drug firms. Nonetheless, the GPO’s 
facilities are not available to produce cancer drugs; so the GPO has to be the agent 
for procuring the four generic cancer drugs from pharmaceutical companies by 
considering a certified drug production process and drug quality. The details of each 
drug are summarised in Table 3.2.   
 
 
Table 3. 2 The list of drugs granted compulsory licensing (CL) in Thailand 
 
No. Trade names Patent owners Indications Generic names Generic firms 
1. Stocrin® Merck  HIV/AIDS Efavirenz (EFV) Indian and Thai firms 
2. Kaletra® Abbott HIV/AIDS Lopinavir & ritonavir combination  (LPV/r) 
Indian and 
Thai firms 
3. Plavix® Bristol-Myers Squib  Cardiovascular disease  Clopidogrel Indian firms 
4. Femara® Novartis Breast cancer Letrozole Indian firms 
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No. Trade names Patent owners Indications Generic names Generic firms 
5. Taxotere® Sanofi-Aventis Lung cancer and breast cancer Docetaxel Indian firms 
6. Glivec® Novartis Gastrointestinal stromal tumours and chronic myeloid leukaemia  Imatinib Indian firms 
7. Tarceva® Roche Lung cancer Erlotinib Indian firms 
 
Important events concerning implementation processes 
After the Thai government had decided to issue CL policy in November 
2006, an announcement was made by Merck concerning the global price reduction 
for Efavirenz (Stocrin®) to patients living with HIV/AIDS in the least developed 
countries and countries suffering the burden of the HIV/AIDS pandemics. Merck 
reduced the price of Efavirenz by 14.5% globally, and the price for Thailand was 
decreased from 2,000 Baht (US$62) to 780 Baht (US$ 24) per bottle. Merck stated 
that an improved manufacturing process enabled them to pursue their price 
reduction. Nonetheless, the Efavirenz generic versions remained lower at 650 Baht 
(US$ 20) per bottle and Thailand persisted to continue its attempt to increase access 
to drugs for its citizens through CL policy [81].  
 In March 2007, the USTR elevated Thailand to its “Special 301” Report 
Priority Watch List. The USTR cited “In addition to these longstanding concerns 
with deficient IPR protection in Thailand, in late 2006 and early 2007, there were 
further indications of a weakening respect for patents, as the Thai Government 
announced decisions to issue CLs for several patented pharmaceutical products. 
While the United States acknowledge a country’s ability to issue such licenses in 
accordance with WTO rules, the lack of transparency and due process exhibited in 
Thailand represented a serious concern.”[108] Pharmaceutical Research and 
Manufacturers of America (PhRMA) supported the USTR’s decision to elevate 
Thailand to the Priority Watch List [109].  
At the same time, Abbott Laboratories withdrew seven medicines from drug 
approval applications to the Thai market and stated that it would not launch new 
medicines in retaliation on CL for Kaletra®. Those drugs included Aluvia (lopinavir 
and ritonavir in a new heat-stable form, which required no refrigeration for HIV 
treatment), Abbotic (clarithromycin in granule of oral suspension for upper and 
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lower respiratory tract infections), Brufen (ibuprofen in suspension form for fever 
and pain relief), Clivarine (reviparin sodium for thrombosis, thrombo-embolism, and 
anti-platelet aggregation), Humura (adalimumab for osteoarthritis, rheumatoid 
arthritis), Tarka (trandolapril-verapamil combination for idiopathic hypertension), 
and Zemplar (paricalcitol for hyperparathyroidism in chronic renal disorders) [110].  
However, the CL policy was supported by international activists. Over 140 
organisations, NGOs and individuals sent letters to the US Secretary of State 
Condoleezza Rice, and USTR Susan Schwab to require the US government not to 
interfere with the Thai government decision to subject the CL on the ARV drug 
[111]. In addition, in January 2007, twenty-two members of the US Congress also sent a 
letter to Susan Schwab urging her to respect Thailand’s decision to issue CL for 
Efavirenz [106]. Moreover, the practice by Abbott was strongly criticised by 
treatment advocate groups around the world. Eventually, one month later, in April 
2007, Abbott restated such withdrawal from the Thai market and offered to reduce 
the price of Kaletra by more than 55% for 40 LMICs [110]. 
The Thai government gained benefits from the CL policy through technology 
transfer by foreign generic drug producers. The GPO contemplated to pursue a 
sustainable system for long-term access to essential drugs for Thai citizens. Since 
October 2007, the GPO has made partnerships with Indian drug companies with the 
aim of improving its ARV manufacturing plant to meet WHO GMP standards [112]. 
In December 2012, the GPO successfully obtained knowledge and technology 
transferred by Indian industry and produced EFV and LPV/r drug for HIV/AIDS 
patients, and their quality and safety were approved by the Thai FDA [103]. In 
addition, clopidogrel is on the pipeline for domestic development. Due to 
environmental concerns about the cytotoxic chemo substance from anti-cancer 
production, the plan to produce generic anti-cancer drugs has not been pursued.  
As of 2016, five CL drugs have been distributed to Thai patients under the 
policy. Although Thailand issued CL policy on seven drugs, two cancer drugs were 
not actually granted. Novartis agreed to provide imatinib for all UC patients under 
the Glivec® International Patient Assistance Program (GIPAP) [83], and the Thai 
government cannot find a generic version of erlotinib with adequate quality to 
substitute the patented version. Therefore, CL policy is only implemented in reality 
for five drugs for three diseases: efavirenz, LPV/r, clopidogrel, docetaxel and 
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letrozole. These became available in state hospitals in January 2007, February 2008, 
September 2008, February 2010 and May 2010, respectively. 
  
3.5 The diseases and drugs under CL policy in Thailand 
The former government implemented a CL policy in medicines for treatment 
of three diseases: HIV/AIDS, cardiovascular disease, and cancer. These diseases 
were selected through need assessment based on national epidemiological data and 
disease problem projections. The need assessment was conducted by national 
experts from concerned governmental and academic sectors. The availability and 
quality of epidemiological data in Thailand is sufficient for public health policy 
planning. The MoPH has established a disease registry system to support 
epidemiology, service monitoring, and policy development. Here are examples of 
methods used to generate epidemiological data on non-communicable and 
communicable diseases in Thailand. 
For non-communicable disease, I give an example of cancers. Cancer 
registries in Thailand have been working for more than 20 years. The data from five 
registries of Chiang Mai, Lampang, Khonkaen, Bangkok, and Songkhla were used 
as the main sources for projection of cancer problems. Statistical modeling of the 
trend is needed to project cancer problems in the near future. A linear regression 
model was used when the trend was increasing and a logarithmic regression model 
was applied when it was a declining trend. Age-standardized incidence rates (ASR) 
for cancer sites were calculated. Expected cancer cases for each region were 
calculated based on the age specific incidence rates and the population in each 5-
year age group. The incidence rates in Chiang Mai and Lampang were used for 
estimating expected cancer cases in the northern region. Khonkaen was used to 
represent the Northeastern region. Bangkok was the representative of the Central 
region, and the Southern region was represented by Songkhla. All the cases were 
accumulated to estimate the expected number of cancer cases for the whole Thai 
Kingdom in future time periods.  
Methods to generate epidemiological data for communicable diseases, for 
example HIV, are more complicated than those for non-communicable ones. The 
HIV seroprevalence data are reliable in Thailand. However, HIV surveillance in 
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some target populations (such as MSM and IDUs) is not always available, and 
information from asymptomatics or those unaware of their HIV status is not always 
recorded as well. Given the limitations, the epidemiological data can only be 
determined through the available serosurveillance data in conjunction with other 
relevant information on levels of risk behaviors, protective behaviors and the 
magnitude of affected populations. The Asian Epidemic Model (AEM) was used to 
replicate the transmission dynamics of HIV in Asian settings. Parameters used in the 
AEM are based on comprehensive reviews, primarily surveys and research studies 
of population size estimates and behavioral trends: sexual risk behaviors, levels of 
condom use, injecting risk behaviors, level of sexually transmitted infections. The 
outputs of that process reasonably match the observed HIV surveillance trends. The 
AEM was continually used to produce the national HIV projections, for the National 
AIDS Plan including plan for the CL policy.   
 
A. Rationales for selecting two HIV/AIDS medicines:  
Since 2003, the accessibility to ARV drugs among patients has significantly 
improved when universal access to ARV drugs was implemented [113]. The 
government increased its national health budget in response to its commitment, but 
the budget was still insufficient to achieve the goal of universal access for the first 
line ARVs. In addition, the Department of Disease Control expected that in 2007, 
there were around 500,000 people living with HIV/AIDs, and at least around 10% 
(50,000 people) of them would develop drug resistance and require second-line 
ARVs [81]. If the patients having the drug resistance did not receive second-line 
ARVs, they would develop opportunistic infections of HIV/AIDS and die. These 
were deaths happening in the midst of an availability of effective treatments. The 
proposed expansion of the antiretroviral treatment (ART) program required 
additional policies to promote drug access, and CL policy was selected to promote 
the ARV drug access for efavirenz (the first line ARVs) and LPV/r (the second line 
ARVs).  
Efavirenz for treatment HIV/AIDS: Efavirenz is an effective drug for the 
first line ARV treatment. It is less toxic than nevirapine, which was used as the 
standard treatment before the grant of CL policy. Nevirapine was locally produced 
in Thailand within triple based ARV formula with the trade name GPO-VIR®. 
However, around 20% of patients receiving GPO-VIR® developed adverse drug 
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events, which sometimes could be life threatening. This raised concerns among 
healthcare specialists and health policy makers. Empirical evidence revealed that 
nevirapine could cause serious and life-threatening adverse drug reactions, such as 
Toxic Epidermal Necrolysis (TEN), Steven Johnson Syndrome (SJS), and severe 
hepatic toxicity [114-117]. These serious adverse drug reactions affected the 
patients’ quality of life and also increased the costs for treatment of co-morbidity 
from nevirapine adverse effects. Substitution by a less toxic alternative, such as 
efavirenz recommended in the treatment regimen, but it was reserved only for 
patients having a severe adverse drug reaction because of its higher cost [118].  
Due to the high price of efavirenz, all new HIV/AIDS patients had to be 
treated by the more toxic Nevirapine as their first line ARV treatment. Only patients 
developed severe adverse events; they would be switched to efavirenz of which the 
price is more than twice of GPO-VIR®. In 2006, the Thai Ministry of Public Health 
(MoPH) granted the CL policy for efavirenz, patented by Merck Sharp & Dohme 
under the trade name of Stocrin®. As a result, there were no need to subject the new 
HIV/AIDS patients with the more toxic regimen of nevirapine. With the CL, the 
monthly price of efavirenz dropped from 1,400 Baht (US$43) to 650 Baht (US$20) 
per patient [98]. This allowed more than 20,000 new patients per year to be treated 
by the efavirenz regimen [81].  
Lopinavir and ritonavir combination (LPV/r) for treatment of 
HIV/AIDS: One of effective second-line ARVs is the Lopinavir and Ritonavir 
combination (LPV/r), patented by Abbott Laboratories Limited. LPV/r is a Protease 
Inhibitor (PI), which is commonly used in many countries as a second-line treatment 
for HIV/AIDS patients who have developed resistance to first-line ARV treatment. 
A study also found that patients on indinavir and ritonavir combination (IDV/r) were 
less likely to achieve viral suppression compared to patients on LPV/r [119]. 
However, due to the high price of LPV/r, it was recommended that patients with 
first-line drug resistance be treated with the indinavir/ritonavir combination (IDV/r), 
rather than LPV/r.  LPV/r could only be provided to patients who could not tolerate 
the toxicity of IDV/r [120].     
The price of LPV/r was unaffordable by the Thai government to provide the 
drugs for all patients in need. The monthly cost for the patented LPV/r was 6,000 
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Baht (US$186) approximately in 2007, and this meant 72,000 Baht (US$2,235) per 
year per patient. The treatment cost required for 50,000 patients would be 3,600 
million Baht (US$112 million). This was more than 100 percent of the health care 
budget for ARVs treatment in 2007 [81]. The high burden of the second line ARVs 
costs was the main factor hindering the intention to achieve the universal access to 
ARV treatment. In 2007, the Thai government were able to support less than 2,000 
patients who had developed resistance to the first-line regimen [81]. With the CL, 
the Thai government expected the price of drug to drop at least to 20% of the current 
price, which would allow the government to save more than 8,000 lives [98].  
 
 
B. Rationales for selecting one cardiovascular medicine 
Cardiovascular disease can be classified into several types of sub-diseases: 
cerebrovascular event (stroke), and ischemic heart event (angina and myocardial 
infarction). In East Asian, stroke causes more deaths than other subtypes of 
cardiovascular diseases [121]. According to the Thai Ministry of Public Heath, more 
than 50,000 people died from stroke annually [122].  Stroke claimed approximately 
50,000 lives annually. In addition, it was estimated that there were more than 
250,000 new cases of stroke recorded each year [123].   
 
Clopidogrel for preventing cardiovascular event: Clopidogrel is an 
antiplatelet drug in the Thienopyridine drug group. It can be used as an alternative, 
or in addition, to aspirin for secondary prevention of stroke [124]. It has also been 
found that the use of clopidogrel for secondary prevention in cerebrovascular 
patients could reduce the death rate of stroke compared to aspirin [124]. The 
National Health Security Office found that the high cost of clopidogrel was an 
obstacle to access to this drug, as only the patients who could afford to purchase this 
drug out-of-pocket or those under the Civil Servant Medical Benefit Scheme 
(CSMBS), could have access to clopidogrel [81]. Therefore, the Thai government 
has granted CL policy for clopidogrel, patented by Sanofi Synthelabo under the 
trade name of Plavix®. Due to the CL implementation, the price of generic drugs 
was 7 Baht (US$0.2), while that of patented drug was 70 Baht, representing a price 
differential of 10 times [98].  
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C. Rationales for selecting two anti-cancer medicines 
Cancer disease is one of the top life-threatening diseases in Thailand for over 
a decade. There were more than 30,000 deaths annually, and more than 100,000 new 
cancer cases each year [83]. Therefore, cancer was no less serious than the 
HIV/AIDS and cardiovascular disease. The leading types of cancer in Thailand are 
lung and breast cancer. There are many new chemotherapeutic and targeted 
therapies that have been developed in the last decade. Most of the patented new anti-
cancer drugs were unaffordable by the government [83]. Many of these drugs, 
therefore, were not covered by the National Health Insurance system. Patients had to 
pay their expenses out of pocket. Some of them have to stop taking the drugs 
because catastrophic illnesses caused bankrupt their family [83].  
 
Letrozole for treatment breast cancer: Letrozole is a hormone therapy 
drug, which inhibits the production of estrogen that is required for the growth of 
breast cancer cells. The drug is used for the treatment of early or advance stage of 
breast cancer that is hormone receptor-positive, or unknown receptor status in 
postmenopausal women. A study of health benefits of letrozole as the first-line 
hormone therapy for breast cancer compared to tamoxifen reported higher health 
benefits in patients receiving letrozole [125]. The Thai government issued CL policy 
on letrozole, patented by Novartis under the trade name of Femara®. The price of 2.5 
mg tablet of the patented version was 230 Baht (US$7), while that of the generic 
versions were 6-7 Baht (US$0.2), representing a difference in price at 30 times [98]. 
 
Docetaxel for treatment of lung cancer: Docetaxel is a chemotherapy drug 
used for the treatment of several types of cancers such as breast, lung, gastric and 
prostate cancers.  Among several indications of treatment by docetaxel, lung cancer 
has the highest number of patients compared to other types of cancers. For the lung 
cancer treatment, docetaxel is recommended for the stage IV non-small cell lung 
cancer (NSCLC), including Stage IIIB NSCLC with malignant pleural effusion 
and/or malignant pericardial effusion with performance status of 0 or 1 with 
recurrent or relapse after platinum-based chemotherapy. The Thai government has 
granted CL policy for docetaxel, patented by Sanofi-Aventis under the trade name of 
Taxotere®. Under the CL policy, the price of 80 mg injection is 25,000 Baht (US$ 
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776) for Taxotere®, while the generic equivalents cost 4,000 Baht, (US$124) 
representing a price differential of 6 times [98]. 
 
3.6 Conclusions 
 
This study focuses on the CL policy in Thailand. Because the CL policy has 
been implemented to improve access to essential drugs for treatment of 
communicable (HIV/AIDS) as well as non-communicable diseases (cardiovascular 
disease and cancer), Thailand is the only LMIC which has implemented the policy 
for a wide range of medicines. In addition, because the former government decided 
to issue the CL policy in 2006 and the policy is still actively implemented in the 
country, the eight-year CL experience is sufficiently long to analyse the policy 
performance and draw concrete insights for decision making and implementation of 
drug policy, focusing on CL policy. Therefore, the policy insights derived from the 
experiences of the Thai former government were used to develop and strengthen the 
framework.   
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Chapter 4: Study methods   
 
4.1 Overview of methods 
This section gives an overview of the research methodologies. As mentioned 
in Chapter 1, the aim of this study is to develop a framework to aid decision-making 
and implementation of drug policy, focusing on CL policy. This study is not a policy 
process analysis, but focuses on specific elements, which are essential to the policy 
framework. There are four objectives to achieve the overall aim. For objective 1, a 
framework for decision-making and implementation was developed. The findings 
from objective 1 were strengthened by insights from experiences of CL in Thailand 
in subsequent objectives. In objective 2, comparative cost savings were estimated 
across different types of drugs. The findings were used to help identify key 
parameters to incorporate into the criteria for drug selection within the decision-
making process. In objective 3, the performance of the Thai government on drug 
procurement, substitution of generic drugs for patented versions, and drug access 
improvements were evaluated over the eight years of CL policy. The findings from 
this evaluation were used to help identify strategies for improving policy 
performance during the implementation process. In objective 4, an analysis of the 
applicability of the framework in the Thai context was undertaken through 
stakeholder interviews, document analyses, and observations. Figure 4.1 presents 
links between the four thesis objectives. 
 
       Figure 4. 1 Conceptual framework 
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Objective 1: To develop a preliminary framework for CL policy 
Data collection: Information from the literature was used to develop a 
preliminary framework to guide the decision-making and implementation of drug 
policy, focusing on CL policy. A document review was conducted to identify key 
elements affecting the CL policy process. Several sources of information, including 
official documents, guidelines and handbooks published by inter-governmental 
organisations (the WTO, WHO and partners) were included. Such documents were 
included because they contain generic policy elements and recommendations, which 
can be commonly applied in any country. 
Data analysis: A well-known analytical model, the policy triangle 
developed by Walt and Gilson (1994), was initially used to guide the identification 
of policy elements and conceptualisation of the framework. This model was selected 
because it has been commonly used to study policy in the context of LMICs [126]. 
The policy triangle model presents a greatly simplified approach to explore a 
complex set of inter-relationships among four elements; policy content, context, 
actors and process [127]. Policy content refers to the substance of policy: what the 
policy aims to achieve, and the conditions required to implement the policy process. 
Actors refer to the stakeholders involved in the policy. Context refers to the factors, 
which influence the process of decision making and implementation. Process refers 
to the stages associated with developing and implementing policy and also 
interactions between them [128]. I analysed relevant documents to identify the key 
elements in the CL policy process and the role each element played in the process.  
 
Objective 2: To estimate lifetime treatment costs savings  
Data collection: Secondary data were used to analyse implications of 
deciding to issue CL policy for different types of drugs. The implications were 
evaluated in terms of comparative lifetime treatment costs for patients receiving the 
five CL drug compared with the comparator recommended by Thai clinical practice 
guidelines (CPGs). Secondary data parameters used to estimate the lifetime 
treatment costs were comparative treatment effects and health care costs. Treatment 
effect parameters were obtained from published clinical studies or meta-analysis 
literature where available. Treatment costs consisted of drug costs and health care 
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services costs for the treatment of HIV/AIDS, cardiovascular disease, and cancer 
and related complications. Costs of drugs were estimated from the mean drug price 
per dose multiplied by the mean daily dose per person as recommended by the Thai 
CPGs. Other treatment costs (disease complications and adverse drug effects) were 
retrieved from cost studies in Thailand. As mentioned in Chapter 3, although the 
Thai government announced seven drugs to be included under CL policy, the policy 
was only implemented for five drugs (efavirenz, LPV/r, clopidogrel, letrozole and 
docetaxel). Therefore, I analysed the lifetime cost savings only for the five 
medicines in question. The timeframe of analysis was a patients’ lifetime after 
receiving the drug under CL policy. 
Data analysis: State transition ("Markov”) models were constructed to 
calculate the lifetime costs of patients using such drugs. The Markov model was 
employed because it can reflect the continuing risk of disease progression as the 
common characteristic of many chronic conditions [129] including HIV/AIDS, 
cardiovascular disease and cancer. For each of the CL drugs, I used factual and 
counter-factual scenarios to evaluate policy implications [130]. I compared two 
treatment options suggested in the Thai CPGs before CL (using alternative 
treatments prior to CL as counter-factual of without CL scenarios) and after CL 
(using CL drugs as factual scenarios). The individual lifetime cost saving (at the 
average age of patients in each disease) was multiplied by the total number of 
patients who accessed the drugs in order to estimate the cost saving. Identifying total 
cost savings by comparing different types of drugs helped identify parameters to 
guide the selection of the most beneficial drug. This policy insight could develop a 
decision-making framework and drug selection criteria for CL policy. 
Objective 3: To analyse performance of the Thai government  
Data collection: Retrospective data were used to analyse the performance of 
authorised agencies in implementing Thai CL policy. In the analysis, performance 
was classified into three sections; drug procurement, drug substitution, and drug 
access. All data were obtained from government agencies: the Government 
Pharmaceutical Organization (GPO) as the main procurement agency under CL; the 
Health Insurance Systems Research Office (HISRO) as the research institute which 
monitors CSMBS scheme; the National Health Security Office (NHSO) of UC 
scheme and Social Security Office (SSO) of SSS scheme. For the same reason as the 
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previous objective, this objective analyses data for the five medicines actually 
licensed under CL (efavirenz, LPV/r, clopidogrel, letrozole and docetaxel) in order 
to evaluate the Thai government performance in implementing CL. The timeframe 
of the analysis was eight years of policy implementation from implementation (in 
2007) until 2014. 
Data analysis: The policy implications were evaluated by using factual and 
counter-factual scenarios [130]. Policy performance was evaluated in terms of an 
achievement in the three implementation areas of CL policy. Where policy 
objectives were not achieved, I evaluated the implications of such defective 
performance or unanticipated results by comparing actual performance (as factual 
scenarios) with full performance (as counter-factual scenarios). First, the Thai 
government’s performance in drug procurement was analysed: (i) whether there was 
a sufficient supply of generic drugs under CL policy to meet the national demand, 
and (ii) the implications of an incomplete supply of a drug occurred, where this 
occurred. Second, I analysed the Thai government’s performance in promoting 
generic drug substitution: (i) whether patented drugs were fully substituted by its 
generic version, and (ii) the implications of incomplete substitution, where this 
occurred. Third, I analysed the Thai government’s performance in promoting drug 
access among patients: (i) whether the numbers of patients who had access to the 
drugs reached prior expectations; (ii) the implications of incomplete access where 
this occurred. The findings were useful to identify the magnitude of implications 
from defective performance or unanticipated results and prioritise areas of policy 
implementation to be improved in cases of CL. These insights were employed to 
strengthen the content of the CL policy framework. 
 
Objective 4: To assess applicability of the framework in Thailand 
 
Data collection: Document analysis, semi-structured interviews, and 
observations were conducted to assess the applicability of the framework in 
Thailand. For semi-structured interviews, five groups of Thai stakeholders were 
interviewed: (i) government sectors, (ii) academics, (iii) non-profit organisations 
(NGOs), (iv) the private sector and (v) health care professionals. Interview 
respondents were purposely selected according to their roles within the CL policy 
decision and implementation process. Stakeholders were identified from a 
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combination of secondary sources (e.g. meeting reports), and a snowball approach. 
Using the snowball technique, preliminary interviews with stakeholders helped to 
identify further key informants for inclusion. I continued to collect data until I was 
confident that all relevant contacts had been interviewed. New interviewees were 
included in the sample until nothing new was being generated or the information 
came to the point called ‘saturation’. The interviews took 30 minutes for each 
informant and were held between September 2014 and March 2015. During the 
fieldwork, I observed four meetings concerning the topic of access to essential 
medicines in Thailand. The observations were conducted between September 2014 
and July 2015, using observational guides. For this objective, qualitative data was 
obtained for all seven medicines (not the eventual five medicines as in objectives 2 
and 3), because qualitative information on all medicines is beneficial in generating 
lessons learnt for identifying policy elements.  
  
Data analysis: Applicability was assessed in terms of the consistency between 
the initial framework developed in objective 1 and practical matters obtained from 
the real case of Thai CLs. The interviews were conducted and analysed in Thai 
language. The information was coded in order to sort data and generate inputs for 
the thematic analysis process. The codes were annotated by a respondent number 
and their affiliations to government sectors (GS), academics (AS), NGOs (NS), 
private sectors (PS), and health professionals (HS). Information under the codes was 
analysed by searching for patterns of relationship and seeking explanations for these 
factors within the data. Information obtained from the informants was analysed to 
gain insights into key elements that lead CL into policy decision and 
implementation. 
 
4.2 Quality control of research  
 
Mixed methods, which integrate quantitative and qualitative approaches, were 
employed in this study. The purpose was to extend understanding of the quantitative and 
qualitative matters of the key elements in the framework, as well as to strengthen the 
findings and recommendations [131] [132]. In the quantitative parts, I validated the 
findings by comparing with previous studies and/or verified the results in expert panel 
meetings. In the qualitative parts, a triangulation approach was used in order to 
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enhance the quality and credibility of findings, by comparing information obtained from 
various document sources and interviews. Moreover, I combined findings obtained 
from various methods of these three objectives in order to broaden and deepen 
understanding and the study conclusions. When results generated from different 
sources and methods converged and agreed it enhanced the quality of findings and 
interpretations. When results were not consistent, I explored further to understand the 
reason for the inconsistencies. 
I adopted other common approaches to improve the quality of investigation 
[133]. The study quality was controlled by: considering the validity and reliability of 
data sources, key informants and documents; illustrating methods of data collection 
and analysis; and incorporating a wide range of different perspectives. In addition, I 
embedded verification mechanisms such as expert panel meetings and stakeholder 
consultations. The study findings were presented through a series of stakeholder 
meetings: three domestic meetings and one international conference, with the aim of 
validating findings with views from different stakeholders, including decision-
makers, policy elites, academics, NGOs, health professionals and representatives 
from patient groups. 
 
4.3 Ethical considerations 
Key informants participated in this study on a voluntary basis. I sent them an 
invitation letter with the information on the aims, objectives, methods and expected 
benefits of the research, as well as the outline of interview questions in advance. 
Those who agreed to take part were informed about their rights to refuse to answer 
any particular questions or to leave the study at any time. Every interviewee was 
asked to sign a consent form before the interview started. The thesis received ethics 
approval from Thailand's Ministry of Public Health on 13th August 2014 and the 
London School and Tropical Medicine's Ethics Committee on 8th September 2014. 
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Chapter 5: A preliminary framework to aid decision-
making and implementation of drug policy, focusing on 
CL policy.   
 
5.1 Introduction 
Based on the literature review in Chapter 2, few LMICs have made use of CL 
policy. One possible explanation is that policy makers in many LMICs are concerned 
about negative consequences resulting from the policy, and are uncertain about effective 
strategies to avoid these. There is value in developing aframework for CL policy. This 
framework should suggest elements and strategies that could be beneficial to LMIC 
policymakers who expect to use CL in the future. In this thesis, an initial framework 
was developed by conducting a review of literature published by inter-governmental 
organisations to obtain a set of common elements affecting the CL policy process. The 
identified common elements were used as a starting point for developing a framework 
for CL policy in Thailand. Policy elements indicated in this chapter were strengthened 
by experiences of Thai CLs in the following chapters. 
The objective of this chapter is to develop a preliminary framework to aid 
decision-making and implementation of drug policy, focusing on CL policy. To develop 
the preliminary framework, I conducted a literature review in order to obtain the set of 
common policy elements affecting the process of decision-making and implementation 
of the policy. Literature such as standard practices, guidelines and policy documents, 
was primarily obtained from site resources of the World Trade Organization (WTO) and 
the World Health Organization (WHO). In addition, an analytical model for analysing 
public health policy was employed as guidance for classifying and conceptualising 
policy elements in a systematic way, in order to create a preliminary framework of CL 
policy. The details of review and the policy analysis model used for guiding the 
development of CL policy are mentioned below.         
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5.2 Scope of the review 
A literature review was conducted with the aim of identifying key elements 
affecting CL policy processes. Using the site resources of the WHO and WTO, the 
search terms were “compulsory licensing” or “non-voluntary license” or “government 
use license” in different combinations. The document review included only literature 
from International organizations (the WHO and WTO) and excluded studies from 
NGOs and academic research. The reason was that literature of NGOs and academics 
provided recommendations which were specific to a certain group of countries or 
interests, while the literature from the WHO and WTO contained general 
recommendations, which took into account the circumstances of a wide range of 
countries. In addition, the main objective of literature from the inter-governmental 
organizations is to advise countries. Therefore, the recommendations or advisories from 
these organizations were suitably helpful to be employed for developing the preliminary 
framework. The search period was from 1995 (the introduction of TRIPS) to 30 October 
2015. Literature was included in the analysis when it met the inclusion criteria as 
follows: official policy articles, standard practices or guidelines, published by inter-
governmental organisations, or highlighted issues reflecting global perspectives on 
TRIPS agreement on public health and access to medicines. 
The database search gave 590 references (Figure 5.1). 531 papers were screened, 
after excluding 26 non-English articles and 33 duplicates. After title and abstract 
review, 505 references were excluded because they were news or conference meeting 
articles; not relevant to policy guidelines, regulation, or standard practices; not relevant 
to medicine products; published by non-intergovernmental organisations; context-
specific literature; or not available in full report. Full-text reviews were completed for 
26 references. A total of 18 references were excluded; 8 references were not standard 
practices or guidelines, but rather technical reports, and 10 references mentioned the 
TRIPS agreement as a side issue. Therefore, 8 papers were included: 1 papers published 
by the World Health Organization (WHO), 2 papers published by World Bank, 2 papers 
published by the United Nations Development Program (UNDP), 1 paper published by 
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the United Nations Conference on Trade and Development (UNCTAD), and 2 paper 
published by the South Centre. I summarise findings of literature in table 5.1. 
 
Figure 5. 1 Systematic review flowchart 
 
 
Table 5.1: List of literature used to develop the preliminary framework 
 
Titles Contents 
1. Title: Good Practice Guide: 
Improving Access to 
Treatment by Utilizing Public 
Health Flexibilities in the 
WTO TRIPS Agreement. 
 
The guide was published by the United Nations 
Development Program (UNDP). The guide analyses 
issues relevant to the TRIPS flexibilities in public health 
and provides examples where and how they have been 
used by national governments. In addition, it provides 
various recommendation of the national practices about 
how to use the public health flexibilities and mitigate 
efforts to limit their effect. 
2. Title: Compulsory licensing 
for public health: a guide and 
model documents for 
implementation of the Doha 
Declaration Paragraph 6 
Decision.  
 
 
The paper was published by the World Bank. This paper 
provides model legal documents to assist countries in 
implementing the Doha Declaration. This is a 
convenient starting point for implementation of the 
Paragraph 6 Decision. The documents include the 
notification by developing country members to council 
for TRIPS of intention to use the policy as importer; the 
notification of importation by least-developed country 
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Titles Contents 
member, and developing country member; the 
notification to right holder of issuance of CL, the model 
provisions for the legislative or regulatory amendments 
for exporting and importing countries.  
3. Title: Using Intellectual 
Property Rights to Stimulate 
Pharmaceutical Production in 
Developing Countries: A 
Reference Guide. 
The paper was published by the United Nations 
Conference on Trade and Development (UNCTAD), 
Division on Investment and Enterprise (DIAE). The 
guide aims to assist developing countries, and least 
developed countries. It is an important tool for guiding 
the countries to establish domestic IP regimes that 
facilitate increased access to affordable medicines 
through a variety of policy tools, focusing on the 
flexibilities provided under the Agreement on TRIPS. 
The guide is an important tool for training activities for 
stakeholders, in an effort to build capacities for the 
creation of domestic legal frameworks conducive to the 
promotion of drug access. 
4. Title: Pharmaceutical 
innovation, incremental 
patenting and compulsory 
licensing.  
The paper was published by the South Center. The study 
covers issues of pharmaceutical patents, including patent 
proliferation and patentability standards for drug 
innovation. The study confirmed many available drugs 
would not be deemed patentable if more rigorous 
standards of patentability were applied. The application 
of well-defined patentability standards could help 
governments avoid granting CL.  
5. Title: Remuneration 
guidelines for non-voluntary 
use of a patent on medical 
technologies.  
The paper was published by the UNDP. This paper 
addresses the following issues: WTO provisions 
regarding remuneration for non-voluntary use of patents; 
experience of royalty setting in voluntary and non-
voluntary settings; the policy framework for setting 
royalties on medicines in developing countries; and 
proposed royalty guideline frameworks, which will be 
desirable for countries to adopt guidelines to enhance 
transparency and predictability.  
6. Title: Battling HIV/AIDS: 
A Decision Maker's Guide to 
the Procurement of Medicines 
and Related Supplies  
 
The paper was published by the World Bank. This Guide 
on procurement of HIV/AIDS medicines and supplies is 
meant as a guide for implementing agencies and donors. 
The guide sets out principles and guidance to ensure that 
such procurements will fit within an overall well-
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Titles Contents 
 functioning supply management system such as product 
selection, quality assurance, and countries’ intellectual 
property right systems. 
7. Title: Regional framework 
for action on access to 
essential medicines in the 
Western Pacific (2011–2016). 
The paper was published by the WHO regional office for 
the Western Pacific. The paper was endorsed by 
Member States to provide guidance for developing 
actions to improve access to essential medicines and to 
strengthen pharmaceutical systems. The Framework for 
Action provides strategic direction and guidance for 
WHO collaboration with Member States.  
8. Title: Utilizing TRIPS 
flexibilities for public health 
protection through South-
South regional frameworks.  
The paper was published by the South Center. This 
paper provides strategies for developing countries to 
overcome national constraints in the use of TRIPS 
flexibilities. This study provides a conceptual as well as 
strategic basis as the first step for further thinking and 
decision-making on how effectively to use TRIPS 
flexibilities for public health purposes through regional 
South-South mechanisms and cooperation. 
 
According to the literature summarised in Table 1, I found all documents were 
beneficial to be used for developing the framework, but some issues were omitted from 
the literature. The first three papers: the good practice guide published by the UNDP, 
the model document published by the World Bank, and the reference guide published 
by UNCTAD, were used as the main references to identify common elements for policy 
makers to consider procedures to obtain TRIPs flexibilities and develop CL policy. In 
addition, the paper number four published by the South Center gave recommendations 
in areas of drug patent, and key issues to be considered before initiating or in parallel to 
obtaining CL policy. The paper number five published by the UNDP provided guidance 
to determine adequate and reasonable remuneration of patent use. Although these five 
papers well addressed policy elements especially in the stage of policy decision, the 
issues seem to vary across the countries and need to be further explored through 
empirical research. In addition, relevant issues in the stage of policy implementation, 
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such as procurement, regulatory system, supply chain management and stakeholder 
participation, were omitted from the literature. 
The last three papers addressed policy elements throughout the process of 
decision making and implementation. The paper number six published by the World 
Bank addressed key elements for procurement of medicines and related supplies of 
HIV/AIDS treatment. However, the paper focused the procurement of health goods to 
only the HIV/AIDS context. The paper number seven: the WHO’s regional framework 
and the paper number eight: the south center’s regional framework, suggested policy 
elements to promote access to essential medicines in the context of collaboration 
between the Member States. As both papers are regional frameworks, the 
recommendations are more practical than other six papers. However, they do not 
separate actions for countries. In addition, the frameworks pinpointed only issues that 
were the key problems at the particular time. These papers do not provide a framework 
of policy action from A to Z until the completion of policy implementation.  
In conclusion, it is clear that countries vary enormously with respect to their 
political and economic situations, legal frameworks, public health systems and drug 
policy objectives. The authorities of each country have to prepare their own solution 
that is right for their situation, because the actual implementation will take place within 
the existing regulatory policy, health system capacity and practice. Therefore, the 
preliminary framework needs to be further explored and strengthened by information 
and knowledge derived from experiences of the Thai former government, in order to 
incorporate practical issues based on the specific context of Thailand. 
5.3 Analytical model 
The model of the “policy triangle” was used in this study. The purpose of the 
policy triangle is to help in systematically categorizing and comprehensively listing the 
elements of concern in CL policy that need to be considered by policy makers[128]. The 
four sections of the policy triangle are: policy content, context, actors and process. This 
policy triangle  model provides a systematic approach for thinking about elements of the 
policy process to be included in the CL policy framework [128]. For this study, I made 
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a framework containing the four sections (Figure 5.2). Details of each section are 
explained below.   
 
Figure 5. 2 The framework developed from the policy triangle approach 
 
Regarding the four sections, policy content refers to substances, which details its 
component parts, of the policy in question [128]. In this study, policy content focused 
on the policy aims requiring a set of concrete activities and supportive instruments. The 
supportive instruments included, for instance, policy legislation, operational guidelines, 
administrative systems, and databases of relevant information. Therefore, in terms of 
the framework, activities and supportive instruments are components of the policy 
contents that make it possible to implement a policy.  
The contexts were classified into four factors affecting the policy process: (i) 
situational factors, which are transient and impermanent conditions, (ii) structural 
factors, which are relatively unchangeable elements of society, (iii) cultural factors, the 
social values of stakeholder groups, and (iv) environmental factors, factors beyond the 
boundaries of a political domestic system, such as the role of transnational companies 
and international agreements [134].  
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As CL is a public policy, relevant actors involved in the policy could come from 
government sectors as well as from for-profit and not-for-profit organisations at national 
and international levels. Various types of interested groups in the public sector have 
different roles, resources, capacities and strategies to involve in or influence the policy 
[128]. In this study, I classified actor/stakeholders into three groups: government, non-
government and international actors.  
The policy processes were divided into four sections: agenda setting, 
formulation, implementation and monitoring. Agenda setting refers to a stage where 
public policy problems get the attention of decision-makers, leading to a selection of 
policies to solve the problem. In the formulation stage, policy elite bodies design and 
enact the policy. Implementation refers to a stage where governments operate the 
designed policy in practice; and in the monitoring stage the policy implications are 
analysed [135]. Policy analysts criticise this conception of the policy process as 
composed of linear and discrete stages, arguing that this does not reflect reality [136]. 
However, I decided to use the linear stages because it helped me to clearly situate 
influencing elements in each of the discrete stages in the policy framework.  
 
5.4 Framework development 
According to the framework, there are four stages of the policy process: agenda 
setting, policy formulation, implementation and monitoring. Each stage contains four 
elements: contexts, policy contents (activities and supportive instruments), and actors; 
therefore, sixteen themes were analysed. A deductive approach was used to develop the 
framework to aid decision-making and implementation of drug policy, focusing on CL 
policy. The retrieved documents were reviewed, conceptualised and interpreted 
according to the sixteen themes of analysis. Pieces of information relevant to the 
defined themes were selected and arranged to link with the framework. Finally, 
information under particular headings of the thematic topics were narrated as key policy 
elements in each of the discrete stages of policy process.  
 
 73 
 
 
 
The framework for agenda setting and formulation 
Results within each process are presented under thematic headings: contexts (C), 
activities and supportive instruments under each activity (A) and actors or players (P).  
Figure 5.3 shows the eleven key elements of CL policy process in the stages of agenda 
setting and policy formulation. Agenda setting is an initial stage in the policy process 
when a list of issues or problems move an idea onto an agenda, while policy 
formulation is the next stage when policymakers opt for a particular policy (CL policy) 
over other alternative measures.  
The first stage in policy process is the agenda setting. Six elements were 
identified, including:  
• One contextual element: the combination of unmet public health needs due to 
drug patent barriers and an availability of TRIPS flexibilities (C1.1);  
• Four activities: identification of unaffordable drugs which are essential for the 
public health system (A1.1); consideration of patent opposition measures 
(A1.2); consideration of price negotiation measures (A1.3); and consideration of 
TRIPS flexibilities (A1.4);  
• One set of actors: Multi-ministry and patented firms (P1). 
The second stage in the policy process is the policy formulation. Five common 
elements were identified, including:  
• One contextual element: common interpretation of the TRIPS flexibilities 
(C2.1);  
• Three activities: development of CL policy proposal (A2.1); identification of 
generic drug sources (A2.2); adoption of streamlined procedures to implement 
the CL policy (A2.3). 
• One set of actors: Multi-ministry and patented firms (P2).  
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Figure 5. 3 The preliminary framework for agenda setting and policy formulation 
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5.4.1 Key elements in agenda setting  
 
Context of the agenda setting  
 
The combination of unmet public health needs due to drug patent barriers 
and an availability of TRIPS flexibilities (C1.1): An unmet public health need due to 
poor access to patented essential medicines is likely to be the main situational context 
required for agenda setting. Unmet public health needs can prompt society and 
governments to address the issue of unaffordable drugs due to drug patent barriers. The 
growing disease burden leads to a growing need for essential medicines, which in turn 
requires sufficiently large budgets to meet that need. To meet the increasing need, 
countries have to ensure efficient and reasonable use of the resources available to the 
public health system and/or patients [137]. There are several solutions to the problem of 
unmet public health needs. For example, TRIPS flexibilities are a key policy solution to 
where patent barriers limit access to essential drugs. The UNDP recommends that 
countries should adopt a robust set of remedial TRIPS flexibilities if barriers to access 
to medicines arise [24]. 
 
Contents of agenda setting process 
 
Identification of unaffordable drugs (A1.1): The first activity required at this 
stage is to identify areas of unmet public health need. It is suggested that transparent 
processes and evidence-based methodologies are required to identify areas of public 
health need and to select essential but unaffordable drugs [137]. According to WHO 
recommendations, many essential factors are considered, such as the prevalence of 
disease, demographic patterns, health care facilities, experiences of local staff, financial 
resources, and environmental factors. The WHO Expert Committee on the Selection and 
Use of Essential Medicines prefers drugs that have adequate and concrete evidence on 
safety and efficacy in using a diversity of health care settings  [138]. However, the 
decision-making becomes more complex when unaffordable medicines are needed.  
 76 
 
Key elements to support this activity: there are additional instruments, which are 
required to identify and prioritise unaffordable drugs. Supportive instruments for 
identifying unaffordable but essential drugs include need assessment systems for 
identifying type and quantity of drugs that are required [139]. Important variables to 
quantify and prioritise needs include the size of the affected population, the social and 
economic consequences of the disease, and the financial resources required to meet the 
need [140]. There should be an accurate and transparent system for identifying 
unaffordable drugs. This is because underestimates may deprive some patients of 
treatments. Overestimations may waste budgets and resources, for example if unused 
drugs expire, or diagnostic and treatment protocols change [140]. Therefore, careful 
judgement is necessary, and common methods have been published elsewhere [141, 
142].  Quantified needs could be prioritized by predetermined criteria developed from 
any existing guidelines of national drug programs and expertise, in order to achieve the 
best drug selection for national public health needs [140].  
After identifying unaffordable drugs, policy makers need to consider strategies to 
overcome patent barriers to these medicines. There are several alternatives, which WTO 
country members may use to promote drug access such as patent opposition, price 
negotiation, and TRIPS flexibilities.  Patent oppositions should resolve problems where 
drugs are unaffordable due to patent barriers. This measure can exclude unqualified 
patents of pharmaceuticals from obtaining the patent protection that prevents more 
affordable generic versions of the drugs to come onto the market. Second, the 
government or authorised sectors may negotiate on price, if the drugs are protected by a 
verified patent, in order to obtain a more affordable price. Finally, TRIPS flexibilities 
are an alternative measure to consider because they also indicated as one of the key 
measures to secure access to affordable drugs. Measures to overcome patent barriers to 
access to pharmaceutical products are highlighted below as the next step for 
policymakers [24, 137, 140]. 
Consideration for patent opposition (A1.2): Depending on contents in a 
national body of law, an invention is legally patentable if it meets the predetermined 
legal conditions to be granted a patent protection. Countries should use rigorous 
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methods to assess the novelty and inventiveness of drug’s patent applications in order to 
ensure an acceptable quality and validity of drug patents and also diminish frivolous 
patents (such as patents on secondary features, different uses or therapeutic approaches 
of the same pharmaceutical substances) [143]. A verification of patent validity can be 
made through a pending patent application (called pre-grant opposition), or a granted 
patent (called post-grant opposition) [24]. This approach plays an important role in 
screening a particular drug before granting a patent. Authorised agencies should 
consider the patent status of unaffordable drugs, which are associated with an unmet 
public health need. If the drugs are not under patent protection, generic versions can be 
launched to promote competition and reduce the market price. However, if the drugs are 
in the process of patent application or already protected by a patent, a verification of the 
drug’s patent validity through pre-grant or post-grant opposition, respectively, should be 
considered [24].   
Key elements to support this activity: there are additional instruments, which are 
required to support the patent opposition of pharmaceutical products. Supportive 
instruments in this activity are patentability database and guidelines. National laws 
should include patent opposition as a legal administrative proceeding, which permits 
third parties to legally oppose or dispute the quality and validity of drug patent [143]. 
Therefore, it is important to ensure that information pertaining patent-status permits 
relevant stakeholders to effectively implement patent oppositions and TRIPS 
flexibilities. However, since patent oppositions in LMICs seem to be hindered by the 
lack of reliable pharmaceutical information systems [143], countries should pay more 
attention to developing these. In addition, it is suggested that countries should adopt 
rigorous criteria for patentability; implement guidelines for patent examination; offer 
liberal pre- and post-grant opposition proceedings [24]. Standard guidelines to examine 
patent applications have been developed by ICTSD, UNCTAD, and WHO [144].   
 Consideration for price negotiations (A1.3): Price negotiation is an effective 
measure used by procurement agencies to achieve affordable drug prices. It is suggested 
that countries should develop mechanisms that contribute to price reductions of patented 
drugs [137]: (1) Bulk purchasing is a direct contracting procurement strategy that 
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improves the public purchaser’s ability to negotiate lower prices depending on the 
magnitude of the procurement contract; (2) Price comparison is a measure that 
procurement organizations can use to improve their negotiating power (by collecting 
information of international drug prices based on prices at similar points in the drug 
supply chain); (3) Equity pricing is the concept that poor countries should pay less than 
rich countries in order to make drugs affordable to patients of all country income 
groups. Patent drug firms may lower their product’ price, but gain more sales volume to 
maintain their total business profits [140].    
 Key elements to support this activity: there are additional instruments, which are 
required to support the price negotiation system. Supportive instruments to facilitate 
authorised agencies in the activity of price negotiation are drugs price information 
systems and guidelines for price negotiation. Effective price negotiation requires an 
accurate and comprehensive information system, in order to maximise the bargaining 
power of procurement agencies. Purchasing agencies also require an information system 
that allows them to assess need and consider appropriate quantities of the drug to 
respond to that need, thus developing an effective procurement proposal for the bulk 
purchasing mechanism. In addition, information on the international price of each drug 
also plays an important role in international price comparison and equity pricing. It is 
suggested that authorised agencies should exchange information about regional drug 
prices and promote cross-country comparisons [137]. Collating such information could 
provide a valid benchmark of the lowest drug prices available worldwide. Several 
strategies to deal with the price of drugs are already mentioned elsewhere, for example 
the WHO guideline on country pharmaceutical pricing policies [89]. 
 Consideration for using TRIPS flexibilities (A1.4): TRIPS flexibilities should 
be another measure to meet the need for particular drugs. TRIPS flexibilities are 
indicated as one of the key measures to secure access to more affordable medicines 
[24]. This measure should be applied after the first two approaches mentioned above 
have been carefully considered, but have been unsuccessful to solve the unmet public 
health needs. The TRIPS flexibilities include three main measures: parallel imports 
(PIs), voluntary licensing (VL) and compulsory licensing (CL).  
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 Key elements to support this activity: there are additional instruments, which are 
required to support the use of TRIPS flexibilities. Supportive instruments for 
considering TRIPS flexibilities are policy guidelines and drug information systems. 
Policy guidelines under the TRIPS flexibilities have been published elsewhere [24, 
145]. This activity also requires a comprehensive information system, including 
information about patent status and sources of drugs for procurement through PI or CL. 
If the database is incomplete, the use of TRIPS flexibilities, such as CL, can be 
uncertain because procurement agencies cannot define sources of generic drugs and the 
patent status of the drug in question [143]. The main points of each measure are 
described as follows. 
1) Parallel import (PI) As mentioned in Chapter 2, PI allows countries to 
import a patented drug when the product has been marketed anywhere in the world by 
the patent holder or by another authorised party. The TRIPS Agreement and Doha 
Declaration acknowledge that nations have the freedom to implement parallel import 
[24]. However, three points should be borne in mind when PI is considered. First, drug 
sources are normally limited to PI because drug producers aim to satisfy only the 
demands of their domestic market. Second, the patent holders may react by increasing 
drug prices or curtailing drug supply where PI undercuts efforts to promote their local 
business. Third, some PI may not be directly sold and delivered by drug producers, but by 
wholesalers or middlemen, leading to potential quality issues. Therefore, drugs procured 
through PI may require adequate capacity for quality assurance [140, 145].  
2) Voluntary licensing (VL) is where a person or party uses the license of a 
patented medicine with the permission of the patent holder. The party must attempt to 
obtain a voluntary license from the patent owner on reasonable commercial terms and 
conditions [146]. Therefore, in order to grant VL, there must be an agreement between 
the patent owner and the patent users; the patent owner may have requirements in 
exchange for the patent use. For example, the patent owner may impose additional 
restrictions, such as what price the drug can be sold, where the patent users can sell the 
drug, and any other terms or conditions that the patent owner can insist on. Therefore, 
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before granting VL, the exchanges should be carefully considered whether they do not 
create new barriers to the drug access [147].  
3) Compulsory licensing (CL) is where a person or party uses the license of 
any patented medicine without permission of the patent holder. CL can be granted to 
remedy a variety of anticompetitive practices, to address a national emergency or other 
circumstances of extreme urgency, or for public non-commercial use (or government 
use), as mentioned in Chapter 2 [24]. Although common practice requires licensees to 
first request a VL from the patent owner, certain requirements are waived in order to 
hasten the process [148, 149]. It is noteworthy that most countries issuing CL policy 
have been faced with negative political impacts (Chapter 2). Therefore, authorised 
agencies should consider alternative measures before issuing CL: patent applications 
should be correctly scrutinised; drug price reduction, parallel import or voluntary 
licensing should be thoughtfully considered. After other alternative measures, CL policy 
may be applied when necessary [148].  
 
Actors in the stage of agenda setting   
Actors in the agenda setting (P1) should work as a multidisciplinary team. The 
agenda setting process should involve a wide range of stakeholders through a 
consultative procedure [137]. First, drugs may be selected by various groups of experts, 
including representatives of the national public health committee or council and the 
national drug formulary committee, including representatives of the ministry of public 
health, together with health specialists [140]. Second, the government may establish a 
committee for identifying alternative measures to promote access to the drugs in 
question. This process may require an expert body, as a broad-based committee 
including policy analysts and technical staff with appropriate knowledge and skills 
[140]. For example, the Ministry of Trade or equivalent should be involved in this 
process because they are regularly responsible for the intellectual property issues and 
TRIPS. The effective use of TRIPS flexibilities may require patent specialists to 
consider the right under any patent necessary to promote drug access [140, 145]. In 
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addition, national and international experts need to be identified to provide advice and 
information to support activities at the agenda setting stage [140].  
 
5.4.2 Key elements in policy formulation  
 
Context of policy formulation  
Common misconceptions of TRIPS flexibilities (C2.1): An important context 
for formulating the policy is the common interpretation of TRIPS flexibilities to 
safeguard public health interests through CL policy. The Doha Declaration affirms that 
“the TRIPS Agreement can and should be interpreted and implemented in a manner 
supportive to protecting public health and promoting access to medicines for all” [24]. 
However, there are a number of common misconceptions that may deter countries from 
using the policy. According to TRIPS Article 31, the use of CL is not restricted to 
situations of national emergency, but rather in the case of other circumstances of 
extreme urgency or “in cases of public non-commercial use” [24]. In addition, the Doha 
Declaration clarified that WTO members “have the right to determine what constitutes a 
national emergency or other circumstances of extreme urgency, it being understood that 
public health crises, including those relating to HIV/AIDS, tuberculosis, malaria, and 
other epidemics, can represent a national emergency or other circumstances of extreme 
urgency” [25]. To better clarify the statement, such situations exist in any number of 
public health crises, including, “but not restricted to”, HIV and AIDS, tuberculosis, and 
malaria [24]. Therefore, when a policy is formulated, the correct conception and 
interpretation by concerned stakeholders on the provision of TRIPS flexibilities is a 
contextual element that should be taken into account. 
 
Contents of CL policy formulation  
 
Development of a CL policy proposal (A2.1): The main objective in 
formulating the policy is to develop a policy proposal. For when developing a proposal, 
several points must be taken into account: grounds for the policy application, policy 
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authorities, scope, duration, remuneration and conditions of the CL implementation 
[24]. The details of each issue are explained below. 
1. Grounds for the policy application: Under the TRIPS Agreement and the 
Doha Declaration, members have the freedom to determine grounds for issuing a CL 
policy. It is important to highlight the fact that the right to grant such licenses does not 
only depend on a state of emergency or other circumstances of urgency, but also public 
non-commercial use. In particular, the public non-commercial use of a patented drug 
through government authorities, which is called the “government use of license”, may 
be determined in many ways. For example, the term “public” correspondingly refers to 
the purpose of use for the public benefits. In addition, the term “non-commercial” may 
be acknowledged as characterising the nature of the operation as “not-for-profit” use. It 
may also be referred to the purpose of the use, such as the drug supply to public 
institutes that do not function as commercial sectors [145]. 
2. Policy authorities: According to the TRIPS Agreement, WTO members have 
the freedom to designate an authority to grant CLs. The appropriate authorities to issue 
CL policy have to be clearly identified.  In most CL countries, the policy is granted by a 
governmental authority. The authorised agency should be provided with a reasoned 
justification, legal provision and clear grounds for the policy application. This must 
comply with restrictions under national law [148]. Authority to issue CL may also be 
conferred upon the courts, after lawsuits between the patent owner and the applicant for 
a license. It is worth noting that where CL is granted by government sectors, this could 
save time and resources because experts who are familiar with public health issues 
already involved in the process [145]. 
3. Policy scope and duration: According to the TRIPS Agreement, the policy 
scope and duration of CL policy should be restricted to the purpose for which the patent 
use was authorized. The policy should specify the scope and duration of the requested 
license, and CL may apply to all of the subject elements covered by a patent, or only to 
certain parts of a patent, or to certain uses of patented drugs. It is also suggested that 
authorised agencies should request the use of a patent for the full remaining term of the 
patent [148]. Therefore, in general, the duration to a license also should be terminated 
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when the situation, which leads to the grant of CL has ended and is unlikely to return 
[148]. In addition, national laws should be formulated to include a review mechanism, 
where both the patent holder and the patent user may submit requests for the 
discontinuation or continuation of the license use. Therefore, if during the CL period the 
patent owner succeeds in demonstrating that the situation leading to the grant of CL has 
ceased to exist, or is unlikely to reappear, the CL would have to be revoked [145].  
4. Policy conditions: Common practice is that the patent owner should be 
notified by the patent user as soon as reasonably practicable and should also be paid 
with an adequate remuneration. The government authority can propose an adequate 
level and kind of remuneration [150]. The common rule is that remuneration should be 
adequate for each CL case, taking into account the economic value of the authorization 
[150]. However, it may be reasonable to provide a relatively low rate of remuneration to 
the patent owner if a government uses the policy to secure affordable medicines in 
response to a public health problem [140]. Finally, the time of the payment, the basis on 
which remuneration as calculated, payment currency, the payee bank account, and other 
concerned details should be specified [148]. 
5. Operational strategies: The period of time required to formulate the policy 
should be as short as possible in order to expedite the process to satisfy the public health 
demand. However, according to TRIPS Article 31 (i and j), the legal validity of any 
policy decision concerning the authorization of CL by using a patent without permission 
from patent owners and any decision concerning the kind and level of royalty fee 
provided to the patent owner, can be subject to judicial or other independent reviews by 
a higher authority [148]. This means that the use of CL may be significantly delayed if 
the patent holder appeals the validity of the license used or the kind and level of 
remuneration arranged under the policy. For this reason, it is suggested that CL policy 
may be implemented even while appeal processes are pending [148]. 
Key elements to support this activity: there are additional supportive instruments 
for developing CL policy proposal. The supportive instruments are national laws 
incorporating TRIPS flexibilities. It is suggested that countries should include the 
public health safeguards of TRIPS in national IP laws and regulations [137]. In 
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addition, if the authorised agencies want to use the policy, but lack domestic production 
capacity, procurement authorities may request a foreign country to grant a CL for export 
[140]. Countries with the potential to export generic drugs have to include the CL for 
export into its laws. Therefore, legislations have to be in place both in exporting and 
importing countries. The World Bank provides notification models, which could be 
used by exporters and importers [151]. 
Identification of generic drug sources (A2.2): At the policy formulation stage, 
it is essential to identify the availability and quality of generic drug products. The 
authorised agency should identify sources of generic drugs and investigate whether drug 
manufacturers have sufficient capability to supply drugs under the expected demand. 
The authorised agency may identify sources of generic drugs from local producers or 
foreign manufacturers [24]. The WHO list of prequalified medicinal products 
(especially essential medicines for priority diseases) is a useful supporting tool for this, 
and details are explained in the next section. In addition to the WHO prequalification 
list, verification may be conducted through manufacturer certification provided by 
national drug regulatory agencies. However, capacities of the national drug regulatory 
agencies and requirements of national good manufacturing practices vary across 
countries [140]. It is therefore suggested that countries should gather information from 
several reliable procurement bodies, institutions and governments, which already have 
experience of given suppliers [140]. 
Key elements to support this activity: there are additional supportive instruments 
to identify sources of a generic drug. The supportive instrument are lists of 
prequalified generic medicines established by reliable organizations. Global initiatives 
for prequalification of essential medicines are beneficial for the authorised agencies of 
countries lacking the capacity to assess the quality of generic products. For example, the 
WHO List of Prequalified Medicinal Products contains a comprehensive list of 
prequalified generic products and manufacturers that is reviewed and updated at regular 
intervals [139]. The list is the result of close cooperation between national regulatory 
bodies and the WHO, listing medicines for HIV/AIDS, malaria, tuberculosis, influenza, 
neglected tropical diseases, diarrhoea, and reproductive health [152]. This project’s key 
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strategies are: to evaluate the quality, efficacy and safety of drugs, based on 
manufacturer evidence and inspection from the corresponding industrial and clinical 
sites; to prequalify sources of active pharmaceutical ingredients (API) by 
comprehensively evaluating the quality of the API based on evidence developed by the 
manufacturers, and inspection from the corresponding industrial sites; and to prequalify 
laboratories of quality control for pharmaceutical products [152]. The list of 
prequalified generic drug manufacturers is a key instrument to enable authorised 
agencies to investigate the availability of generic drug manufacturers and to prepare the 
products for procurement in the implementation stage. 
Development of streamlined procedures (A2.3): It is suggested that countries 
adopt streamlined administrative procedures for issuing CL policy and consider 
approaches to prevent any injunction, which may delay policy operation [24]. Several 
streamlined procedures should be used in the process of CL generic drug production and 
registration in preparation to supply the drug upon policy implementation. The TRIPS 
agreement allows countries to use provisions called “regulatory exception” or “bolar 
provision” that permit generic drug manufacturers to obtain marketing approval without 
the patent holder’s permission [146]. Therefore, countries should adopt the bolar-
provision as the exclusion from patent rights, which allows CL generic producers to 
prepare generic drug registrations prior to the CL policy implementation [24]. In 
addition, countries should establish a fast-track procedure to register CL drugs, in 
particular for any country where drug registration is essential before launch into the 
local market [140]. The fast-track registration process should be reserved for certain 
categories of medicines such as well-established generics (as manufacturing facilities 
and quality of active pharmaceutical ingredients are assured or where a product is 
approved by qualified laboratories) [140]. Therefore, countries with local medicine 
registration systems should take advantage of this measure to accelerate the CL 
implementation. 
Key elements to support this activity: in addition to the prequalified generic 
drugs, there are other additional instruments, which are essential in the streamlined 
procedures. Supportive instruments for developing streamlined CL implementation 
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procedures are lists of prequalified quality control laboratories. Agencies authorised 
to control generic drug quality should also be prequalified through international 
standard approaches, and the generic drugs should be fully approved through a 
comparison of quality, efficacy and safety against its reference biotherapeutic product 
[153]. The WHO has established a list of prequalified quality control laboratories; on 11 
March 2016 the (updated) list contained 41 quality control laboratories, which had 
volunteered to participate in the WHO prequalification procedure and had met WHO 
standards [154]. The WHO also provides guidance on good practice for pharmaceutical 
quality control laboratories (GPCL) and on the related parts of good manufacturing 
practices (GMP). The guidance was developed through an international standardised 
quality assessment procedure [155]. Therefore, any generic drug manufacturers, which 
aim to supply their product under CL policy should submit their products for quality 
assurance in certificated laboratories, thus avoiding the need to undergo quality 
assurance procedures in each country to which they aim to export. This practice could 
improve the speed and efficiency of procedures to assure drug quality. 
 
Actors in the stage of policy formulation  
Actors in policy formulation (P2) Policy formulation requires collaboration 
between health, industry and trade sectors. If the government aims to produce the drugs 
locally, sharing information between health and industry sectors should better orient 
existing local industries to serve public health needs [140]. Experts from each ministry 
should provide technical assistance in expounding legal requirements for procedures 
under their authorities to address any problems that may occur during policy 
formulation. Experts at national, regional, or international levels should provide 
information and advice to support technical assistance, policy analysis and capacity 
building at the national level [140]. Comprehensive cooperation among concerned 
ministries and government partners seems to be essential to policy formulation.  
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The framework for policy implementation and monitoring 
Figure 5.4 shows key elements for the implementation of CL policy. The 
previous section mentioned the stages of agenda setting and policy formulation as the 
first and second stages of the policy process. This section explains the third and fourth 
stages in the policy process. Ten elements were identified from the literature review.  
The third stage in the policy process is policy implementation. Six common 
elements were identified: 
• One contextual element: the capacities of agencies implementing the CL policy 
(C3.1).  
• Four activities: production or procurement of generic CL drugs (A3.1), quality 
assurance of CL drugs (A3.2), distribution of CL drugs to health care facilities 
(A3.3), and utilisation of CL drug at health care facilities (A3.4);  
• One set of actors: Authorised implementing agencies, generic firms, and 
international concerned agencies (P3).  
The fourth stage in the policy process is policy monitoring. Four common 
elements were identified:  
• One contextual element: institutional capacity to monitor performance and 
evaluate implications (C4.1).  
• Two activities: performance monitoring and evaluation of policy implications 
(A4.1) and the development of policy feedback to improve performance (A4.2);  
• One set of actors: Authorised monitoring agencies (P4) 
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Figure 5. 4 The preliminary framework for policy implementation and monitoring  
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5.4.3 Key elements in policy implementation 
 
Context of policy implementation   
Capacities of agencies implementing CL policy (C3.1): Depending on 
domestic law, any applicant aiming to utilise CL policy may need to provide 
evidence of sufficient capacity to implement it [148]. Therefore, the capacity of 
local implementing agencies in terms of financial and resource requirements, 
personnel qualifications and infrastructure, are the key contextual element 
influencing the sustainability of CL policy implementation. The personnel should 
have sufficient expertise to carry out their responsibilities in the implementation 
process [140]. In addition, an efficient and successful infrastructure depends on 
adequate funding, so authorised agencies should not make a commitment, which 
exceeds their internal capacities and resources, because resources will have to be 
allocated to fulfil the commitments [140]. Local capacity should be strengthened 
throughout the policy implementation stage: medicine production, import, export, 
distribution, and utilisation, and ensuring they follow internationally accepted 
standards [137]. Therefore, where authorised agencies demonstrate adequate 
capacity throughout the implementation stage, this undoubtedly acts as the main 
structural context, which enables successful policy implementation [139, 140]. 
 
Contents of policy implementation   
 
Procurement of generic drug products (A3.1): As the aim of procurement 
is to obtain the required generic drugs at the right time, in the correct quantities, and 
at the most favourable prices, meeting the public health need and complying with 
agreements between drug suppliers and the procurement agency [140]. Authorised 
procurement agencies should carefully select and procure qualified generic drugs 
from potential drug manufacturers. There are three key procurement activities, and 
each activity requires guidelines for drug procurement as a supportive instrument. 
In this section, the drug production, importation and tendering activities are 
included, and the recommendations of each activity are provided below. 
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First, recommendations where countries have sufficient manufacturer 
capabilities: the drugs under the CL policy may be obtained through direct 
production or technology transfer. Technology transfer refers to the process by 
which a developer of a generic drug transfers knowledge/know-how and makes its 
technology available to the recipients exploiting the technology. If technology 
transfer is pursued, recipients have to acquire knowledge, and replicate and adapt the 
new manufacturing technology to local conditions [156]. Therefore, the key 
supportive instruments seem to be guidelines on how local generic industries can 
best choose and replicate new technologies for equipping the transferred technology 
with its indigenous technologies [157]. The local industries may adopt the guidelines 
of technology transfer in pharmaceutical manufacturing developed by the WHO 
[156]. 
Second, recommendations for any country that lacks production capacity: 
the countries can pursue direct importation of generic drugs made under CL policy 
from foreign suppliers. It is possible to rely on procurement by international non-
profit organisations who have experience with the procurement of generic drug 
products [139]. It is clear that directly importing CL drugs can save more time than 
using technology transfers. However, the selection of foreign drug suppliers should 
be carefully conducted because weak suppliers can impede supply chain 
performance and create unnecessary costs. The supportive instrument in this activity 
is guidelines for selecting generic drug products and suppliers based on evaluations 
of individual medicine dossiers and compliance with good manufacturing practices 
(GMP), respectively [139]. The details of common practices have been published by 
WHO [158].    
Third, recommendations for drug tendering: competitive open tenders are 
recommended for pharmaceutical procurement [159] as these provide all qualified 
generic drug suppliers with an equal opportunity to participate. In most cases, a 
grant is based on the most attractive proposal from candidate suppliers who are able 
to meet the terms of the tender [139].  Procurement agencies should 
comprehensively scrutinise and continually monitor the performance of qualified 
suppliers, and monitor price trends of qualified medicines through comprehensive 
tendering information [137]. Therefore, the supportive instruments required in this 
activity are tendering guidelines and an information system, which is 
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comprehensive, accurate and timely. The information system under CL policy 
should be able to: produce information for drug quantification and tendering 
processes; compare suppliers’ offers for procurement decisions; formulate 
notifications of award and purchasing orders; track the purchasing order status and 
compliance with agreed procurement contract terms; arrange effective 
communication with contract drug suppliers; and monitor performance of drug 
suppliers for future tenders. All general issues to be considered in the tendering 
process are mentioned in the WHO guidelines [159].     
Quality assurance of generic products (A3.2): The aims are to make health 
personnel trust the quality and therapeutic effectiveness of CL generic drugs 
compared to patented versions [139]. Parts of the assurance procedures (product 
registration and pre-marketing regulation) may be conducted from the policy 
formulation stage. Post-marketing, after the drugs are launched into the market, 
generic versions must be regularly monitored to ensure consistent quality. The 
purpose of post-marketing control is to ensure that the quality of generic drugs 
distributed to consumers consistently complies with drug standards [139]. GMP 
compliance inspections of generic drug factories must be conducted together with an 
analysis of product samples by an accredited laboratory to ensure compliance with 
legal requirements [139]. The inspections aim to enforce GMP compliance and 
monitor drug quality throughout the supply chain, from manufacture to delivery to 
the patients. This could improve the confidence of practitioners and patients in the 
quality, effectiveness and safety of CL drugs, helping them believe that the drugs are 
equivalent to patented drugs and meet international standards. 
Key elements to support this activity: there are additional instruments, which 
are essential in the quality control activities of generic drugs. The supportive 
instruments in this activity are guidelines for quality assurance of generic drugs. 
Quality control refers to the procedures attempting to ensure the identity and purity 
of certain pharmaceutical substances in compliance with acceptable standards. The 
WHO formulated a series of guidelines on quality assurance procedures from simple 
chemicals to more complex pharmaceutical products [160]. In addition, the WHO 
developed regulatory standards on related issues, including bioequivalence, stability, 
packaging and storage [161]. Moreover, it is important to support the establishment 
of functional mechanisms to monitor the quality of pharmaceutical products 
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throughout distribution channels, from the point of production to delivery to the 
users. The WHO also developed guidelines for inspections of drug to ensure the 
safety of medicines [162].    
Drug distribution to health facilities (A3.3): Mechanisms are required to 
secure the constant availability of qualified drugs for all health care facilities in 
need. It is suggested that drug products should be obtained from the authorised 
supply chain and reliably stored, transported and handled under conditions which 
comply with predetermined standards, as required by product specifications, until 
the drugs reach local health care facilities [163]. In addition, authorised drug 
distribution agencies should identify competent mechanisms to improve the 
accuracy and efficiency of the drug inventory system through an availability of 
accurate, updated, and accessible information on the drugs for concerned parties. 
The required characteristics of drug distribution systems are as follows: (1) constant 
supplies of drugs should be secured, (2) drugs should be distributed in good 
condition until they reach the patient, (3) losses due to damage, spoilage or 
expiration should be diminished, (4) theft and fraud should be strongly prevented, 
(5) accurate inventory information should be constantly maintained, (6) rational 
storage sites should be organized for security, timely supply, and quality 
maintenance, (7) transportation resources should be used efficiently, and (8) 
accurate and comprehensive information should be continually collected for 
predicting drug needs [140]. 
Key elements to support this activity: there are additional instruments, which 
are essential in the activity of drug distribution. The supportive instruments for 
distributing CL drugs to health care facilities are guidelines for drug distribution. 
The WHO has developed a number of international standard guidelines concerning 
drug supply chain management [164], and authorised agencies may apply the 
guidelines to inspect drug distribution channels. In addition, it is suggested that 
countries should strengthen collaboration and information-sharing between those 
responsible for drug supply management, and those responsible for public health 
programs, to increase the efficiency of the supply chain system [137]. The ultimate 
aim is to ensure that adequate supplies of qualified drugs are constantly provided to 
health care practitioners and patients at every level of health care facility.  
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Drug utilisation by health practitioners (A3.4): The utilisation of drugs 
at health facility units requires the provision of medicine information, 
encouragement of rational drug use, and supervision of drug utilisation [140]. 
Activities to promote drug utilisation in compliance with national drug policy are as 
follows: (1) strengthening mechanisms for drug information-sharing and developing 
up-to-date clinical practice guidelines; (2) advocating the incorporation of training 
modules and continuing education programmes on rational use of medicines for 
health care workers. This is because supportive and educational supervision of 
rational use in compliance with the clinical practice guidelines is more effective and 
better accepted by prescribers than regular inspection and penalty; (3) supporting the 
monitoring of practitioner prescribing practices according to the guidelines [165]. 
Effective monitoring methods of drug utilisation are prescription audit and feedback. 
Audits should check whether prescribers’ prescriptions comply with accepted 
guidelines or policy protocol [165]. This provision is essential to ensure the good 
practice of health care professionals at health care facilities.  
Key elements to support this activity: there are additional instruments, which 
are essential in the activity of drug utilisation. The supportive instruments for 
utilising drugs at health care facilities are clinical practice guidelines. The 
utilisation of CL drugs at hospital units requires activities to promote rational drug 
use. Authorised central agencies may establish expert committees to develop 
guidelines related to rational drug use. Evidence-based clinical practice guidelines 
and prescribing policies play an important role in helping prescribers to choose 
proper treatments for particular clinical conditions. To promote rational drug use, the 
development of clinical practice guidelines should take into account the following 
points: (1) they should be developed with the participation of prescribers as the end-
users; (2) the guidelines should be easy to read and supported with an official 
introduction, continuous training and extensive dissemination; (3) the guidelines 
should be reinforced through prescription audit and user feedback; (4) the guidelines 
should be regularly updated in order to assure credibility and acceptance by health 
care practitioners [165]. Practitioners need to provide health care services in 
compliance with clinical practice guidelines, but some may have difficulty changing 
their traditional practices to meet the guidelines, or may be unwilling to comply with 
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the new policy. Therefore, adherence to guidelines in local hospital units may be 
measured in the form of utilisation review under an auditing system [165].  
 
Actors at the stage of policy implementation  
Actors in policy implementation (P3).  Authorised implementing agencies 
consist of drug procurement, quality assurance, distribution and utilisation. First, 
drug procurement agencies may request useful advice and guidance from country, 
regional or international procurement agencies. Some international organisations, 
such as UNICEF and the World Health Organization’s Essential Drugs and 
Medicines Policy (WHO/EDM), as well as NGOs such as MSF and the International 
Dispensary Association (IDA), have long experience in drug procurement and have 
established procedures for this matter. They can provide product lists, specify 
sources of drugs, and assist in comparing drug prices [140].  
Second, in terms of quality assurance, domestic laboratories approved by the 
national drug regulatory authority should participate in the WHO prequalification 
system for quality control laboratories and plan for the enhancement of their 
capacity for both local and foreign demands. In addition, laboratories of 
international non-profit procurement agencies and private laboratories may be 
acceptable if they meet international requirements; for example, laboratories which 
are accredited by private agencies such as International Organization for 
Standardization (ISO) and Organisation for Economic Co-operation and 
Development (OECD) norms and standards [140].  
Third, the government may authorise an organisation, which has expertise in 
national drug management systems to be responsible for drug distribution and 
utilisation management, and local health care professionals may participate in the 
implementing process at their facilities [140]. It is suggested that countries should 
develop a system to strengthen personal expertise and local infrastructures to ensure 
appropriate management of the drug supply system at all levels of health facilities. 
The link between each stage is essential, for example, supporting collaboration 
between the national drug procurement agency and the national drug regulatory 
agency to prevent the risk of purchasing poor quality drugs from unqualified 
suppliers [137]. 
 
 
95 
 
 
 
5.4.4 Key elements in policy monitoring 
 
Context of policy monitoring   
 
Institutional capacity to monitor performance and evaluate implications 
(C4.1): When a policy is implemented, not only should the performance of 
implementing organisations be monitored, but implications of policy 
implementation should be evaluated, in order to provide information on whether the 
policy has achieved the expected outputs and outcomes. Therefore, the institutional 
capacity of authorised agencies to monitor policy performance and evaluate policy 
implications seems to be a key structural contextual element at this stage. By 
strengthening the institutional capacity of both central and local agencies, the 
monitoring agency should be equipped with capable workers and sufficient 
resources to monitor performance and evaluate policy implications [166]. This aims 
to provide evidence and information to help policy makers decide whether to 
continue, improve, or discontinue the policy; as well as to develop strategies for 
improving the efficiency and effectiveness of the policy [137].  
 
 
Content of policy monitoring   
 
Monitoring and evaluation of CL policy (A4.1): To monitor policy 
performance, local authorised agencies should conduct routine reporting of 
performance data through a system of information management. This activity may 
require close supervision from a central or national agency through continual 
monitoring of implementation and progression. In addition, if any unanticipated 
situation occurs, more detailed reporting and monitoring (for example sentinel sites 
or special studies) are essential in order to develop strategies to resolve problems 
[140]. The key activities in this stage are as follows: (1) the central agency should 
implement indicator-based monitoring of policy performance with the aim of 
guiding local agencies to collect adequate information to evaluate policy outputs and 
outcomes. (2) Workers in local agencies should be advised on the adoption of 
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indicator-based tools to monitor policy implementation. (3) Throughout the 
monitoring stage, the central agency should monitor policy implementation at 
intervals adequately frequent for the management purpose with local agency [137]. 
Information obtained from the activities mentioned above could be beneficial to 
develop strategies to improve performance and maximise benefits of the policy. 
Key elements to support this activity: there are additional instruments, which 
are required to support the monitoring and evaluation activities. The supportive 
instruments for this activity are information systems for policy monitoring. The 
policy monitoring stage requires an effective data collection system for gathering 
inputs and outputs. Indicators for data collection should be chosen wisely to provide 
adequate, accurate and reliable information to the central or national agency who 
need it for management and planning [140]. Monitoring indicators should be 
selected based on local conditions, such as implementation means and resources 
available, with the aim of maximising the effectiveness and efficiency of data 
collection. The required features of data monitoring systems are as follows: (1) 
improved links between systems of data generation, monitoring and evaluation, in 
order to generate the most beneficial data and avoid underutilization; (2) 
harmonisation of multiple data collection and reporting systems to reduce 
unnecessary duplication. [140]. 
Development of policy feedback (A4.2): Findings from the policy 
monitoring stage can be used to develop feedback on the problems, obstacles, and 
defects arising during policy implementation and to develop strategies to resolve 
problems and improve performance [166]. Therefore, countries should use policy 
monitoring information to refine policy implementation by communicating with 
national policy-makers, system managers, health workers and drug user groups. The 
feedback could provide suggestions to improve performance in a specific activity in 
any policy stage (agenda setting, policy formulation, and policy implementation), 
and could connect a relationship between each policy stage in order to present a full 
and honest pictures of end results. In addition, countries should also provide lessons 
learnt from their experiences and share the information to contributions to literature 
on national, regional and global trends [137].  
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Key elements to support this activity: there are additional instruments, which 
are required to support the policy development feedback. The supportive instruments 
in this activity are channels to deliver policy feedback. There were several issues 
to consider when initiating channels to deliver policy feedback to decision makers 
and stakeholders. A broad range of stakeholders is involved in the policy process, 
including policy planning and development, health system management, health 
service management, and advocacy. Each level has diverse technical disciplines with 
specific terminological expressions and communication approaches. Therefore, 
dissemination should be wisely developed for each stakeholder, and the most 
effective campaign and communication channel to deliver policy messages should 
be judiciously chosen. The timing of information dissemination should also be 
scheduled to fit in with each policy process and the needs of the intended recipients 
[24, 137]. This instrument plays an important role in the effective achievement of 
any policy.  
 
Actors at the stage of policy monitoring     
Actors in policy implementation (P4).  Implementing agencies should play 
an important role in monitoring their performance all the way through the policy 
process. Local authorised agencies have to closely monitor policy performance with 
technical and policy staff to ensure the process is efficient and effective [140]. In 
addition, as the activities in the monitoring and evaluation process involve all local 
authorised agencies across the country, the central or national authority should be a 
moderator and/or supervisor to facilitate and supervise all concerned sectors [140]. 
Moreover, policy feedback should not only be delivered to the authorised agencies 
but also to the public. Therefore, other domestic and international stakeholders such 
as healthcare workers, academics, civil society and the private sector should receive 
accurate and timely information to help them keep track of the policy situation.  
They may be asked to participate in the policy if necessary [137]. 
5.5 Discussion and conclusions 
 In this chapter, a preliminary framework was developed by identifying policy 
elements from generic recommendations from inter-governmental organisations. 
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The identified elements were analysed and classified into four sections: policy 
contents, context, actors and process, according to the policy triangle model of Walt 
(2005) [128]. Regarding the research findings in this Chapter, 21 policy elements 
were identified as essential, to be included in the framework. The framework 
assumed that the policy process can be classified into four stages, including agenda 
setting, policy formulation, policy implementation and policy monitoring. The 
processes of agenda setting and policy formulation contain 6 and 5 elements 
respectively, while the processes of policy implementation and monitoring contain 6 
and 4 elements respectively.  
According to Joseph S, et.al., there are several approaches of policy analysis, 
namely (1) process approach to examine a part of the policy process e.g. agenda 
setting and policy implementation, (2) substantive approach to examine a 
substantive area with special expertise, e.g. environmental matters, (3) logical 
positivist approach to examine causes and consequences of policy using scientific 
methods, (4) economic approach to test economic theories, (5) phenomenological 
approach to analyze events through a discipline of sound intuition, which is itself 
born of experience not reducible to models, hypothesis, or quantification, (6) 
prescriptive approach to prescribe policy to decison makers or others to achieve a 
determined end state, (7) ideological approach to analyze from a liberal or 
conservative point of view which comes from within individuals rather than 
externally imposed by the outside environment, and (8) participatory approach to 
examine the role of multiple actors in  policymaking [167].  
Among these eight approaches, two can be useful for developing a 
framework which decision makers might use to help in thinking through the 
development and use of CL policy: (1) Process approach for examining a part of the 
CL policy process and (2) Participatory approach for examining the role of multiple 
actors in CL policy. The development of a CL policy framework requires an analysis 
of each policy process and the actors who participate in the process. Therefore, the 
policy triangle model was selected because it presents a greatly simplified approach 
to analyse a complex set of inter-relationships among policy elements, including 
policy process and actors [127]. In addition, the model has been successfully used to 
analyse policies in several areas of public health in Thailand, for example: a policy 
analysis for the Universal Coverage Schemes in Thailand [168]; a policy analysis for 
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the Universal Access to anti-retroviral drugs in Thailand [169]; and an analysis for 
the health and trade negotiation in Thailand [170]. In addition, it has been confirmed 
that this 'policy triangle' framework 'can be applied in any country, to any policy, 
and at any policy level.'[128]. 
However, it is noteworthy that the policy process is not always linear, as the 
methodology assumes. The four sections may occur in parallel during the CL policy 
process. For example, according to the TRIPS agreement, the legal validity of any 
CL decision concerning the use of patent use without permission from patent 
owners, and any decision concerning the kind and level of remuneration or royalty 
fee provided to the patent owner regarding such use, can be subject to judicial 
review or other independent review by courts or other authorised agencies [146]. 
Given this, the use of CL may be delayed if the patent owner appeals the validity of 
the license used or the kind and level of remuneration granted under the policy. For 
this reason, the government can fully implement the policy even while appeal 
procedures are operating [148].  
The literature review found that there is limited literature contributing to the 
development of a CL framework. Some focused on legal issues rather than how to 
adopt the policy in reality. Some researches had been conducted at a very early 
phase of CL introduction, at which point very little practical work had been 
undertaken. Some focused on a specific stage of the policy and did not cover the 
whole policy process. Therefore, to contribute to the literature, I developed a 
preliminary framework for CL by identifying common policy elements affecting the 
process of CL policy covering the whole process of public health policy: decision-
making (agenda setting and policy formulation) and policy implementation 
(implementation and monitoring).  
However, there were limitations to this study. The aim of this chapter is to 
develop a preliminary framework, which is not an action plan. The implementation 
guideline for each content activity, for example drug procurement, transfer of 
production technology, quality assurance, drug distribution, and clinical practice 
guidelines to utilize the drugs, are available elsewhere. Therefore, I do not provide 
an action plan for CL policy, but I do put the available guidelines as key elements in 
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the  content of each activity, so that readers are aware of further detail available 
elsewhere.  
The preliminary framework was developed based on general 
recommendations from inter-governmental organisations, including the WHO, 
WTO, UNDP, UNCTAD and World Bank. However, these organizations provided 
policy recommendations to advise countries in general. The information omitted 
context-specific elements of each country such as indigenous culture, domestic 
policy and law, limitations of local capacity and resources. Therefore, elements of 
policy context in the preliminary framework were unsatisfactory in relation to 
guiding Thailand and required adjustment by domestic data. In addition, there is still 
a lack of evidence for practical implementation issues within the framework. In 
response to the limitations, empirical evidence and lessons from the eight-year 
experience of the former government in implementing CL policy were analysed in 
order to strengthen the contents of the framework. This is discussed in the following 
chapters. 
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Chapter 6: Lifetime treatment cost savings due to 
CL implementation  
 
6.1 Introduction 
 
The preliminary framework in chapter 5 required complementary 
information to strengthen the content in the framework. As the framework was 
divided into two sections: decision-making and implementation, chapter 6 was 
dedicated to analyse potential implications of CL policy in order to strengthen the 
“decision-making part of the framework”. There are five areas of analysis: two drugs 
against HIV/AIDS (efavirenz and LPV/r), one against cardiovascular disease 
(clopidogrel), one against lung cancer (docetaxel), and one against breast cancer 
(letrozole). I clarify the differences in efficacy between the CL drugs and the 
comparators in table 6.1.  
This chapter aims to estimate lifetime treatment costs savings among patients 
using the CL drugs compared to its comparator. The comparative benefits in terms 
of the national budget savings (lifetime treatment cost savings in total population of 
patients) across different drug types could be used to develop drug selection criteria, 
in order to strengthen contents of the decision-making parts in the preliminary 
framework in chapter 5. Therefore, the research questions are as follows: (i) what 
are the differences in benefits in terms of national budget savings from the use of CL 
drugs compared to its comparator (the drugs which could be used without CLs)?; (ii) 
what are factors which create the highest benefits to the government and should be 
incorporated in the drug selection criteria, in order to strengthen contents of the 
framework?. 
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Table 6: Summary of comparative efficacy for CL drugs versus its comparator 
 
 Drugs of interests Comparative efficacy 
1. Efavirenz versus 
Nevirapine 
Probability of patients failed treatment in Efavirenz and 
Nevirapine was 16.7% and 20.7%, respectively [171].  
2. LPV/r versus  
IDV/r 
Probability of patients to obtain virological success at 12th 
month in LPV/r and IDV/r was 88.2% and 73.1% respectively. 
[172]  
3. Clopidogrel versus 
Ticlopidine 
Rate ratio of composite of undesirable vascular events was 
0.87% for clopidogrel over ticlopidine [173]. 
4. Letrozole  
versus Tamoxifen 
Patients receiving letrozole and tamoxifen had five-year overall 
survival at 91.8% and 90.4%, respectively [174]. 
5. Docetaxel versus 
Best supportive care 
Patients receiving docetaxel and the best supportive care had 
time to progression at 10.6 and 6.7 weeks, respectively; and 
median survival at 7.0 and 4.6 months, respectively. [175] 
Note: Although the efficacy units are different across five studies of drug comparison, my study 
converted them into the same monetary units. 
6.2 Methods 
Outcomes of interest were simulated by Markov models for the five 
medicines. Using the government perspective, the lifetime treatment cost savings 
due to CL were evaluated by comparing the CL drugs with alternative drugs used 
prior to CL. Costs were estimated in 2015 US$ using the exchange rate of 32.719 
baht per US$ [176]. All costs reported in earlier years were adjusted by consumer 
price indexes (CPIs) published by the Thai Ministry of Commerce for the price year 
2015 [177]. Future costs were adjusted by using a 3% discount rate, as 
recommended by health technology assessment guidelines of Thailand [178]. 
 
6.2.1 Rationale for model selection 
The two common types of models employed in decision analysis are decision 
trees and Markov models [129]. The decision tree model is the simplest form of 
decision models, and it is not suitable for diseases where symptoms and severity 
change over time. Instead of possible consequences of health outcomes over time 
being modelled by a large number of possible pathways in a decision tree, the more 
complex prognosis can be simplified by employing a Markov model. The Markov 
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model is commonly employed to handle the complexity of modelling options of 
infectious diseases for HIV/AIDS [179] and chronic diseases for stroke [180] and 
cancers [181]. Therefore, Markov models were used to estimate future implications 
of lifetime treatment costs for the five medicines. 
 
6.2.2 Overview of options for interventions and comparators 
I compared drug regimens recommended by the Thai clinical practice 
guidelines (CPGs) before and after CL was implemented for the five drugs. The 
drug regimens that the CPGs used before CL implementation were set as the 
counterfactual scenarios (baseline comparators). After the availability of generic 
drugs under the CL policy, the drug regimens recommended in the CPGs were 
changed, and this was set as the factual scenario. Long-term effects on lifetime cost 
savings were evaluated by comparing the treatment cost of CL drugs with that of its 
comparator used prior to CL implementation (Table 6.1). 
 
Table 6. 1 The regimens of CL drugs and its comparators  
Models  CL drugs 
(Factual scenarios) 
Comparators 
(Counter-factual scenarios) 
Efavirenz  Efavirenz 600 mg per day  
treatment of HIV/AIDS [182]  
Nevirapine 200 mg every 12 
hours for treatment of 
HIV/AIDS [118] 
LPV/r  LPV/r 800/200 mg per day  for 
treatment of HIV/AIDS [182] 
IDV/r 1,600 mg per day for 
treatment of HIV/AIDS [118] 
Clopidogrel  Clopidogrel 75 mg per day for 
treatment of stroke [183] 
Ticlopidine 500 mg per day for 
treatment of stroke [184] 
Letrozole  Switching therapy by tamoxifen 
20 mg per day for two years 
followed by letrozole 2.5 mg 
per for three years [185] 
Mono-therapy by tamoxifen 20 
mg per day until completion of 
five-year treatment [186] 
Docetaxel  Docetaxel 100 mg/m2 every 21 
days (1 cycle) for 4 cycles for 
treatment of advance NSCLC 
[187]  
Best supportive care as there is 
no other alternative treatment of 
docetaxel for advance NSCLC 
[186] 
Abbreviation: LPV, lopinavir and ritonavir combination; IDV/r, indinavir and 
ritonavir combination; NSCLC, Non-small cell lung cancer 
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6.2.3 Model structure 
Five Markov models for the five CL medicines were developed in Microsoft 
Excel 2007 (Microsoft Corp., Redmond, WA, USA). The Markov models for each 
medicine are shown in Figures 6.1 – 6.5. The cycle length of moving from one 
health state to another was set at 1 year. The time horizon was patients’ lifetime. The 
treatments with ARVs and cancer drugs were modelled by three health states: 
treatment responsiveness, disease progression and death. The treatment 
responsiveness refers to the health state of patients who respond to the treatment, 
while the disease progression refers to the health state of patients who failed to 
respond the treatment. Clopidogrel is used for stroke prevention. This model 
contains three health states: secondary prevention of stroke, disease progression, and 
death. Patients remain in the first health state until the next cycle. Moving to the 
other health states depends on the disease progression during treatment. The arrows 
in the figures represent the transitional possibilities of patients moving from one 
health state to another at the end of each cycle length. Some patients might die at the 
end of each cycle. 
Efavirenz model: Since CL was implemented, efavirenz has been 
recommended by the Thai CPGs as the first-line therapy for patients living with 
HIV. The starting age of the patient group used in this study was assumed as 30 
years, as an average age of HIV/AIDS patients in Thailand [118]. If the patients 
respond to the first-line treatment by the efavirenz or nevirapine (the counter-
factual), they stay in the treatment responsiveness state. However, some patients 
may have treatment failure and move to the disease progression state, or may move 
to the death state (Figure 6.1).  
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Figure 6. 1 The Markov model structure used for the first line ARV treatment of 
efavirenz 
 
 
LPV/r model: Since CL, LPV/r has been recommended by the Thai CPGs 
as second-line therapy for patients living with HIV. Similarly to the efavirenz 
model, the starting age of the cohort was assumed as 30 years [186]. Patients can 
stay in the treatment state if their symptoms respond to the second-line treatment of 
LPV/r or IDV/r (the counter-factual). However, some patients may fail to respond 
and move to the disease progression state of HIV/AIDS, or may move to the state of 
death (please see 6.2). 
 
 
Figure 6. 2 The Markov model structure used for the second line ARV treatment of 
LPV/r 
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Clopidogrel model: Clopidogrel is recommended by the Thai CPGs to use 
for secondary prevention for patients with stroke. The starting age of the cohort was 
assumed as 60 years, as an average age of patients requiring secondary stroke 
prevention in Thailand [186]. The patients can stay in the treatment state if their 
symptoms respond to the treatment. However, some patients may fail to respond and 
have a secondary stroke. The patients then move to the progression health state of 
secondary stroke or may move to the state of death (please see 6.3). 
 
 
Figure 6. 3 The Markov model structure used for the secondary prevention of stroke 
 
Letrozole model: Letrozole is recommended by the Thai CPGs to use for 
patients with breast cancer. The starting age of is the cohort was assumed as 60 
years, as an average age of postmenopausal breast cancer patients [186]. The 
patients can stay in the treatment state if their symptoms respond to the treatment. 
However, some patients may have treatment failure and move to the disease 
progression state of breast cancer, or may move to the state of death (please see 6.4). 
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Figure 6. 4 The Markov model structure used for the postmenopausal breast cancer 
 
Docetaxel model: Docetaxel is recommended by the Thai CPGs to use in 
patients suffering from advanced stage of non-small cell lung cancer (NSCLC). The 
starting age of is the cohort was assumed as 60 years, as an average age of advanced 
stage NSCLC [186]. The patients can stay in the treatment state if their symptoms 
respond to the treatment. However, some patients may have treatment failure and 
move to the progression state of lung cancer, or may move to the state of death 
(please see 6.5). 
 
 
Figure 6. 5 The Markov model structure used for the non-small cell lung cancer 
(NSCLC) 
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6.2.4 Model Parameters 
 
6.2.4.1 Transitional probability of changing health states: An extensive 
literature review was conducted and several relevant studies that compared 
treatments of interests were identified. The PubMed database was searched using the 
specific keywords and identified literature was analysed according to the inclusion 
criteria as follows. (1) Studies written in English and Thai, (2) Studies conducted 
clinical treatment protocol consistent with the drug indication and regimens 
recommended by the Thai clinical practice guidelines, and (3) Studies conducted to 
measure outcomes of interest consistent with those analysed in this study. 
Four types of parameters were identified: (1) Transitional probabilities of 
patients moving from the treatment responsiveness to the disease progression and 
directly to death were used as baseline parameters. The parameters obtained from 
cohort studies and observational studies. Studies that provided the most 
comprehensive set of parameters for defined health states were selected. (2) Relative 
risks to prevent disease progression and death by the CL drugs compared to its 
comparator were used to multiply with the baseline transitional probabilities, in 
order to estimate the benefits of treatment by the CL drugs over its comparators. The 
relative risk parameters were selected from the most up to date studies, and study 
types included systematic reviews and meta-analysis if available. (3) The transitional 
probabilities of patients moving from disease progression to death were obtained 
from Thai studies because they were usually affected by the context-specific of the 
Thai health care system. (4) The probability of disease complications and adverse 
events from the treatment were obtained from cohort studies and observational 
studies that provided the parameters of treatments in question of my study. The 
findings of the parameter review are summarised as follows. 
Efavirenz: For the efavirenz as the first line treatment of HIV/AIDS, the 
search term was Human Immunodeficiency Virus [MeSH Terms] AND efavirenz 
AND nevirapine. The identified parameters show in Table 6.2. The baseline 
transitional probabilities of nevirapine to prevent disease progression and death of 
nevirapine at 0.15 and 0.02, respectively were obtained from a randomised 
controlled trial study [188]. For the relative risk of progression and dying of 
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efavirenz compared to nevirapine at 0.75 and 0.81, respectively, were obtained from 
a meta-analysis study [171]. In addition, there are common adverse events of the 
drugs during the treatment period. These probabilities were obtained from a Thai 
thesis [189]. The yearly probabilities of adverse events occurred for nevirapine 
contain skin reaction, SJS, hepatitis, hepatotoxicity and high triglyceride at average 
0.13, 0.012, 0.025, 0.025 and 0.029 respectively [189]. The yearly probabilities of 
adverse events occurred for efavirenz contain skin reaction and high triglyceride at 
0.009 and 0.162 respectively. The transitional probability of dying among patients 
after disease progression at 0.029 was obtained from Thai cohort study [190]. 
 
Table 6. 2 Treatment effect parameters of efavirenz and its comparator 
 
Parameters Means References 
Transitional probability of progression  (baseline)  0.15 [188] 
Transitional probability of dying  (baseline) 0.02 [188] 
Relative risk of progress of efavirenz compared to nevirapine 0.750 [171] 
Relative risk of dying of efavirenz compared to nevirapine 0.810 [171] 
Probabilities of skin reaction events of nevirapine 0.13 [189] 
Probabilities of  steven johnson syndrome events of nevirapine 0.012 [189] 
Probabilities of hepatitis events of nevirapine 0.025 [189] 
Probabilities of hepatotoxicity events of nevirapine 0.025 [189] 
Probabilities of high triglyceride events of nevirapine 0.029 [189] 
Probabilities of skin reaction events of efavirenz 0.009 [189] 
Probabilities of high triglyceride events of efavirenz 0.162 [189] 
Transitional probability of dying with HIV/AIDS progression 0.029 [190] 
 
  
 
 
110 
 
LPV/r model: For LPV/r as the second line treatment of HIV/AIDS, the 
search terms were Human Immunodeficiency Virus [MeSH Terms] AND lopinavir 
AND ritonavir AND indinavir. The identified parameters are shown in Table 6.3. As 
no meta-analysis study providing relative risks of LPV/r compared to IDV/r was 
found, I used parameters of transitional probabilities from single studies. The 
transitional probabilities to prevent disease progression and dying of LPV/r at 0.06 
and 0.01, respectively, were obtained from an observational study [172]. The 
transitional probabilities to prevent disease progression and dying of IDV/r at 0.29 
and 0.02, respectively, were also obtained from observational studies [172, 191]. In 
addition, there were adverse events during the treatment period equivalent for both 
drugs. The yearly probabilities of adverse events occurred for rash, clinical hepatitis 
and neutropenia were at 0.135, 0.173 and 0.019 respectively [190]. The transitional 
probability of dying among patients in the disease progression at 0.036 was obtained 
from a Thai cohort study [190].  
 
Table 6. 3 Treatment effect parameters of LPV/r and its comparator 
 
Parameters Means References 
Transitional probability of progression of patients using IDV/r 0.29 [172] 
Transitional probability of dying of patients using IDV/r 0.02 [191] 
Transitional probability of progression of patients using LPV/r 0.06 [172] 
Transitional probability of dying of patients using LPV/r 0.01 [172] 
Probabilities of hepatitis events of patients using IDV/r 0.173 [190] 
Probabilities of skin rash events of patients using IDV/r 0.135 [190] 
Probabilities of skin rash events of patients using LPV/r 0.018 [190] 
Probabilities of neutropenia events of patients using IDV/r 0.019 [190] 
Probabilities of neutropenia events of patients using LPV/r 0.018 [190] 
Transitional probability of dying with HIV/AIDS progression 0.036 [190] 
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Clopidogrel model: For the clopidogrel as the secondary prevention of 
stroke, the search terms were Stroke [MeSH Terms] AND clopidogrel AND 
ticlopidine. The identified parameters are shown in Table 6.4. The relative risk of 
progression and dying of clopidogrel compared to ticlopidine at 0.87 and 0.97, 
respectively, were obtained from a meta-analysis [173]. For the baseline transitional 
probabilities to prevent disease progression and dying of ticlopidine at 0.352 and 
0.005, respectively, were obtained from a multicenter randomised control trial study 
[192]. In addition, the main adverse event of the drugs during the treatment period is 
neutropenia. The yearly probabilities of adverse events occurred for ticlopidine and 
clopidogrel at 0.023 and 0.010 respectively were obtained from a systematic review 
[193]. Transitional probability of dying among patients after disease progression at 
0.073 was obtained from a national data of stroke outcomes in Thailand [194]. 
 
Table 6. 4 Treatment effect parameters of clopidogrel and its comparator 
 
Parameters Means References 
Transitional probability of progression  (baseline) 0.352  [192] 
Transitional probability of dying  (baseline) 0.005  [192] 
Relative risk of progress of clopidogrel compared to ticlopidine 0.870 [173] 
Relative risk of dying of clopidogrel compared to ticlopidine 0.970 [173] 
Probabilities of neutropenia events of ticlopidine 0.023 [193] 
Probabilities of neutropenia events of clopidogrel 0.010 [193] 
Transitional probability of dying with stroke recurrence 0.073 [194] 
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Letrozole model: For the letrozole as the treatment of early stage breast 
cancer, the search term is Breast Neoplasms [MeSH Terms] AND letrozole And 
Tamoxifen. The identified parameters are shown in Table 6.5. The relative risk of 
disease progression and dying of switching-therapy compared to mono-therapy at 
0.8 and 0.82, respectively, were obtained from a meta-analysis [174]. The baseline 
transitional probabilities to prevent disease progression and dying of tamoxifen in 
monotherapy at 0.006 and 0.005, respectively, were obtained from a randomise 
double-blind trial [195]. In addition, the main ADR for breast cancer treatment is 
virginal breeding. The yearly probabilities of adverse events occurred during the 
treatment of tamoxifen and letrozole were at 0.091 and 0.042, respectively [195]. 
Transitional probability of dying among patients after disease progression at 0.394 
was obtained from a cancer surveillance in KhonKhan provinces in Thailand [196].  
 
 
Table 6. 5 Treatment effect parameters of letrozole and its comparator 
 
Parameters Mean Reference 
Transitional probability of progression (baseline) 0.006  [195] 
Transitional probability of death (baseline) 0.005  [195] 
Relative risk of progression of switching compared to monotherapy 0.800 [174] 
Relative risk of death of switching compared to monotherapy 0.820 [174] 
Probabilities of virginal breeding events of tamoxifen 0.091 [195] 
Probabilities of virginal breeding events of letrozole 0.042 [195] 
Transitional probability of dying with breast cancer progression 0.394 [196] 
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Docetaxel model: Docetaxel as the chemotherapy for NSCLC, the search 
terms were Carcinoma, Non-Small-Cell Lung [MeSH Terms] AND docetaxel AND 
best supportive care. The identified parameters show in Table 6.6. As meta-analysis 
was not found, I used parameters of transitional probability from single studies 
instead. The transitional probabilities to prevent disease progression and dying of 
docetaxel at 0.203 and 0.63, respectively, were obtained from a randomise control 
trial [175]. In addition, there are common adverse events of the drugs during the 
treatment period. The yearly probabilities of adverse events occurred for docetaxel 
contain neutropenia and febrile neutropenia at 0.0673 and 0.018 respectively [175]. 
As the comparator of docetaxel is the best supportive care, there is no transition 
probability from treatment responsiveness to disease progression. All patients were 
assumed to be in the health state of disease progression as there was no treatment for 
them. The transitional probability of dying among patients after disease progression 
at 0.89 was obtained from the RCT study in a different country, as there is no 
evidence in Thailand [175]. 
 
 
Table 6. 6 Treatment effect parameters of docetaxel and its comparator 
 
Parameters Mean Reference 
Transitional probability of progression of docetaxel 0.203 [175] 
Transitional probability of dying of docetaxel 0.630 [175] 
Probabilities of neutropenia events of docetaxel 0.0673 [175] 
Probabilities of febrile neutropenia events of docetaxel 0.018 [175] 
Transitional probability of dying from best supportive care 0.890 [175] 
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6.2.4.2 Age-specific background mortality of the Thai general population: 
It is noteworthy that moving to the final health state (death) might be or might not be 
related to the disease of interest since patients could die from other causes, such as 
accidents or other diseases. Age-specific data on the probability of dying for the 
Thai general population were taken from the Thai Working Group on Burden of 
Disease and Injuries report [197] (Table 6.7). However, each model has different 
groups of patients. The starting ages of yearly probability of patients using different 
drugs were: efavirenz and LPV/r for HIV/AIDS patients at the age of 30 years; 
clopidogrel for primary stroke patients; letrozole for postmenopausal patients, and 
docetaxel for patients with the advanced stage of NSCLC, all at the age of 60 years.    
 
 
Table 6. 7 Age-specific probability of dying in Thai general population 
 
Parameters Mean 
Yearly probability for age 0 yr 0.012076 
Yearly probability for age 1-4 yr 0.000380 
Yearly probability for age 5-9 yr 0.000580 
Yearly probability for age 10-14 yr 0.000610 
Yearly probability for age 15-19 yr 0.001499 
Yearly probability for age 20-24 yr 0.001828 
Yearly probability for age 25-29 yr 0.002577 
Yearly probability for age 30-34 yr 0.003414 
Yearly probability for age 35-39 yr 0.004072 
Yearly probability for age 40-44 yr 0.004968 
Yearly probability for age 45-49 yr 0.006290 
Yearly probability for age 50-54 yr 0.008761 
Yearly probability for age 55-59 yr 0.012353 
Yearly probability for age 60-64 yr 0.017269 
Yearly probability for age 65-69 yr 0.026142 
Yearly probability for age 70-74 yr 0.042194 
Yearly probability for age 75-79 yr 0.066767 
Yearly probability for age 80-84 yr 0.124062 
Yearly probability for age 85-90 yr 0.204775 
Yearly probability for age 90-95 yr 0.300283 
Yearly probability for age 95-100 yr 0.395008 
Yearly probability for age 100+ yr 0.471076 
 
Sources: Burden of Disease Project in Thailand [197] 
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6.2.4.3 Treatment costs:  There are four main components of costs: costs of 
the CL and the counterfactual drugs, costs of adverse effects from the drug in 
question, costs of treatments of disease complications during the treatment period, 
and costs of treatments if disease progression occurred. The cost parameters came 
from Thai studies, and all costs were converted to be in the present year of the study 
by using the Thai consumer price indexes for the price year 2015 [177].  
Annual costs of drugs were calculated as the mean procurement price 
multiplied by the yearly dose of treatment. Drug price data were obtained from the 
Drug and Medical Supply Information Centre (DMSIC), which is an affiliation of 
the Ministry of Public Health. The DMSIC is responsible for collecting drug price 
information from all public hospitals across the country [198]. An average price of 
each drug reported by hospitals was used to estimate the drug cost. The yearly doses 
of drugs were determined from the recommended treatment regimens by the national 
clinical practice guideline of HIV/AIDS, stroke, breast and lung cancers, as shown 
in Table 6.1.  
In addition, treatment costs for the main adverse event of drugs in question 
and the main complication of the diseases in question were included. All of the 
adverse events of the drugs and complications of the diseases during treatment 
periods were assumed to resolve in less than one annual cycle length. This is a 
conservative assumption that has been used in several studies [199] [200]. For the 
costs of treatments, if disease progression occurred, data were directly obtained from 
relevant cost studies. As my study was a comparison of treatment options, cost 
items, which were approximately identical in the regimens in question such as 
administration costs of hospitals, and health professional fees were excluded. The 
parameters for treatment costs for all five medicines are presented below. 
Efavirenz model: Average monthly costs for treatments with efavirenz and 
nevirapine regimens at 1,127 baht and 1,470 baht, respectively, were multiplied by 
12 to estimate annual costs. Treatment costs for the main adverse events of ARV 
treatment containing the events of skin reaction, SJS, hepatitis, hepatotoxicity, and 
high triglyceride were 536, 4,186, 2,200, 7,538 and 4,467 baht per episode, 
respectively [189]. The costs were multiplied by probabilities of the adverse event 
mentioned in the previous section. In addition, treatment costs of disease 
complications in terms of opportunistic infections of HIV/AIDS during the period of 
 
 
116 
 
using efavirenz and nevirapine were 357 and 2,148 bath per year respectively [189]. 
Finally, costs for treatment during the state of disease progression from ARV first 
line therapy at 72,233 baht per year was obtained from Leelukkanaveera 2009. This 
is a cohort study conducted in 16 community hospitals in Thailand. The cost 
contained treatment costs with second line ARVs of IDV/r regimen base and 
laboratory tests [190]. The identified parameters are shown in Table 6.8.   
 
 
Table 6. 8 Cost parameters of efavirenz and its comparator 
Parameters of annual costs per patient   Mean Reference 
Cost of nevirapine used for treatment of HIV/AIDS  17,640  [120, 198] 
Cost of efavirenz used for treatment of HIV/AIDS 13,521  [120, 198] 
Cost for treatment of skin reaction  536  [189] 
Cost for treatment of Steven Johnson syndrome  4,186 [189] 
Cost for hepatitis treatment 2,200 [189] 
Cost for hepatotoxicity treatment 7,538 [189] 
Cost for treatment of high triglyceride 4,467 [189] 
Cost for disease complications in nevirapine 2,148 [189] 
Cost for disease complications in efavirenz 357 [189] 
Cost for progression of 1st line ARV treatment 72,233  [190] 
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LPV/r model: Average monthly cost for treatments with LPV/r and IDV/r 
regimens at 3,444 baht and 4,107 baht, respectively, were multiplied by 12 to 
estimate annual costs. The cohort study by Leelukkanaveere described above was 
also used to estimate ADR costs. Costs for treatment of ADR containing the events 
of rash, clinical hepatitis and neutropenia as the main adverse events were at 50.3, 
179.6 and 1,203 baht respectively per episode [190]. The costs were multiplied by 
probabilities of the adverse event mentioned in the previous section.  For the costs 
for treatment of disease complications, the cost was assumed to be equal at 1,788 
baht per year for both drugs, as only the average cost was provided [190]. After 
patients had failed to respond the treatment, costs for treatment during the state of 
disease progression from ARV second line therapy was at 188,825 baht per years. 
The cost contained costs for treatment with the more advance ARVs of Atazanavir 
regimen, costs for health care, and laboratory tests [190]. The identified parameters 
are shown in Table 6.9. 
 
Table 6. 9 Cost parameters of LPV/r and its comparator 
Parameters of annual costs per patient Mean Reference 
Cost of IDV/r used for treatment of HIV/AIDS 49,821  [120, 198]  
Cost of LPV/r used for treatment of HIV/AIDS 41,327  [120, 198] 
Cost for treatment of rash 50.3 [190] 
Cost for treatment of clinical hepatitis  179.6  [190] 
Cost for treatment of neutropenia  1,203 [190] 
Cost for disease complication in 2nd line ARVs  1,788  [190] 
Cost for progression of 2st line ARV treatment 188,825  [190] [198] 
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Clopidogrel model: An average costs of clopidogrel 75 mg per day was 
multiplied by the price of drug at approximately 2 baht per tablet used for 365 days. 
Average costs for treatments of ticlopidine 200 mg every 12 hours used for 365 days 
was multiplied by the price of drug at approximately 5 baht per tablet. Costs for 
treatment of disease complications were excluded because the drugs are used for 
prevention. An average cost for treatment ADR contains the event of neutropenia at 
20,362 baht per episode as the main adverse events [201]. The ADR cost was 
multiplied by probabilities of the adverse event mentioned in the previous section. 
Finally, after patients failed to respond the prevention, an average cost for treatment 
during the disease progression of non-fatal stroke (as the secondary stroke) at 50,979 
baht per year was obtained from a Thai cohort study Khiaocharoen, 2012 [201]. This 
cost contained costs for treatment for stroke with inpatient rehabilitation service in 
every 4 months. The researcher collected the cost from medical record review from 
the Nareasuan University hospital [201]. The identified parameters are shown in 
Table 6.10. 
 
Table 6. 10 Cost parameters of clopidogrel and its comparator 
 
Parameters of annual costs per patient Mean Reference 
Cost of ticlopidine used for 2nd prevention 3,879  [198, 202] 
Cost of clopidogrel used for 2nd prevention 730  [198, 202] 
Cost for treatment of neutropenia 20,362  [201] 
Cost for health care during the progression of stroke 50,979  [201] 
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Letrozole model: An annual cost for treatments with tamoxifen (20 mg 
daily) at 3,549 baht was calculated by using the drug price at approximately 9.7 baht 
per 20mg tablet used daily for 365 days. An annual cost for treatments with letrozole 
(2.5 mg daily) at 2,847 baht was calculated by using the drug price at approximately 
7.8 baht per 2.5 mg tablet used daily for 365 days. The costs were used to estimate 
costs for treatment by switching therapy for tamoxifen for three years followed by 
letrozole for two years, or monotherapy of tamoxifen for five years. The main ADR 
for breast cancer treatment is virginal breeding, which is required inpatient care. The 
inpatients care cost was calculated based on relative weights (RW) of Diagnostic 
Related Groups (DRG). The cost was estimated from the RW of virginal bleeding 
(2.2163 RW) multiplied by the cost per RW (8,000 baht). In addition, costs for 
complementary treatment during being on the therapy accounted for 37,357 baht per 
year [203]. The cost was multiplied by probabilities of the adverse event mentioned 
in the previous section. Costs for treatment of disease complications during the 
disease responsiveness accounted for 4,510 baht per year. Costs for treatment during 
the state of disease progression after patients failed to respond the treatment in 
question accounted for 91,518 baht per year [203]. The cost information obtained 
from Limwattananont 2005. The researcher collected costs from a medical record 
review in Khonkhan University Hospital [203]. The identified parameters are shown 
in Table 6.11 
 
Table 6. 11 Cost parameters of letrozole and its comparator 
 
 Parameters of annual costs per patient Mean Reference 
Cost of tamoxifen used for treatment of breast cancer 3,549  [186, 198] 
Cost of letrozole used for treatment of breast cancer 2,847  [186, 198] 
Cost for treatment of  virginal breeding 17,730 [203] 
Cost for health care during being on the therapy 37,357  [203] 
Cost for health care during the disease responsiveness  4,510 [203] 
Cost for health care during the disease progression 91,518  [203] 
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Docetaxel model: An annual cost for treatments of docetaxel 100 mg /m2 
every 21 days (1 cycle) for 4 cycles was multiplied by an average price of drug at 
2,999 baht per 100mg [186, 198]. A cost for treatment adverse effects of neutropenia 
was at 1,899 baht per year [204]. The costs were multiplied by probabilities of the 
adverse event mentioned in the previous section. In addition, costs for health care 
during the disease responsiveness and disease progression of advanced NSCLC, 
were obtained from Thai study Thongprasert 2012 [204]. The researcher collected 
costs by medical record review from Maharaj Nakorn Chiang Mai Hospital. The cost 
of health care during the disease responsiveness was at 38,210 baht per year [205]. The 
cost of health care during the disease progression after patients failed to respond the 
treatment in question was at 59,200 baht per year [205]. This cost contains costs for 
treatment for malignant pleural effusion, palliative radiation, pain control and 
nutrition. For the comparator, patients receive the best supportive care, as the 
docetaxel for NSCLC has no alternative treatments. Although there was no cost in 
the first year, it was assumed that the disease progressed rapidly and then the 
patients moved to the health state of disease progressiveness in the next year of 
model cycle with the costs of 59,200 baht per year [205]. The identified parameters 
are shown in Table 6.12 
 
Table 6. 12 Cost parameters of docetaxel and its comparator 
 
 Parameters of annual costs per patient Mean Reference 
Cost of docetaxel used for treatment NSCLC 23,988  [186, 198] 
Cost for adverse effect treatment of docetaxel 1,899  [204] 
Cost for health care during the disease responsiveness 38,210  [205] 
Cost for health care during the disease progression        
(Best supportive care) 
59,200  [205] 
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6.2.5 Number of patients 
 According to background information of the Thai health system in chapter 3, 
among the three public health schemes, only patients under the CSMBS have been 
eligible to access the patented drug. Therefore, the CL policy affects only patients 
under the UC scheme of NHSO, and the SSS scheme of SSO. The numbers of 
patients receiving the drugs under CL policy were obtained from secondary data 
collected by the NHSO and SSO. The NHSO and SSO obtain the data from 
hospitals across the country. All hospitals that provide the CL drugs have to report 
the number of patients, drug dosages, and medical care costs to the NHSO and SSO 
every month in order to disburse health care budgets. I used the total annual number 
of patients receiving CL drugs to estimate policy implications. After the 
implementation of CL policy, the number of patients who received the CL drugs 
during 2007 and 2014 is shown in table 6.13.  
 
Table 6. 13 The number of patients receiving the drug under CL policy 
 
Drugs 2007 2008 2009 2010 2011 2012 2013 2014 
Efavirenz 15,582  23,302  29,291  36,623  44,378  51,931  59,918  61,298  
LPV/r N/A 3,889  6,708  10,717  15,111  18,789  21,758  22,259  
Clopidogrel 
N/A N/A 2,856  6,683  10,282  5,868  9,048  10,857  
Letrozole N/A N/A N/A 1,558  2,629  1,330  1,382  871  
Docetaxel 
N/A N/A 264  434  724  1,186  1,192  882  
Sources: NHSO and SSO 
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6.2.6 Data analysis 
I employed Markov models to estimate lifetime treatment cost savings. The 
Markov models were used to simulate the progression of diseases in question. The 
models were divided into three distinct states (from when patients started the 
treatment until the patients died) and transitional probabilities were assigned for 
movement between these states over one year of cycle time period. By attaching 
estimates of resource use per patient to the states and the transitions in the model, 
and then running the model over the large number of cycles until reaching the 
patient’s lifetime limit, it is possible to estimate the lifetime costs of the patients 
receiving the drugs of interest. After obtaining the lifetime costs per patient 
receiving either the treatment of factual scenario or counter-factual scenario, the 
costs were multiplied by the total number of patients under the policy. As the costs 
for treatment with drugs used prior to CL policy were more expensive than those of 
the CL drugs, the differences between total costs of treatment in factual scenario and 
counter-factual scenario were the lifetime treatment cost savings.    
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6.3 Results 
In the result section, all costs presented in this section were converted to be 
in 2015 US$. The total life-time costs for treatment per patient by efavirenz 
compared to nevirapine were 24,486 US$ and 26,605 US$, respectively (Table 
6.14). There were savings from the treatment costs during the responsiveness and 
progression states at 429 and 1,690 US$, respectively. The total difference in 
treatment costs per patient was 2,119 US$. For the eight-year of CL implementation, 
the total number of patients receiving the drugs was at 322,323 patients. Lifetime 
treatment costs saved by around 683 million US$ (Table 6.15).  
 
Table 6. 14 Life-time costs of treatment during responsiveness and progression 
per patient receiving NVP and EFV regimens (2015 US$) 
 
 
Costs per patient Nevirapine Efavirenz Difference 
Costs in responsiveness 3,223 2,793 429 
Costs of progression 23,383 21,693 1,690 
Total 26,605 24,486 2,119 
 
Table 6. 15 Life-time treatment costs for new patients receiving NVP and EFV 
regimens (2015 US$) 
 
The year at the 
treatments start 
Number of 
new cases 
Lifetime costs of the patients  Policy implications 
Nevirapine Efavirenz Cost savings 
2007 15,582 414,563,555 381,543,304 33,020,251 
2008 23,302 619,956,357 570,576,439 49,379,918 
2009 29,291 779,295,410 717,224,035 62,071,375 
2010 36,623 974,365,362 896,756,541 77,608,821 
2011 44,378 1,180,689,349 1,086,646,691 94,042,658 
2012 51,931 1,381,639,069 1,271,590,638 110,048,431 
2013 59,918 1,594,135,482 1,467,161,577 126,973,905 
2014 61,298 1,630,850,776 1,500,952,474 129,898,302 
Total 322,323 8,575,495,359 7,892,451,698 683,043,661 
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The total life-time costs of treatment per patient by LPV/r compared to IDV/r 
were around 52,151 US$ and 62,279 US$, respectively (Table 6.16). There were 
savings from treatment costs during the responsiveness and progression states at 
2,513 and 7,614 US$, respectively. The total difference in treatment costs per patient 
was 10,128 US$. For the eight-year of CL implementation, the total number of 
patients receiving the drugs was 99,231 patients. Lifetime treatment costs were 
saved by around 1,005 million US$ (Table 6.17). 
Table 6. 16  Life-time costs of treatment during responsiveness and progression 
per patient receiving the drugs, IDV/r and LPV/r regimens (2015 US$) 
 
Costs per patient IDV/r LPV/r Difference 
Costs in Responsiveness                    12,615              10,102            2,513  
Costs of progression                    49,664              42,050            7,614  
Total                    62,279              52,151           10,128  
 
Table 6. 17 Life-time treatment costs for new patients receiving the drugs, 
IDV/r and LPV/r regimens (2015 US$) 
Years at the 
treatments start 
Number of 
new cases 
Lifetime costs of the patients  Policy implications 
IDV/r LPV/r Cost savings 
2008 3,889 242,202,980 202,816,827 39,386,153 
2009 6,708 417,767,443 349,831,646 67,935,797 
2010 10,717 667,443,901 558,906,642 108,537,259 
2011 15,111 941,097,769 788,059,930 153,037,839 
2012 18,789 1,170,159,882 979,872,809 190,287,073 
2013 21,758 1,355,066,194 1,134,710,340 220,355,854 
2014 22,259 1,386,267,966 1,160,838,195 225,429,771 
Total 99,231 6,180,006,136 5,175,036,389 1,004,969,747 
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The total life-time costs for treatment per patient by clopidogrel compared to 
ticlopidine were around 12,517 US$ and 13,050 US$, respectively (Table 6.18). 
There were savings from treatment costs during the responsiveness and progression 
states at 280 and 254 US$, respectively. The total difference in treatment costs per 
patient was 533 US$. For the six-year of CL implementation, the total number of 
patients receiving the drugs was of 45,594 patients. Lifetime treatment costs were 
saved by around 24 million US$ (Table 6.19). 
Table 6. 18 Life-time costs of treatment during responsiveness and progression 
per patient receiving the drugs, ticlopidine and clopidogrel regimens (2015 
US$) 
 
 
Costs per patient ticlopidine clopidogrel Difference 
Costs in Responsiveness            353                74             280  
Costs of progression      12,697       12,443             254  
Total      13,050       12,517             533  
 
Table 6. 19 Life-time treatment costs for new patients receiving the drugs, 
ticlopidine and clopidogrel regimens (2015 US$) 
 
The years at the 
treatments start 
Number of 
new cases 
Lifetime costs of the patients  Policy implications 
Ticlopidine Clopidogrel Cost savings 
2009 2,856 37,274,530 35,751,410 1,523,121 
2010 6,683 87,215,424 83,651,607 3,563,817 
2011 10,282 134,177,576 128,694,780 5,482,796 
2012 5,868 76,575,142 73,446,111 3,129,032 
2013 9,048 118,076,266 113,251,406 4,824,860 
2014 10,857 141,691,520 135,901,687 5,789,832 
Total 45,594 595,010,459 570,697,000 24,313,458 
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The total life-time costs for treatment per patient by switching therapy of 
tamoxifen and letrozole compared to monotherapy of tamoxifen were around 7,190 
US$ and 7,297 US$, respectively (Table 6.20). There were savings from treatment 
costs during the responsiveness and progression states at 22 and 84 US$ 
respectively. The total difference of treatment costs per patient was at 107 US$. For 
the five-year of CL implementation, the total number of patients receiving the drugs 
was at 7,770 patients. Life-time treatment costs were saved by around 0.83 million 
US$ (Table 6.21). 
Table 6. 20 Life-time costs of treatment during responsiveness and progression 
per patient receiving the monotherapy and switching therapy regimens (2015 
US$) 
 
 
Costs per patient Monotherapy Switching therapy Difference 
Costs in Responsiveness            6,844               6,822             22  
Costs of progression               453                 369             84  
Total           7,297               7,190             107  
 
 
Table 6. 21 Life-time treatment costs for new patients receiving the 
monotherapy and switching therapy regimens (2015 US$) 
 
 
Year at the 
treatments start 
Number of 
new cases 
Lifetime costs of the patients  Policy implications 
Monotherapy Switching therapy Cost savings 
2010 1,558 11,369,024 11,202,527 166,496 
2011 2,629 19,184,316 18,903,366 280,949 
2012 1,330 9,705,264 9,563,133 142,131 
2013 1,382 10,084,718 9,937,030 147,688 
2014 871 6,355,853 6,262,774 93,080 
Total 7,770 56,699,175 55,868,830 830,345 
 
 
 
 
 
 
127 
 
The total life-time costs for treatment per patient by docetaxel compared to 
the best supportive care (BSC) were around 2,948 US$ and 3,281 US$, respectively 
(Table 6.22). Although there was a cost for treatment during the responsiveness state 
at 2,165 US$, the treatment during the progression state could save at 2,499 US$. 
The saving of treatment costs per patient was at 334 US$. For the six-year of CL 
implementation, the total number of patients receiving the drugs is 4,682 patients. 
Life-time treatment costs were saved by around 1.56 million US$ (Table 6.23). 
Table 6. 22 Life-time costs of treatment during responsiveness and progression 
per patient receiving the best supportive (BSC) care and docetaxel regimens 
(2015 US$) 
 
 
Costs per patient BSC Docetaxel Difference 
Costs in Responsiveness                    -                 2,165              - 2,165  
Costs of progression             3,281                   783                2,499  
Total             3,281               2,948                    334  
 
Table 6. 23 Life-time treatment costs for new patients receiving the drugs best 
supportive care and docetaxel regimens (2015 US$) 
 
Year at the 
treatments start 
Number of 
new cases 
Lifetime costs of the patients  Policy implications 
BSC Docetaxel Cost savings 
2009 264 866,681 778,516 88,165 
2010 434 1,424,771 1,279,833 144,938 
2011 724 2,376,421 2,134,674 241,748 
2012 1,186 3,890,409 3,494,648 395,762 
2013 1,192 3,912,038 3,514,076 397,962 
2014 882 2,892,799 2,598,522 294,277 
Total 4,682 15,364,278 13,801,308 1,562,971 
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The comparative benefits per patient in terms of life year gains and lifetime 
cost savings are seen in Table 6.24. The total life year gained per person was 2.99 
years, and life-time cost savings were 13,221 US$ per person. For the total 
population of 479,600 patients, the total life-time treatment costs by the five CL 
drugs compared to its comparators were 15,442 and 13,708 million US$, 
respectively (see Table 6.25). It was found that the eight-year of CL implementation, 
the total life-time treatment costs were saved by around 1,715 million US$.  
Table 6. 24 Comparative benefits per patient in terms of life-year gains and life-
time treatment costs across five drugs (2015 US$) 
 
  Year Comparators Interventions Policy implications 
  Life 
years 
Lifetime 
costs 
Life 
years 
Life-time  
costs 
Year 
gains 
Cost 
savings 
Efavirenz 24 26,605 25 24,486 1 2,119 
LPV/r 26 
 
62,279 27.5 
 
52,151 1.5 10,128 
Clopidogrel 10.8 
 
13,050 11 
 
12,517 0.20 533 
Letrozole 16.1 
 
 
7,297 16.4 
 
7,190 0.31 107 
Docetaxel 1.1 
 
3,281 1.4 
 
2,948 0.34 334 
Total 78.05 112,809 81.04 99,292 2.99 13,221 
Abbreviation: LPV, lopinavir and ritonavir combination;  
 
Table 6. 25 Life-time treatment costs in the total population across five drugs 
(2015 US$) 
 
  Year Number of 
patients 
Comparators Interventions Policy implications 
  Life-time costs Life-time costs Cost savings 
Efavirenz 322,323 8,575,495,359 7,892,451,698 683,043,661 
LPV/r 99,231 6,180,006,136 5,175,036,389 1,004,969,747 
Clopidogrel 45,594 595,010,459 570,697,000 24,313,458 
Letrozole 7,770 56,699,175 55,868,830 830,345 
Docetaxel 4,682 15,364,278 13,801,308 1,562,971 
Total 479,600 15,422,575,408 13,707,855,225 1,714,720,182 
Abbreviation: LPV, lopinavir and ritonavir combination;  
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6.4 Discussion and conclusion 
In this chapter, lifetime treatment cost savings, resulting from CL 
implementation, were estimated in five drugs for HIV/AIDS, stroke and cancer. The 
drugs are: efavirenz, lopinavir and ritonavir combination (LPV/r), clopidogrel, 
letrozole and docetaxel. Markov models were employed to predict lifetime treatment 
cost savings using CL drugs compared to alternatives. Comparative benefits across 
different drug types were used to identify the key parameters, which should be 
incorporated in the drug selection criteria in order to gain the most benefit from CL 
implementation. The key parameters affecting policy implications include the 
number of patients in need of drugs, treatment effects of drugs in question, and drug 
costs for treatment of diseases in question. Regarding the of lifetime treatment for 
patients receiving CL drugs from 2007 to 2014, it was found that the second line 
ARV therapy with LPV/r created the highest cost savings at US$ 1,005 million, 
followed by the first-line ARV treatments with efavirenz at US$ 683 million, and 
the secondary prevention of stroke with clopidogrel at US$ 24 million. For the other 
two drugs, docetaxel used for treatment of lung cancer and letrozole used for 
treatment of breast cancer, the cost savings were 1.56 and 0.83 million US$, 
respectively.  
The findings are consistent with previous literature in Thailand. For example, 
HIV/AIDS and stroke were the leading causes of public health burden, which 
includes not only the number of patients but also morbidity and mortality of diseases 
in Thailand. Empirical evidence of the Thai disease burden indicates that HIV/AIDS 
was the 1st rank for male and the 2nd rank for female, while stroke was the 1st rank 
for female and the 3rd rank for male. However, using clopidogrel for stroke 
treatment creates budget savings significantly lower than HIV/AIDS because the 
other factors (such as comparative treatment effects and costs of drugs compared to 
its alternatives) affected total budget savings. For cancer drugs, the total cost savings 
were lower than that of HIV and stroke, because breast cancer and lung cancer were 
11th and 18th rank. In addition, letrozole and docetaxel are recommended to be used 
for specific types of breast and lung cancers. Therefore, one of the key parameters, 
which could help policy makers to select the drugs for treatment of a certain disease is 
the national data of disease burden published by the Burden of Disease Department, 
the International Health Policy Program [206]. In addition, in a comparison of two 
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cancer drugs, docetaxel saved more treatment costs. The key explanation was that 
docetaxel had no alternative treatment [186], and without treatment the disease could 
progress quickly, leading to increased treatment costs through the high cost of 
treatment when the disease progressed. Therefore, the issue of drugs used for diseases 
with no alternative treatments is another important factor that should be included in 
the criteria for drug selection. The criteria were also mentioned in the meeting of 
health economic working group under the Thai NLEM committee [207].    
Previous studies provided explicit parameters for drug selection: (1) the 
number of patients in need of the drugs, which could be estimated by using 
epidemiological data of disease prevalence and incidence; (2) the safety and efficacy 
of the drug, gained by comparing them with available alternatives; (3) the difference 
in prices between the currently available patented versions and the proposed 
generics; (4) the remaining period of patent protection of the drug; (5) variations in 
prescription practices of health care practitioners and the potential for irrational drug 
use; and (6) the preparedness of streamlined procedures for registration, importation 
and distribution of generic drugs under CL policy [70].  
The findings of my study are consistent with previous suggestions, but add 
other important factors especially for the first three parameters relevant to the 
aspects of drugs. It suggests that the drug selection criteria should be adjusted as 
follows: (1) it should not target only the number of patients, but consider the 
diseases which are the leading causes of public health burden, because it measures 
patient numbers as well as morbidity and mortality of the diseases in question; (2) it 
should not only look at the difference in prices between patented and generic drugs, 
but rather analyse the difference in total treatment costs between the potential CL 
drugs and current practices; (3) it should not only select the drug with the highest 
safety and efficacy profile, but also drugs which are required to treat diseases with 
no alternative treatments.  
Limitations of this study are that the implications of CL policy were 
evaluated by comparing the lifetime treatment cost of patients in the situation with 
and without CL policy. However, it is clear that measuring the same person in two 
different states at the same time is impossible. At any given moment in time, an 
individual either participated in the program or did not participate. The person 
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cannot be observed simultaneously in two different states of with and without the 
CL policy. This is called “the counterfactual problem”: How do we measure what 
the outcome would have been for participants in the absence of the policy, or if the 
policy had not been implemented. In the case of my study evaluating implications of 
CL policy, for instance, it is not possible to construct a counterfactual by creating a 
control group or a comparison group.  
One of the common approaches to deal with the counterfactual problem is 
comparisons of the outcomes of program participants prior to and subsequent to the 
introduction of a program (before-and-after, or pre-and-post comparisons). 
Therefore, in my study, I compared drug regimens recommended by the Thai 
clinical practice guidelines (CPGs) before and after CL was implemented for the 
five drugs. I selected the comparators from the drug regimens that the Thai CPGs 
recommended as the first choice of treatment before CL implementation to be the 
counterfactual scenarios (baseline comparators). All of the baseline comparators 
were out of patent protection. After the availability of generic drugs under the CL 
policy, the drug regimens recommended in the Thai CPGs were changed, and this 
was set as the factual scenario. I accordingly assumed that outcomes of interest as 
measured before and after the CL were acceptable to evaluate implications of CL 
policy. 
The numbers of patients receiving the drug were total annual numbers, which 
were not possible to disaggregate into individual data. Therefore, several 
assumptions were made in the analysis. First, although there may be drop-off in 
some patients during the treatment period or recurrent after the treatment may occur 
in some cases of patients, the data could not be used to identify that patient group. 
Therefore, it was assumed that all patients received complete drug treatment 
according to the protocol. Second, in practice, drug regimens may be adjusted by 
physicians for each patient leading to case-by-case variation in treatment cost. This 
study used the common regimen suggested by Thai CPGs to calculate an average 
cost for treatment to all patients. Third, the cost of treatment may vary according to 
the age of patients. This study used the average age of patients living with each of 
the diseases in question as the age for all patients in each specific disease. It was 
assumed that younger patients consuming higher costs would compensate for the 
lower costs of older patients. 
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In conclusion, the findings in this chapter could be used to help identify a set 
of explicit parameters for inclusion in the drug selection criteria within the 
preliminary framework of CL policy. Comparative costs across different drug types 
were used to identify key elements, which created the highest cost saving, in order to 
shape the criteria for CL drug selection. Key elements in the drug selection criteria 
are: (1) Drugs for treatment of a disease, which is a leading cause of public health 
burden; (2) Drugs which create the highest difference in treatment cost compared to 
current practices; (3) Drugs which are required for diseases with no alternative 
treatment. The revisions of drug selection criteria suggested above could not only 
promote the transparency of the policy decision process, but also help policy makers 
and elites to consider which drugs could potentially create the greatest benefits to 
society. 
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Chapter 7: The Thai government’s performance in 
implementation of CL policy  
 
7.1 Introduction 
The preliminary framework in Chapter 5 required complementary 
information to strengthen the policy content. While the findings from Chapter 6 
were used to strengthen the contents of criteria for drug selection at the decision-
making stage, this Chapter aims to strengthen contents at the policy implementation 
stage through evaluating the policy performance. The objective of this chapter is to 
evaluate the performance of the Thai government in implementing CL policy in the 
areas of drug procurement, substitutions of generic drugs for the patented version, 
and improving drug access improvements.  Success or failure in each area of policy 
implementation was investigated, and key elements affecting CL policy performance 
were identified in order to develop strategies to improve the policy performance. 
The findings could help strengthen the policy implementation framework. In this 
chapter, I evaluated the Thai government’s performance in implementing CL policy 
for the five CL drugs: Efavirenz, LPV/r, clopidogrel, letrozole and docetaxel. The 
conditions for implementing the policy were different across these five medicines, 
and these may create different effects on the performance for drug procurement, 
drug substitution and drug access. The details of each area are as follows.  
First, drug procurement performance was evaluated to assess whether the 
drug supply completely met demand. Drug supply referred to the volume of drug 
procured by the Government Pharmaceutical Organization (GPO) as the main 
procurement agency for CL drugs, and drug demand referred to the purchase order 
from the three public health benefit schemes: the Civil Servants Medical Benefit 
Scheme (CSMBS), the Social Security Scheme (SSS), and the Universal Coverage 
(UC). However, the market conditions for each drug differ in terms of the numbers 
of generic drug suppliers. For example, there are more generic manufacturers in the 
ARV market than for other drugs. The limited number of generic drug suppliers for 
clopidogrel, letrozole and docetaxel made it difficult for the GPO to procure enough 
drugs to completely meet the demand. Therefore, different market conditions among 
generic drug suppliers of the five CL medicines could create different effects on 
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drug procurement, and the incomplete supply of CL drugs could reflect an area of 
improvement for government performance. 
Second, The Thai government has sought to build up the practitioners’ 
confidence through quality assurance of CL drugs.  Substitution of CL generic drugs 
for patented versions was evaluated in terms of changes in practitioners’ prescribing 
patterns. Changes in prescribing behavior result from the confidence of practitioners 
in the quality, safety and effectiveness of CL drugs, and accepting them as 
substitutes for patented drugs. The quality of efavirenz, LPV/r and clopidogrel are 
approved by the Thai Food and Drug Administration (FDA), the Department of 
Medical Science (DMS) and the Government Pharmaceutical Organization (GPO). 
However, because Thailand lacks the capacity to assure the quality of chemotherapy 
products, international laboratories assure the quality of letrozole and docetaxel. In 
this section, the use of CL drugs under CSMBS is the best case for the evaluation, 
because patented drugs are only reimbursed under the CSMBS scheme and therefore 
physicians can choose either patented or generic drugs for CSMBS patients. 
Changes in the proportion of prescriptions for CL generic drugs versus its patented 
version for patients under CSMBS were evaluated, and the incomplete generic 
substitution could reflect weak government performance in this area.  
Third, the government performance in promoting drug access was evaluated 
in terms of increased numbers of patients accessing drugs under CL policy. The UC 
and SSS schemes are the best cases for the evaluation because patients under both 
schemes paid for the drugs before the CL was implemented. Therefore, 
implementation of CL policy could improve access to drugs for patients under both 
schemes. The CL drugs have been monitored to control uses within treatment 
indications suggested by the CL proposal. This practice is beneficial to not only 
promote rational drug use, but also prevent over-consumption because of the lower 
prices of CL drugs. Each drug is monitored differently which may affect drug 
access. Efavirenz and LPV/r are monitored by the health benefit schemes because 
ARV drugs are operated within a special ARV treatment program. Letrozole and 
docetaxel are monitored by the state committee of the National List of Essential 
Medicines (NLEM) because complicated cancer treatments have been operated as an 
NLEM programme. As clopidogrel is not operated by any special program, the drug 
is monitored at health care facilities. Although CL aims to increase drug access for 
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all patients, the different mechanisms of drug regulation may create different effects 
on drug access, and incomplete access could reflect an area to improve government 
performance.   
    
7.2 Methods 
Each of the areas of policy performance mentioned above contains two 
analytical steps. The first step is to evaluate policy performance by comparing actual 
performance (as factual scenarios) with ideal performance (as counter factual 
scenarios), which allows us to consider the implications of defective performance or 
unanticipated results. In the second step, if there were any unanticipated results from 
implementing the policy, I evaluated the magnitude of its implications in monetary 
terms. The magnitudes of implications in each of the three policy areas were used to 
prioritise areas of performance that the Thai government should improve in order to 
gain maximum financial benefits of policy implementation.  
Data sources on drug procurement, substitution and access were obtained 
from Thai government departments. I sent formal letters requesting retrieval of the 
data with clarification of the research objectives. The data were provided by four 
governmental organisations; the Government Pharmaceutical Organization (GPO), 
the National Health Security Office (NHSO), the Health Insurance Systems 
Research Office (HISRO), and the Drug and Medical Supply and Information 
Centre (DMSIC). Most of retrieved data were from the period of January 2007 to 
June 2014, except data on the section of drug substitution, which are available only 
for the period of January 2012 to June 2014. The data sources are shown in figure 
7.1 and details of data analysis within each section are provided alongside. 
 
Table 7. 1 Sources of data 
Organizations Data details 
Government Pharmaceutical 
Organization (GPO) 
Volumes and prices of generic drugs procured under CL 
policy and volumes of drug ordered from health benefit 
schemes. 
 
Health Insurance Systems 
Research Office (HISRO) 
Volumes of patented and generic drugs purchased under 
the Civil Servants Medical Benefits Scheme (CSMBS).  
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Organizations Data details 
National Health Security 
Office (NHSO) 
The number of patients who accessed CL drugs under 
the Universal Coverage (UC) scheme.  
Social Security Office (SSO) The number of patients who accessed CL drugs under 
the Social Security Scheme (SSS).  
 
Drug and Medical Supply and 
Information Centre (DMSIC) 
Annual prices of patented drugs procured by public 
hospitals across the country. 
 
7.2.1 Implications of incomplete supply of CL drugs  
For the area of drug procurement, the data were analysed at the national level 
by including all the three public health benefit schemes (CSMBS, SSS and UC). 
Procurement data were obtained from the Government Pharmaceutical Organization 
(GPO) as the national drug procurement agency. Performance was evaluated 
according to whether the GPO drug supply met the national demand of the three 
schemes. The volume of drug supply (procurement from drug manufacturers) and 
drug demand (drug purchase order from health benefit schemes) is recorded and 
maintained real-time by the GPO through the vendor managed inventory (VMI) 
system. During the eight-year period of CL policy, all CL drugs except LPV/r were 
supplied by Indian generic drug manufacturers. LPV/r was produced by the GPO 
through technology transfer from Indian firms. However, when the Indian drug 
supply was not sufficient to meet demand, further supplies were procured from other 
sources.  
The Thai government’s performance in drug procurement was analysed in 
two steps: (i) whether the there was sufficient supply of generic drugs under the CL 
policy to meet the national demands, and (ii) if an incomplete supply of CL drug 
occurred, what was the implication. In the period of incomplete supply, the GPO had 
to purchase drugs from other sources at higher prices than that of CL sources. 
Therefore, the Thai government had to shoulder the burden by paying higher prices 
throughout this period. The longer the incomplete supply occurred, the higher the 
costs of using the more expensive sources of drugs. Implications were estimated in 
terms of procurement cost differences between using the drugs obtained from other 
sources and CL sources.   
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There are two steps of analysis. First, CL drug procurement was analysed to 
identify the type of drug and any period of incomplete supply. I compared annual 
volumes of generic CL drug supply (Si) and annual national demand for drugs (Di) 
throughout the CL period. For any incomplete supply of CL drugs, the gaps between 
the supply and demand reflected the magnitudes of the implications from the 
incomplete supply in CL drug procurement. Second, the costs of the incomplete 
supply were estimated by multiplying the magnitudes of the gaps (Di-Si) by the 
respective drug price. Average prices of drugs, which were provided by GPO from 
other sources during the short supply periods (POtsi) represented the factual 
scenario, and average prices of CL drugs (PClsi) represented the counterfactual 
scenario. The formula to estimate implications in terms of costs of failure in drug 
procurement is shown below. 
         IDP = (Di – Si) x (PClSi)) – ((Di – Si) x POtsi)) 
IDP: implications of drug procurement due to the cost of over the period of i (year of each drug commencing 
purchase) to n (year 2014/Q2) 
Di: Annual actual demand under CL policy (in units of milligrams) 
Si: Annual actual supply under CL policy (in units of milligrams) 
POts: Average prices of drugs from other sources (in units of US$ per milligrams) 
PCls: Average prices of generic CL drug (in units of US$ per milligrams) 
 
7.2.2 Implications of incomplete CL generic drug substitution 
As mentioned earlier, this section focuses on the volume of patented drugs 
substituted by CL generic versions under the CSMBS. It was checked whether 
generic CL drugs used by practitioners at health care facilities fully substituted its 
patented versions under the CSMBS. The HISRO monitored the volume of drugs 
through the drug reimbursement system. The HISRO is a research institute, which 
plays an important role in monitoring CSMBS’s performance. However, there are 
limitations to the data used in this section. The volume of patented docetaxel is not 
included in the database because it is an inpatient drug directly reimbursed by the 
DRG payment mechanism. In addition, only three years of data (from 2012 to 2014 
Q2) of patented and generic drug volumes was collected by the HISRO. CL generic 
substitutions under the CSMBS scheme were analysed in two parts: (i) whether the 
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patented drugs were fully substituted by their CL generic versions, and (ii) if an 
incomplete substitution occurred, what was the implication in monetary terms.  
There are two steps of analysis. First, government performance in promoting 
generic drug substitution was analysed through proportions of CL generic within 
total volumes of the drug prescribed to patients. The gap between the actual use of 
CL generic drugs (factual scenarios) and the total use of patented and CL generic 
drugs (counter-factual scenarios) reflected the magnitude of the implications from 
the incomplete substitutions. Second, the implications in terms of the health care 
costs arising from incomplete substitutions were evaluated by multiplying the annual 
difference between use of CL drugs and total use of the drugs (CL and patented 
drugs) by CSMBS patients (Gcsmbsi) with the average prices of CL generic drugs 
(PClsi) and patented drugs (PPtsi). The formula is shown below. 
IDS = (Gcsmbsi x PClsi) – (Gcsmbsi x PPtsi)) 
 
IDS: Implications of drug substitution as the summation of costs over the period of i (year of each drug 
commencing   purchase) to n (year 2014/Q2) 
Gcsmbsi: Annual gaps between actual uses of CL drugs and the total actual uses of the drugs (CL and 
patented drugs) by CSMBS patients (in units of tablet) 
PClsi: Average prices per year of CL drugs (in units of US$/ tablet) 
PPtsi: Average prices per year of patented drugs used prior to CL (in units of US$/ tablet) 
 
 
7.2.3 Implications of incomplete access to CL drugs 
This section focuses on the number of patients who accessed CL drugs under 
the SSS and UC schemes, assessing whether patients numbers under the two 
schemes matched expectations. Expected numbers of patients in need of the CL 
drugs were obtained from a previous Thai study conducted in 2011 by HITAP [70]. 
Data in the HITAP study was estimated by using linear equations based on historical 
epidemiological data, and adjusted by minimum possibilities of patients receiving 
the drugs. As these expected data have been accepted by policy makers and 
stakeholders [70], the data are used as a benchmark of expected number of patients 
in need of CL drugs. This section was classified into two parts: (i) whether the actual 
 
 
139 
 
number of patients receiving the CL drugs matched the expected number of patients 
in need of the drugs; (ii) if incomplete access occurred, what were the implications.  
There are two steps of analysis. First, performance in promoting drug access 
was evaluated in terms of the increase in patients receiving the drugs after CL was 
granted. The difference between expected numbers of patients (EPi) and actual 
numbers of patients (CPi) reflected incomplete access as an unanticipated result. 
Second, the implications of incomplete access were evaluated in monetary terms. 
For any incomplete access, patients who have not received CL drugs are given 
alternative drugs recommended in the CPGs, which have higher costs than CL 
drugs. Therefore, the more incomplete access, the greater the increase in health care 
costs. To estimate the cost, the annual difference in expected and actual drug access 
(EPi – CPi) was multiplied by the difference between treatment costs using CL 
drugs (CCli) and alternative drugs (CAti). The formula to estimate the cost 
implications of failure to promote drug access is shown below.  
IDA = (EPi– CPi) x (CCli) – (EPi– CPi) x (CAti)) 
IDA: Implications of drug access as the summation of costs over the period of i (year of each drug commencing 
purchase) to n (year 2014/Q2) 
EP: Expected annual numbers of SSS and UC patients who access to the CL drug  
CP: Actual annual numbers of SSS and UC patients who access to the CL drug  
CCl: Average drug costs of CL drugs, based on regimens suggested by the Thai CPGs (in units of US$ per patient per 
year) 
CAt: Average drug costs of alternative drugs used prior to CLs, based on regimens suggested by the Thai CPGs, 
(in units of US$ per patient per year) 
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7.3 Results 
 
7.3.1 Implications of incomplete supply of CL drugs 
 The volumes of drug procurement under the CL policy are shown in Figures 
7.1 to 7.5. The figures show the names of the suppliers that delivered the generic 
drugs in a certain period of time. The axis on the left-hand side presents the volumes 
of drug in kilogram supplied under CL policy. According to information from GPO 
staff, there was over-stock in 2011 of all drugs; therefore, the volumes in 2012 were 
decreased as there were some remaining drugs from 2011.   
Efavirenz for the treatment of HIV/AIDS: The generic efavirenz has been 
imported in Thailand since 2007 (Figure 7.1). The drug has been supplied by five 
different Indian generic firms; Ranbaxy Laboratories Ltd, Emcure Pharmaceutical 
Ltd, Aurobindo Pharma Ltd, Matrix Laboratories Ltd and MyLan Laboratories Ltd. 
Because of several sources of generic suppliers in the market, the price of efavirenz 
decreased throughout the period from 28 baht (0.8 US$) in 2007 to 5 baht (0.14 
US$) in 2014 / per 600mg tablet (82% price decrease).  
 
Figure 7. 1 Volume of generic efavirenz drugs and its suppliers 
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Lopinavir and ritonavir (LPV/r) for the treatment of HIV/AIDS: The 
generic version of LPV/r has been imported into Thailand since January 2008. In 
addition, the GPO proposed a strategic plan to obtain technologies transferred from 
Matrix Laboratories Ltd. to produce a generic version of LPV/r. As a result, 
although there were limited generic suppliers, the drug demands were satisfied by 
the locally made generic LPV/r (Figure 7.2). After the drug was locally produced by 
the government sector, the Indian generic firm decreased the price of its product 
from 18 (0.51 US$) in 2008 to 13 baht (0.39 US$) / 250 mg tablet in 2012 (28% 
price decrease).       
 
 
 
 
Figure 7. 2 Volumes of generic LPV/r drugs and its suppliers 
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Clopidogrel for the treatment of cardiovascular disease: The generic 
clopidogrel has been imported to Thailand since June 2008. However, there has only 
been a small number of generic suppliers in the market. Moreover, some of the 
imported generic clopidogrel failed to meet quality standards, and the product was 
recalled from the market, and that led to incomplete supply to satisfy the drug 
demand during 2013 to 2014 (See figure 7.3). Consequently, the GPO had to find 
other sources to maintain the drug supply. During the incomplete supply period, the 
GPO purchased clopidogrel from another source (Apolets®) at the price (15 baht or 
US$0.44/ 75mg tablet), which was more expensive than that of the CL source (1 
baht or US$0.31/ 75 mg tablet).  
 
 
 
Figure 7. 3 Volumes of generic clopidogrel drugs and its suppliers 
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Docetaxel for treatment of lung and breast cancer: The implementation of 
CL policy on docetaxel also had the problems of incomplete supply because generic 
suppliers did not deliver the drugs in time leading to the country had short supply of 
the drug during 2010 to 2013 (Figure 7.4). Because of a small number of generic 
suppliers, docetaxel was substituted by donations from the patented firm (Novartis) 
though the Taxotere Access Program (TAP) with a condition of donation depending 
on a proportion of purchase at the normal price of patented drug (1 unit purchased 
for 5 units donated). Therefore, the GPO had to purchase the patented drug with the 
normal price, in order to obtain the donations of large volume, and the price per 
tablet was reduced to around 1,500 baht (US$154) / 20mg tablet approximately. In 
addition, during the incomplete supply period, Indian generic firms increased the 
price of their generic product from 557 baht (US$50) in 2009 to 981 baht (US$88) / 
20mg tablet in 2014 (76% price increase). 
  
 
 
Figure 7. 4 Volumes of generic docetaxel drugs and its suppliers 
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Letrozole for the treatment of breast cancer: The generic letrozole has 
been distributed to health care facilities since 2010. Due to a limited number of 
generic suppliers, the CL implementation was faced with problems of incomplete 
supply similarly to clopidogrel and docetaxel. The incomplete supply occurred when 
the generic supplier did not deliver the drugs in time during 2010 to 2012, and GPO 
had to find other sources of drug supply (Figure 7.5). The generic letrozole was 
substituted by its patented version with a discounted price from 159 baht (US$5) to 
78 baht (US$2.3) / 2.5mg tablet. The Indian generic firms increased the price of the 
generic products from 6 baht (US$0.18) in 2010 to 12 baht (US$0.35) in 2014/ 
2.5mg tablet (100% price increase).  
   
 
 
Figure 7. 5 Volumes of generic letrozole drugs and its suppliers 
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Implications of incomplete supply of drugs   
 
The incomplete supply occurred for clopidogrel during 2013 and 2014, 
letrozole during 2010 and 2012, and docetaxel during 2010 and 2013. As mentioned 
above, the generic drugs were obtained from other sources during the period of 
incomplete supply occurred. In the factual scenario, the actual prices of drugs from 
the other sources procured by the GPO were used. In the counter-factual scenario, an 
assumption was made that all patients still received the CL drugs. The table below 
shows the monetary implications of the incomplete supply. The total differences 
reflect costs from the incomplete supply of 5.9 million US$ (Table 7.2).     
 
Table 7. 2 The cost of incomplete supply of drug in US$ ($) 
 
 Implication of drug supply 2010 2011 2012 2013 2014 
(Q3s) 
Total 
C
ou
nt
er
fa
ct
ua
l  clopidogrel only from CL sources    123,425  16,983  140,408  
letrozole only from CL sources 38,607  108,455  88,859    235,921  
docetaxel only from CL sources 91,539  206,963  336,907  592,625   1,228,034  
Fa
ct
ua
l  
clopidogrel from the other sources 
   
1,550,318  134,363  1,684,681  
letrozole from the other sources 498,279  1,727,369  1,072,685    3,298,333  
docetaxel from the other sources 280,918  635,153  588,462  1,035,114   2,539,648  
Im
pl
ic
at
io
n Difference for clopidogrel    1,426,893  117,380  1,544,273  
Difference for letrozole 459,673  1,618,914  983,826    3,062,413  
Difference for docetaxel 189,380  428,190  251,555  442,489   1,311,614  
 
Total difference 649,052  2,047,104  1,235,380  1,869,382  117,380  5,918,299  
Abbreviation: Quarter (Q) 
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7.3.2. Implication of incomplete drug substitutions  
 
As mentioned in the introduction, this section focuses on the use of drugs 
under the CSMBS because only this scheme gives freedom to physicians and 
patients to choose patented or CL drugs for their treatment. The volumes of generic 
and patented drugs and the percentages of generic substitution to the total use of 
drugs are shown in Table 7.3. The increasing trends in percentages imply an 
improvement of practitioner’s perception on the quality of CL generic drugs. The 
proportions of efavirenz, LPV/r and letrozole have continually increased, while that 
of clopidogrel has fluctuated throughout the three-year period. Although the 
confidence of practitioners on quality of generic drugs seems to have increased for 
most of the CL drugs, full-substitution has not been achieved.  
 
Table 7. 3 Outpatient drug reimbursement data in CSMBS 
 
Outpatient drug used under CSMBS 2012 2013 2014 (3Qs) 
Volume used of generic efavirenz (tablets) 16.9 x107 55.3 x107 30.8 x107 
Volume used of patented efavirenz (tablets) 55.5 x107 69.8 x107 38.2 x107 
Percentage of generic to total use 23% 44% 45% 
Volume used of generic LPV/r (tablets) 3.2 x107 15.9 x107 9.8 x107 
Volume used of patent LPV/r (tablets) 34.7 x107 47.1 x107 27.4 x107 
Percentage of generic to total use 9% 25% 26% 
Volume used of generic clopidogrel (tablets) 14.5 x107 36.3 x107 17.5 x107 
Volume used of patent clopidogrel (tablets) 106.3 x107 180.1 x107 108.1 x107 
Percentage of generic to total use 12% 17% 14% 
Volume used of generic letrozole (tablets) 0.3 x107 0.8 x107 1.7 x107 
Volume used of patent letrozole (tablets) 0.08 x107 0.11 x107 0.06 x107 
Percentage of generic to total use 3% 7% 23% 
Abbreviation: Quarter (Q); lopinavir and ritonavir combination (LPV/r) 
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The incomplete drug substitution during 2012 and 2014. As mentioned 
above, in the factual scenario, the actual prices of patented drugs were used, while in 
the counter-factual scenario, an assumption was made that all patented uses were 
substituted by generic drugs and actual prices of generic drugs were used. The costs 
of incomplete substitution amounted to 119 million US$ during the three years, as 
shown in Table 7.4. 
 
Table 7. 4 The cost of incomplete substitution of generic drug in US$ ($) 
 
 Implication of drug supply 2012 2013 2014 (Q3s) Total 
C
ou
nt
er
fa
ct
ua
l 
efavirenz with CL drug only           133,429            167,386              91,671  392,486  
LPV/r with CL drug only           496,594            672,314            390,784  1,559,691  
clopidogrel with CL drug only           440,906            840,604            805,809  2,087,319  
letrozole with CL drug only             65,429            139,620              82,101         287,150  
Fa
ct
ua
l  
efavirenz with partial patented drug 705,557            887,686        485,821     2,079,064  
LPV/r with partial patented drug  1,019,152         1,584,398           920,978      3,524,528  
clopidogrel with partial patented drug     30,297,646         51,356,766       30,819,820   112,474,232  
letrozole with partial patented drug        1,609,117          2,151,418        1,054,646       4,815,181  
Im
pl
ic
at
io
ns
 
Differences for efavirenz  572,128   720,300   394,150  1,686,578  
Differences for LPV/r  522,558   912,085   530,195   1,964,837  
Differences for clopidogrel  29,856,740  50,516,162   30,014,010  110,386,912  
Differences for letrozole  1,543,688   2,011,798   972,545   4,528,031  
 Total differences  32,495,114   54,160,344   31,910,900   118,566,357  
Abbreviation: Quarter (Q); lopinavir and ritonavir combination (LPV/r) 
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7.3.3. Implications of incomplete access 
 
The increase in numbers of patients who accessed the five medicines under 
CL policy from January 2007 to June 2014 (3 Quarters/ 3Qs) is shown in Figures 7.6 
- 7.10. The access is shown in areas under the curve, while the ceiling threshold of 
expected access obtained from HITAP’s study is shown as dotted lines. The 
expected data of the HITAP’s study was estimated by using linear equations based 
on historical epidemiological data, and adjusted by minimum possibilities of patients 
receiving the drugs. 
 
 
Figure 7. 6 The number of patients receiving efavirenz under CL policy, and 
the estimation of the expected number of patients receiving the drugs 
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Figure 7. 7 The number of patients receiving LPV/r under CL policy, and the 
estimation of the expected number of patients receiving the drugs 
 
 
 
 
Figure 7. 8 The number of patients receiving clopidogrel under CL policy, and 
the estimation of the expected number of patients receiving the drugs 
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Figure 7. 9 The number of patients receiving docetaxel under CL policy, and 
the estimation of the expected number of patients receiving the drugs 
 
 
 
 
Figure 7. 10 The number of patients receiving letrozole under CL policy, and 
the estimation of the expected number of patients receiving the drugs 
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After the Thai government imported generic drugs under the CL policy, the 
numbers of patients who accessed the drugs have increased in all drugs. As the 
expectations of drug access were suggested based on minimum possibilities of 
patients receiving the drugs, it is not surprised that the actual data of drug access 
exceeded expectation. However, this was not the case for cancer drugs of which 
regulations were made by the state committee of the National Essential Drug List, as 
mentioned in the introduction of this chapter. Although the numbers of patients 
accessing both cancer drugs have been gradually increased, the increasing numbers 
were more delayed than expectations in the early phase of CL policy 
implementation. The unanticipated results lead to the costs from the delay in access 
to cancer drugs during the early phase of CL policy implementation.  
 
Implications of drug access 
Implications of the incomplete access to letrozole and docetaxel were 
analysed. For the factual scenario, the patients in the incomplete access were 
received the alternative treatments suggested by the Thai CPGs, namely the 
alternatives of letrozole for treatment breast cancer is tamoxifen, and the alternatives 
of docetaxel for treatment breast cancer and lung cancer are paclitaxel and palliative 
care, respectively. In the counter-factual scenario, an assumption was made that all 
patients who met the indications of the Thai CPGs were received the CL drugs. 
According to the figures above, the delay in drug access occurred on letrozole 
during 2009 and 2014, and docetaxel during 2009 and 2011. The cost of the 
unanticipated results in drug access accounted for 3.6 million US$ (Table 7.5).   
    
Table 7. 5 The cost of incomplete access in patients under UC and SSS in US$ ($) 
 
 Implication of drug 
access 2009 2010 2011 2012 2013 2014(3Qs) 
 
Total 
   
C
ou
nt
er
 fa
ct
ua
l letrozole with CL drugs 636,005  415,603  266,771  218,682 213,042 166,997 2,049,360  
docetaxel with CL drugs 856,156  702,663  410,392     1,969,211  
Fa
ct
ua
l letrozole with alternatives 
1,678,483  1,096,818  724,002  539,792 326,334 225,435 4,789,799 
docetaxel with alternatives 1,423,162 881,923 515,088    2,820,174  
Im
pl
ic
at
io
ns
 
Difference for letrozole 1,042,478  681,215  457,230   321,110  113,292  58,437  2,740,439  
Difference for docetaxel 567,006 179,260 104,697    850,963 
 Total difference 1,609,484 860,475 561,927 336,271 139,158 84,086 3,591,402 
Abbreviation: Quarter (Q) 
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7.4 Discussion and conclusion 
 
As CL policy has been implemented in the country for eight years, the 
implementation period is sufficiently long to evaluate the Thai government’s 
performance. The evaluations include three areas of policy implementation: drug 
procurement, drug substitution and drug access, because the three areas sufficiently 
cover the overall performance of concerned activities from up-stream to down-
stream of the supply chain. To evaluate the performance, actual performance (as 
factual scenarios) with ideal performance (as counterfactual scenarios) were 
compared to estimate differences between two scenarios; the difference represents 
the implications of defective performance or unanticipated results. If any 
unanticipated result in implementing the policy was found, I evaluated the 
magnitudes of the implications in monetary terms. The findings highlighted the 
differences in magnitudes of implications across the three areas. Therefore, the 
findings could be used to help prioritise areas of focus for the Thai government to 
improve performance. It was found that the highest ranking area of focus was drug 
substitution, followed by drug procurement and drug access, respectively. However, 
it is important to use the findings of this study with caution because there are a 
number of assumptions. The details of each area of focus are provided below. 
For the area of drug substitution, estimates were based on an assumption that 
physicians prescribed CL drugs for all CSMBS patients, and all of the patients were 
also willing to use the CL drugs. In addition, there are limitations to the data used: 
firstly, the volume of patented docetaxel is not collected in the database; and 
secondly, only three years of data (from 2012 to 2014 Q2) on patented and generic 
drug volumes were available to employ in this analysis. Although the implications in 
this section are likely to be underestimates compared to other areas, the implications 
created the highest costs at 119 million US$, two times higher than other areas. 
Therefore, improving physician perceptions of the quality of CL drugs should be a 
key priority for the Thai government. Resolving this issue could result in significant 
savings for the Thai public health system. 
For the area of drug procurement, the implications were evaluated of whether 
drug procurement by GPO met the national demand. Any gap between the actual 
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supply and national demand would reflect incomplete supply. During a period of 
incomplete supply, CL drug demand must be met with drugs from other supply 
sources. In the counter-factual scenario, it was assumed that CL drugs with the same 
sources and prices were used to fulfil the incomplete supply. It was found that the 
implications of incomplete supply created the second highest cost at 5.9 million 
US$. Procurement for two ARVs seems to offer an example of success because 
incomplete supply did not occur, while that for the other three drugs requires 
improvement because foreign suppliers didn’t deliver the drugs on time or the 
quality of drugs supplied failed to meet acceptable standards. Therefore, the external 
factor of foreign generic drug suppliers also plays an important role in the success of 
policy implementation. In addition, as the lesson learnt from the success of LPV/r, 
one effective strategy is to strengthen local generic drug industries rather than 
relying only on foreign drug suppliers.  
Lastly, the implications of incomplete access to CL drugs created costs of 3.6 
million US$. Numbers of patients under UC and SSS who had access to the drugs 
were analysed and compared to expected numbers. The gap between the expected 
and actual number of patients who had access to the drugs would reflect government 
performance in promoting drug access. An assumption was made in the counter-
factual scenario that all patients who met the indications of the Thai CPGs received 
CL drugs. It was found that, in reality, not all patients who met the indications 
received the drugs from the beginning of CL policy implementation. Drug access 
was slower for docetaxel and letrozole than for other drugs. Problems in promoting 
drug access result from regulation that previously allowed only tertiary hospitals to 
prescribe the drugs. However, since 2011 the scope of legitimate hospitals has been 
expanded to qualified secondary hospitals, due to the feedback from health care 
facilities. The number of patients receiving the drugs consequently has increased in 
recent years. Therefore, feedback from local health care facilities played an 
important role in improving CL implications. 
In conclusion, there are four elements that should be prioritised and included 
to strengthen the preliminary framework: (1) strengthening physician’ confidence in 
the quality of CL drugs should be prioritised as vital; (2) reducing interruptions of 
drug supply from foreign suppliers; (3) strengthening the capacities of local drug 
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industries to maintain drug supply in the long run; and (4) encouranging policy 
feedback from local facilities to improve performance and policy implications. 
These important points could help develop strategies to improve Thai government 
performance in implementing CL policy.  
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Chapter 8: An evaluation of the Thai government’s 
performance: qualitative approaches 
  
8.1 Introduction 
 
The preliminary framework was initially developed from generic policy 
elements proposed by inter-governmental organisations such as the WHO and WTO. 
This was presented in Chapter 5. The contents of the decision-making process and 
policy implementation in the preliminary framework were strengthened by using 
quantitative data on implementation of CL policy in Chapters 6 and Chapter 7, 
respectively. In chapter 8, the performance of CL policy throughout the process of 
agenda setting, policy formulation, implementation and monitoring were evaluated 
by qualitative approaches.  
The objective of this chapter is thus to assess the applicability of the 
framework in Chapter 5 by using qualitative data. Applicability was assessed as to 
whether the policy elements identified from inter-governmental organisations were 
consistent with Thai policy elements in implementing CL policy. Any additional 
policy elements found from the Thai CL experiences, but not mentioned in the 
preliminary framework, are highlighted in this chapter. Document reviews, semi-
structured interviews, and observations of meetings were employed to collect 
qualitative data. A wide range of data sources from government sectors and non-
government sectors were used to ensure that the findings comprehensively represent 
all key aspects of the CL policy process.  
The insights were collected from informants in terms of knowledge or 
opinion about key elements that influenced the Thai CL policy process. The policy 
process was classified into four stages: agenda setting, policy formulation, 
implementation, and monitoring. Therefore, in each stage, the insights collected 
through interviews contained four aspects of policy elements: policy activities, 
supportive instruments, contextual factors, and actors. The outline of what key 
insights I collected through interview is as follows. 
• What did contextual elements influence in each stage of CL policy, and did each 
contextual element create positive or negative influence?; and if any contextual 
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element having negative influence was found, which approach was used by the 
former government to deal with the influence?   
• Which alternative measures were used by the Thai government to promote drug 
access, and what were key success factors in implementing each of the 
measures? 
• Which activities were conducted by the Thai government in each stage of CL 
policy?; and which supportive instruments were used to support each of the 
activities? 
• Were there any obstacles or problems of CL implementation?; and if any 
obstacles or problems were found, which strategy was used by the former 
government to overcome them?    
• Were there any unanticipated effects of the CL implementation by the former 
government?; and if any unanticipated effects were found, what was the main 
cause of the unanticipated effects, and what is the key solution suggested to 
avoid it in the future? 
• What were strengths of the Thai health system that should be maintained to 
support CL policy; and what were weaknesses or limitations of the Thai health 
system that should be improved in the future? 
• Are there any new ideas or new knowledge that might improve the Thai 
government's performance in implementing CL policy? 
• Who participated in each stage of CL policy?; what was the role of each actor in 
intervening in the policy process?; did they succeed or fail in intervening in the 
policy process?; and what was the key factor of their success or failure? 
 
8.2 Data collection and analysis 
Document reviews: The aim of the document review was to identify policy 
elements relevant to the decision making and implementation of drug policy, 
focusing on CL policy in Thailand. A wide range of published and grey literature, 
such as journals, study theses, books, conference proceedings, reports, minutes, 
letters and media reports were purposively reviewed. The inclusion criteria were as 
follows: all documents mentioning CL policy in Thailand published between 2007 
(the first use of Thai CLs) to March 2015, and produced by the sectors concerned as 
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summarised in Table 8.1. The documents were read to analyse content relevant to 
CL policy and directions on an appropriate use of the policy in the future. 
Throughout, the process, the information was examined for its content and the 
contexts in which it was produced and functioned. 
 
Table 8. 1 The list of documents 
 
Sectors Types of documents 
1.Governmental 
sectors 
Government notifications, statements, official documents, minutes, 
letters, and reports were obtained from responsible agencies and 
libraries.  
2.Academic 
sectors  
Domestic and international journals, conference proceedings, research 
reports, study theses, and books were obtained from research 
institutions and libraries. 
3. NGOs Local and inter-NGO reports, statements, official documents, and 
books were obtained from responsible agencies and libraries. 
4. Private sectors  Local firm or headquarter reports, statements, official documents, and 
books were obtained from libraries.  
   
 
Semi-structured interviews: These provided the perspectives of respondents. 
The interview respondents were purposely selected according to their roles within 
the process of CL policy decision-making and implementation. Stakeholders were 
identified from a combination of secondary sources (e.g. meeting reports), and a 
snowball approach. Semi-structured interviews were used to allow respondents to 
share their experiences and perceptions of the issue in a free and flexible manner. 
Five groups of stakeholders were interviewed face to face: (i) government sectors, 
(ii) academic sectors, (iii) non-profit organisations (NGOs), (iv) private sectors, and 
(v) health care practitioners. The list of stakeholders is shown in Table 8.2.  
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Table 8. 2 The list of informants 
 
Sectors Key informants No. of 
informants 
1.Governmental 
sectors [GS] 
Government officers from the Ministry of Public 
Health who participated in the CL policy process.  
5 
2.Academic sectors 
[AS] 
Academies in the area of access to medicines from 
universities.  
2 
3. NGOs [NS] Non-profit organisations from patient groups 
including HIV/AIDS, heart disease, and cancer. 
2 
4. Private sectors 
[PS]  
Executive of the Thai Pharmaceutical 
Manufacturers Association. 
1 
5. Health care 
practitioners [HS]  
Health care practitioners in the areas of HIV/AIDS, 
heart disease, and cancer from health care facilities  
3 
 
 
Key informants were asked for insights into the important elements that led 
to the implementation of CL in Thailand. The interviews took around 30 minutes for 
each informant and were held between September 2014 and March 2015. The 
interviews were conducted and analysed in Thai. Spreadsheets were used to collect 
information on all interviewees, date and time of interviews, and the interviewee's 
study IDs. The codes were annotated by a respondent number and their affiliations 
as from government sectors (GS), academic sectors (AS), NGO sectors (NS), private 
sectors (PS), and health professionals (HS). Follow-up interviews were conducted 
with two key informants in order to verify the information.  
 
Observation: I observed four meetings concerning the topic of access to 
essential medicines in Thailand. The observations were conducted in relevant 
meetings to collect policy messages concerning the key elements, which influenced 
the CL policy decisions and implementation in Thailand. The meetings were held 
between September 2014 and July 2015 to discuss the issue of access to medicines 
in Thailand. The list of meeting details is shown in Table 8.3. 
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Table 8. 3 The list of meeting observation 
 
No Dates Meetings Hosting agencies 
1. September 
5th 2014 
[OS01] 
The HSRI steering committee meeting for 
advising research under the project of 
improving capacities for access to medicines 
(ATM) in Thailand.   
Health System 
Research Institute 
(HSRI) 
2. October 17th 
2014 [OS02] 
The consultation meeting with stakeholders in 
the area for access to medicines.  This 
considered the preliminary results of my thesis.  
Food and Drug 
Administration 
(FDA) 
3. November 
5th 2014 
[OS03] 
The expert meeting for developing national 
policy recommendations to promote access to 
essential medicines for Thai citizens.  
International 
Health Policy 
Program (IHPP) 
4. July 7 and 8th 
2015 [OS04] 
The International Trade and Health Conference 
2015, Government use of license: revisiting 
after eight years of implementation. 
International 
Trade and Health 
Programme 
(ITH) 
 
All information from different sources (stakeholder interviews, relevant 
documents and observational notes) was analysed through three steps. The first step 
was to be familiar with the data sources, by re-reading interview transcription and 
documents. As I did the transcribing of interviews, I was entirely familiar with all of 
the data obtained. In the second step, all interview transcripts, relevant documents 
and observational notes were analysed, and key elements and themes were labelled 
by codes and short phrases, in order to sort data and generate inputs for the thematic 
analysis process. A set of initial codes was obtained from the preliminary framework 
in Chapter 5, while a set of subsequent codes was developed after obtaining new 
information. Some categories were combined with other categories or split into 
several categories after revisions and refinements of the category systems. The 
themes based on the study objectives were set, and the code for each theme was 
created to facilitate the retrieval. The last step was to map the associations between 
the theme codes by considering patterns of relationship and seeking explanations for 
these elements within the data. Triangulation of the data was used to verify 
information from different sources. 
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8.3 The framework of CL policy in Thailand 
There were two main sections of the initial framework. First, the framework 
for decision-making contains the stages of agenda setting and policy formulation. 
Second, the framework for policy implementation contains the stages of policy 
implementation and monitoring. The key elements in the proposed framework to aid 
decision-making and implementation of drug policy, focusing on CL policy are 
presented in Figures 8.1 and 8.2, respectively.  
 
Applicability of the framework for agenda setting and 
formulation 
Figure 8.1 shows key elements of the CL policy process in the stages of 
agenda setting and policy formulation with additional elements arising from 
experiences of the former government. The preliminary framework in Chapter 5 was 
strengthened by additional elements identified from the former government’s actions 
and experiences. According to the preliminary framework in Chapter 5, most of the 
common elements are consistent with the case of Thai CLs. In addition, some further 
essential elements identified from the Thai experiences were also included in the 
framework. The additional elements are highlighted in the framework by using 
underlining and italics.  
The first stage in policy process is the agenda setting. Additional elements 
were identified, including:  
• Three additional contextual elements: political commitment to 
universal coverage (C1.2), political standpoints of policy makers 
(C1.3), and strong networks of policy elites and partners (C1.4). 
• One additional set of actors: academics, NGOs, and patient groups 
(P1).  
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The second stage in policy process is the policy formulation. Additional 
elements were identified, including:  
• Three additional contextual elements: transnational drug company 
reactions (C2.2), social values of policy supporters (C2.3) and strong 
networks of policy elites and partners (C2.4);  
• One additional activity: Establishment of evidence base concerning 
the CL policy (A2.4).  
• One additional set of actors: academics, NGOs, and transnational 
firms (P2).  
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Note: Additional elements identified in this chapter are highlighted by using underlining and italics 
Figure 8. 1 The  framework for agenda setting and policy formulation of Thailand 
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8.3.1 Key elements of agenda setting in Thailand 
 
8.3.1.1 Context in the agenda setting  
 In the Thai public health system, the main contextual element leading to the 
decision to issue CL policy was the “combination of an unmet public health need 
and the availability of TRIPS flexibilities (C1.1)”. This is consistent with the 
preliminary framework in Chapter 5. The Thai government’s white paper clearly 
mentions that, due to unmet public health needs for essential drugs, the former 
government raised the issue to the national agenda in order to identify a policy solution. 
[81, 83]. The details were provided in Chapter 3. Moreover, experiences of the former 
government also indicated three additional contextual elements as follows.  
 Political standpoints of policy makers on health over trade interests (C1.2): 
Among several alternative measures to promote drug access, CL policy, in particular, is 
associated with conflicts between trade and health interests. The political ideology of 
Thai policy makers was essential. The former Thai Minister of Public Health who made 
a decision to issue CL policy addressed that “We don’t have any influence or power; we 
only have a strong heart to do it for poor people”. (Mongkol Na Songkhla, expressed in 
[208]:p53). One academic viewpoint mentioned that “the use of CL policy pinpointed 
the intention of the Thai government to prioritise patient lives over private profits” 
(Vitaya Kulsoomboon expressed in [88]). The point was consistently addressed that 
“because the former Health Minister was a strong-minded policy maker who played an 
important role in protecting public health over commercial interests, he resolutely made 
a decision to use the CL policy to promote drug access in the country” [208] cited in 
[209]. It seems clear that the political standpoints of policy makers on public health 
over trade interests strongly influence the direction of CL policy.  
Strong networks of policy elites and partners in agenda setting (C1.3): In 
the agenda setting stage of the Thai MoPH, multidisciplinary committees were 
established. The policy elites involved all concerned MoPH departments, such as the 
Department of Disease Control (DDC), Department of Medical Services (DMS), the 
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Food and Drug Administration (FDA) and health insurance schemes, which are 
responsible for dealing with unmet public health needs. In addition, other stakeholders 
such as medical specialists, NGOs, and representatives from patient groups also played 
an important role in the stage. A viewpoint from stakeholders also supported that the 
success of this policy resulted from policy elites who closely worked with the Minister 
and had strong expertise in political and legal issues concerning CL policy [NS01]. It 
was consistently mentioned by other informants that strengths of Thai CLs were the 
involvement of civil society and patient groups because both groups could raise health 
problems, which seemed to be overlooked by policymakers, while there were strong 
relationships between domestic and international NGOs, who played an important role 
in supporting the policy decision [GS03][NS02].  
Political commitment to achieve universal coverage (C1.4): The political 
commitment to achieve the ideological goals of universal coverage is another contextual 
element that was not included in the preliminary framework. This element played an 
important role in driving decision makers and policy elites to put CL policy onto the 
national agenda. The Thai government mentioned in its white paper that the rationale 
behind the use of CL policy was mainly the mandate to achieve universal access to 
essential medicine for all Thais [81]. The political commitment to universal coverage 
was the main grounds used by the MoPH to justify granting CL policy. “Regarding the 
reason for the MoPH issuing CL policy, the mission of MoPH under the National 
Health Security Act 2002 is to guarantee access to essential health care treatment for all 
Thai citizens […] the MoPH makes its utmost efforts on every feasible measure 
including CL policy to achieve that committed mission” (Suchart Chongprasert, the 
representative of the MoPH, expressed in [210]; p5). The Universal Coverage Program 
was, therefore, an important context influencing the decision to use CL policy. This is 
supported by an academic study, which stated that “The rights to essential health care, 
and the responsibility for administration to meet the rightful needs of its citizens, helped 
to justify the governmental action of introducing the TRIPS flexibilities” [209]. 
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8.3.1.2 Contents in the agenda setting   
Identification of unaffordable drugs (A1.1): For the policy content of the Thai 
agenda setting, the first activity was to identify an unaffordable drug. The Thai 
government clarified that a decision on whether to issue the CL policy depended on the 
work of the committee with comprehensive stakeholder involvement and the evidence 
that they produced [81]. It was clearly mentioned in notifications of the MoPH on the 
selection of the seven medicines (namely efavirenz, LPV/r, clopidogrel, letrozole, 
docetaxel, erlotinib and imatinib [211-217]) that the Thai government made an effort to 
create a transparent process to prioritise high-need medicines in order to solve public 
health problems [98]. In addition, the Thai government’ decisions also largely relied on 
a system to assess public health needs, which are consistent with the preliminary 
framework in Chapter 5. A government officer added that the need assessment system is 
the key supportive instrument for this activity and should be maintained in the long run 
because it is beneficial for prioritising health problems and selecting a proper drug 
[GS03]. The issue was raised as part of the national agenda. The revised national drug 
policy 2011 (BE 2554) included the development of a transparent system to identify 
inaccessible drugs, which are essential for the public health system [218]. 
In addition to the need assessment system, this activity required predetermined 
criteria for drug selection in order to promote transparency and accountability of the 
policy decision. This is an additional element essential to include in the framework. The 
seven drugs were selected according to the following criteria [81, 83]:  
• Drugs on the National Essential Drug List which are necessary to solve 
public health problems or use in an emergency/urgency, or use for the 
management of outbreaks/ epidemics/pandemics, or use for life saving; 
“and”  
• The drug price is too expensive for the government to be able to afford to 
provide the drugs to beneficiaries of the three main national health 
insurance schemes to achieve the universal coverage policy.  
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A Thai study also suggested explicit parameters to be included in the drug 
selection criteria for issuing CL policy as: the number of patients in need of the drugs 
(which could be estimated by using epidemiological data of disease prevalence and 
incidence); the difference in prices between the currently available patented drugs and 
the proposed generic drugs; the safety and efficacy of the drugs of interest by 
comparing with their alternatives currently available on the market; variations in 
prescription practices of health professionals and the potential for irrational use of 
particular drugs; the remaining duration of term of patent protection of the original drug 
in question; and other issues concerning the policy process and practices [70] 
 Consideration for patent opposition (A1.2): As mentioned in Chapters 3 and 
5, patent opposition is an alternative measure to overcome the problems of improper 
patent grants. Rigorous criteria for patentability and implementation guidelines for 
patent examination are essential to facilitate the process of patent oppositions. However, 
several viewpoints from government officers indicated that the patentability database 
for identifying patent status was unstable. For example, even when users keyed in the 
same search term, the database displayed different results [GS01][PS01]. The situation 
caused an unanticipated effect in the case of the previous decision of letrozole. The Thai 
government decided to grant CL for letrozole; however, the patent owner has not yet 
applied the drug for patent protection in Thailand [GS02]. A study analysing the Thai 
drug patent system indicated that the problem of the Thai database was not a random 
but rather a systematic error. It was found that because the system was very complex, 
only 9% of 88 active ingredients were unable to be verified the patent status [219].  
Consideration for price negotiations (A1.3): The second policy option is price 
negotiation. The MoPH established the committee for price negotiation to promote 
access to essential patented medicines. Previously, important negotiations with the 
patent holders had been made on the seven medicines, and details could be classified 
into three groups. First, for the Lopinavir/Ritonavir (Kaletra®) of Abbott Laboratories, 
the patent owner did not agree with the negotiation and stated that they had gradually 
lowered the drug prices [98]. Second, price negotiations occurred for the efavirenz 
(Stocrin®) of Merck Sharp & Dome, and letrozole (Femara®) of Roche, but the 
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discounts offered by the patent owners were slight when compared to expected prices of 
generic drugs with therapeutic equivalence [98]. Third, the patent-owner companies of 
clopidogrel, docetaxel, and erlotinib reduced drug prices under conditions to offer the 
drugs for a limited number of patients only [98]. Novartis agreed to provide imatinib for 
all UC patients under the Glivec® International Patient Assistance Program (GIPAP) 
[83]. Therefore, due to the generous offer of Novartis, CL policy was actually 
implemented for imatinib. Although in most cases negotiation failed to achieve an 
agreement, this action enabled the Thai government to avoid using CL for Imatinib.  
Consideration for using TRIPS flexibility (A1.4): In addition to negotiation 
for a price reduction, the committee for negotiation was also responsible for considering 
the use of TRIPS flexibilities. The MoPH highlighted that in all negotiations, the Thai 
government attempted to form transparent and constructive relationships with all private 
firms both before and after the announcement of the policy. However, if negotiations 
seemed unable to achieve an agreement or public health goal within a reasonable time 
frame, CL policy was applied. It is noteworthy that as the period of time required for 
making a policy decision to promote drug access has to be as short as possible in order 
to satisfy the public health demand, a strategic approach of parallel work was employed 
by the former government. According to information from a government officer, “patent 
owners tended to extend the negotiation period in order to delay the implementation of 
CL policy; therefore, we had to conduct parallel work, negotiating with patented drug 
firms as well as formulating the policy and preparing the local health system to be ready 
for implementing the CL policy” [OS04]. This statement was supported by the Thai 
government’s white paper that “we cannot wait for the results of the discussion and 
negotiation as we do not want to delay the increase in access to these drugs for our 
people” [81]. Therefore, the Thai government implemented the strategy in which 
negotiation and review procedures with patent owners were worked out in parallel to the 
formulation of CL policy. Although the Thai government wanted to improve efficiency 
of the decision-making process, primary intention of the Thai government was still to 
put the most effort to negotiate with patented drug firms, in order to to avoid 
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unnecessary use of the CL policy. If the negotiations achieved an agreement, the 
decision to issue CL policy would be terminated.  
  
8.3.1.3 Actors in the agenda setting   
For the actors in the stage of agenda setting (P1), the government established 
multidisciplinary committees to consider essential drugs that were unaffordable due to 
patent barriers and identify policy solutions to promote access to the drugs. There were 
two national committees playing an important role in the agenda-setting stage. Both of 
the committees had multidisciplinary teams consistent with the preliminary framework 
in Chapter 5.     
First, the subcommittee on selecting essential drugs with access problems under 
the National Health Insurance schemes was established to develop mechanisms for 
selecting the essential drugs, which are inaccessible for Thai patients. The committee 
members contained relevant organizations: Affiliation of the Ministry of Public Health 
(MOPH), including the Food and Drug Administration, the Department of Disease 
Control, and the Department of Medical Services; Public health insurance schemes, 
including the National Health Security Office (NHSO), the Social Security Office 
(SSO), and the Civil Servant Medical Benefit Scheme (CSMBS); Affiliation of the 
Ministry of Commerce (MOC), including the Department of Intellectual Property; 
representatives from the Ministry of Foreign Affair (MFA); representatives from the 
consortium of Thai medical schools, representatives from patient groups such as the 
Thai network of people living with HIV/AIDS and cancer care network [220].  
 Second, the committee on negotiation for patented essential drugs was 
established to negotiate an affordable price with patented drug firms, using all forms of 
negotiation including using TRIPS flexibilities. The committee member contains 
relevant organizations: Affiliation of the Ministry of Public Health (MOPH), including 
the Food and Drug Administration, the Department of Disease Control, the Department 
of Health Service Support, the National Health Security Office; Affiliation of the 
Ministry of Commerce (MOC), including the Department of Internal Trade, the 
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Department of Trade Negotiations; Affiliation of the Ministry of Foreign Affairs 
(MFA), including the Department of International Economic Affairs, the Department of 
Treaties and Legal Affairs; other invited views of the NGOs, academics and individual 
experts on this issue [221]. 
The strength of agenda setting in Thailand came through the participation of 
stakeholders, especially academics, NGOs, and patient groups. The three main groups 
of actors were added in Figure 8.1. This was an additional factor leading to the success 
in setting the agenda, and there is an example that shows the role of stakeholders, 
especially academic groups in directing actions of the government sectors. A study 
conducted by academics revealed that most patent requests in Thailand (84%) were 
made in order to grant a patent on an existing drug or on a minor innovative change, and 
this created significant social costs [222]. In addition, the academic group was initiated 
in 2011 to develop guidelines for the examination of pharmaceutical patents [223] 
consistent with the guidelines developed by ICTSD, UNCTAD, and WHO. This 
academic group played an important role in providing evidence to draw public attention 
to the problem of low-quality patents in Thailand. Subsequently, the Department of 
Intellectual Property (DIP) of the MOC published an official document for patent 
examination guidelines on pharmaceutical products in 2012 [224]. 
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8.3.2 Key elements of CL formulation in Thailand 
 
8.3.2.1 Context in the policy formulation   
Common misconceptions of TRIPS flexibilities (C2.1): As mentioned in 
Chapter 5, a common misconception is that the use of CL is limited to situations of 
national emergency or other circumstances of extreme urgency; however, the case of 
public non-commercial is also eligible for CL [146] and cases of Thai CLs confirm this 
contextual factor. For example, on 13 March 2007, Aumporn Jareansomsak, Country 
Manager of Abbott Laboratories mentioned that Abbot was disappointed with the 
infringment of IPRs through CL policy of the Thai government. Abbott decided to 
withdraw registration of seven new drugs from the Thai market because the decision to 
issue CL policy had been proceeded with [225]. However, after the Thai government’s 
declarations was made to correct the misconception, Abbott restated the withdrawal 
because of pressure from policy advocacy [226].  
In addition, a number of stakeholders also had the misconception that the Thai 
government was breaking the law by abusing CL policy for medicines to treat 
cardiovascular disease and cancer, which were not emergency cases [210].  However, 
the use of CLs for the drugs is legal when implemented for public non-commercial uses. 
Therefore, a correct conception and a consistent interpretation should be achieved 
before implementing CL [210]. This statement was supported by the National Economic 
and Social Advisory Council that “there should be international cooperation for 
interpreting the TRIPS flexibilities” [227]. A government officer also made the point 
that “there is value in developing cooperation among stakeholders including 
transnational drug industries to settle a consistent interpretation of the TRIP agreement 
when CL is used on a case by case basis, so as to avoid improper interrupting the use of 
policy by opponents in the future” [GS04]. Moreover, experiences of the former 
government also indicated three additional contextual elements as follows. 
Pressures of policy opponents (C2.2): In previous cases of Thai CLs, policy 
opponents attempted to prevent the government from implementing CL policy and to 
interfere with authorised agencies and the process of policy formulation [98, 228, 229]. 
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This is another element influencing the policy formulation process. Negative responses 
from opponents of CL policy come mainly from the international sector, including 
transnational drug companies and HICs which are the home country of patent owners, 
especially the trade representatives of the USA (USTR) as mentioned in Chapter 2. 
In addition, the use of CL policy resulted in conflict with other ministries and 
domestic industry sectors, which had different interests. One academic indicated that 
“Ministries have different interests. The Ministry of Foreign Affairs was concerned 
about the image of our country after getting criticism from high-income countries that 
Thailand was cheating and stealing other's property […]. In the same vein, pressure was 
put on the Ministry of Commerce by local industry sectors” (Vatchareeya Thosanguan 
as expressed in [230]; p17).  In addition, a view of representatives from industry sectors 
indicated that “the problem started from reactions of the USA on downgrading Thailand 
from WL to be PWL that would affect the Generalized System of Preferences (GSP) 
[…] The local industries may be affected by GSP. Therefore, there may be another 
stream of opponent reactions from domestic industry sectors if CL affects GSP.” 
(Suthichai Eamcharoenying as expressed in [230]; p10)  
Representatives of the patent drug industry, from Merck Sharp & Dohme 
(MSD), mentioned that “the CL policy may not affect the Thai economy, but it affects 
the credibility and image of the country as well as confidence in the Thai government. 
The patent drug industries will not make further research studies in Thailand” 
(Representatives from MSD as expressed in [226]; p62). Abbot also commented that 
“the CL policy affected the image of the Thai government with respect to the 
intellectual property rights and cordiality in negotiation with patent owners 
(Representatives from Abbot as expressed in [226]; p62).. Novartis supported that “the 
CL policy destroyed confidence of partners on business, trade, foreign investment and 
collaboration in the long term” (Representatives from Novartis as expressed in [226]; 
p62).      
Strong networks of policy elites and partners in policy formulation (C2.3): 
In response to the previous contextual factor, the structural context of policy elites and 
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policy supporters was essential to deal with the negative reactions from policy 
opponents. The policy elite network involved the MOPH, MOC and MFA as well as 
NGOs, academics and patient groups. The MoPH paid attention to building up a strong 
network for CL policy. Information from a government officer indicated that “in the 
first use of CL policy, we didn’t have experience and didn’t invite the Ministry of 
Commerce and the Ministry of Foreign Affairs to participate in the policy process. 
However, after we provided the information and opened the floor for other ministries to 
participate, the reactions from both ministries, which likely objected to the use of CL at 
the beginning, changed to be more positive for the policy [OS01]. The statement was 
confirmed by representatives from the Ministry of Foreign Affairs (MOA) and the 
Ministry of Commerce (MOC) that they recognised the reason why MoPH issued CL 
policy and did their utmost to help the MoPH to communicate with other sectors [210]. 
Consequently, the strong network helped in the policy process. “The strong reactions 
from the USA have been mitigated after justified clarifications were made by concerned 
ministries and supporters” (Amornsat Singha the representative from MFA expressed in 
[210]; p9). 
The former Thai Minister of Public Health, Mongkol Na Songkhla, made the 
point that “We got strong supports from stakeholders, both national and international 
sectors, as never before. We have persistent and capable working groups, including 
academics and senior government officers who have long experiences with the patent 
system. In addition, we have good colleagues from other countries and civil society 
organisations, especially the Knowledge Ecology Institute, Médecins Sans 
Frontières, Third World Network, Oxfam, Clinton Foundation, etc…Some of them tried 
to push policy until they themselves were at risk with patented drug industries. Some 
helped us to seek support from politicians in developed countries such as members of 
the United States Congress and members of the European Commission as well as 
international organisations such as World Health Organization. Moreover, the United 
Nations Program on HIV/AIDS sent letters of support to Thailand. I also heard that the 
Director-General of WTO made a speech to support the Thai government, and the Head 
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of the UN Conference on Trade and Development visited Thailand and support the Thai 
actions.” (Mongkol Na Songkhla expressed in [88]:p57)        
Social values of policy supporters (C2.4): The social value of supporting 
networks was essential to affirming the policy formulation process. The social value of 
policy supporters was stressed by an academic: “I would earn more money if I worked 
for transnational drug industries, but I choose to do research to support public health 
policy because I would like to use my skill and knowledge to help poor people [AS02]. 
In addition, a view from Thai NGOs highlighted that “It is worth trying even if our 
work can help only one patient. Our aim is not to use compulsory licensing, but to help 
patients to get access to essential drugs”. (Nimit Tienudom expressed in [88]; p70). A 
viewpoint from government officers could be used as a conclusion on the common 
value of the Thai society. “Even though we are a small country, we tried to protect our 
rights […] at the beginning, we believed that we were alone fighting on our own, but 
when the battle started we had lots of supporters […] I would like to conclude that all of 
us have the same concern that patients’ quality of life is the most important issue, not 
trade or economy”. (Sorachai Jamniendamrongkarn, expressed in [230]; p14-15).  
 
8.3.2.2 Content in the policy formulation   
CL proposal development (A2.1): As the first activity in the preliminary 
framework is the development of the CL proposal, it was found that this activity is 
consistent with the former government’s action. The government clarified the scope, 
duration and remuneration of CL policy in compliance with national patent law; and the 
Thai law also incorporates with the international agreement on TRIPS. It was supported 
by literature published by Thai academic groups that any country, which aims to grant 
the CL policy must promulgate its local legal framework as a supportive system in line 
with the international agreement [231]. Thai patent law shows that the TRIPs agreement 
article 31 (b) is clearly reflected in the Thai Patent Act. Information from a policy 
maker indicated that: “we can issue the policy because the Thai law authorises us to do 
so. I’m admiring the cautious thought of the former lawyers for including the policy in 
the Thai patent act. However, because no perfect formula for implementing CL policy 
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was available at the time of Thai CL grants, the Thai government implemented the 
policy in the way of learning by doing” [OS01]. The issues to be considered in 
formulating CL policy include: defining authorised agencies, scope of products, 
duration and target population of drug users, and remuneration of CL policy. The details 
of CL cases in Thailand are as follows.  
For the authorised agency, the Government Pharmaceutical Organization (GPO) 
has been authorised by the Thai government to produce or import CL drugs and sell 
these to public health schemes, while profit making is strictly prohibited. If any profit 
was made, this practice would violate the TRIPs Agreement and the Thai Patent Act, and 
would pose serious impacts in terms of the law, reputation and image of CLs in Thailand. 
Therefore, the prices of CL drugs are only based on administrative costs, logistic costs, 
and other relevant costs of importation or production. [GS02].  
For the scope of products under the Thai CLs, notifications of CLs appear to 
allow the government to exercise the right over a patent, which contains a particular 
drug in all formulations, including its derivatives patented in Thailand [81, 83]. There 
are advantages of indicating the scope of product by covering all derivative formulas. 
For example, in the case of clopidogrel, the Thai government issued CL policy for 
clopidogrel (Plavix®) of Sanofi-Aventis, which was polymorphic form II (Clopidogrel 
bisulphate form II). However, during 2013-2014, the GPO was unable to find suppliers 
to provide qualified generic clopidogrel in form II. As a result, the GPO was able to 
procure clopidogrel (Apolets®) from the Berlin Company, which was polymorphic form 
I, in order to substitute the form II during the period, as allowed by the notification 
[GS02]. 
For the scope of target groups of users, notifications of CLs were made that the 
exercise of the right was limited to patients who were entitled under the universal 
coverage scheme (UC), the social security scheme (SSS) and the Civil Servant Medical 
Benefit Scheme (CSMBS) [81, 83]. Information from two stakeholder meetings 
consistently indicated that such limitation deprived some patient groups who need to 
use the drugs but were not eligible under the three main public health schemes. For 
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example, stateless people in Thailand were the most important group ignored by the 
policy, although most of them were poor and could not afford to access to the said 
drugs. It was recommended that the Thai government needed to pay more attention to 
neglected and minority groups of patients in Thailand [OS02], [OS03].    
For the duration of CL policy; CL policy can be exercised until the patent 
expires or there is no more essential need for the drug. A view from informants 
mentioned that for the cases of ARVs, the notifications of CLs to use the right over 
patented drugs: efavirenz (Stocrin®) of Merck Sharp & Dome and lopinavir/ritonavir 
(Kaletra®) of Abbott Laboratories, were previously indicated the duration for only five 
years, from 29th November B.E. 2549 (2006) through 31st December B.E. 2554 (2011). 
However, after the stated period there was still a significant need for the drugs. 
Therefore, the Thai government had to revise the notification of both ARV drugs by 
extending the duration until the patent expiration or until the drug was no longer 
essential to meeting need [GS01]. This practice was also applied for the other CL drugs 
[81, 83].  
Finally, the remunerations for the use of patent, the proposal indicated the 
remuneration under CL policy and clarified the calculation method. Regarding the 
approach to calculating the royalty rate, although there were several methods proposed 
by international organisations, the Thai government chose the method mentioned in the 
document “Use of patented products for international humanitarian purposes” 
developed by the Minister of Justice under the government of Canada [98]. The 
government of Canada has strong experiences in using the policy for humanitarian 
proposes, and they developed a common approach used to calculate the remuneration of 
royalty rate [98]. The royalty was then adjusted with other LMICs to be 0.5% for ARV 
drugs, which was consistent with Indonesia issuing CL policy on ARV drugs, and 3% 
for other drugs as an average rate of CLs in other countries [98]. No evidence was found 
that patent owners complained about the remuneration rate made by the Thai 
government.  
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After developing the CL policy proposal, there are two important movements: 
First, the GPO identified sources of generic drugs (A2.2) as the main procurement 
agency. The GPO used prequalified generic medicines from the WHO’s list of 
prequalified medicinal products; and the USFDA’s list of generic drug approvals. It was 
noted that directly imported generic drugs from approved manufacturers saved the GPO 
time and effort in procuring the drugs [GS02]. Second, activity to develop streamlined 
implementation procedures for CL policy (A2.3) was mainly conducted by the Thai 
FDA on the registration of CL generic drugs. The MoPH invited foreign and domestic 
manufacturers of these generic drugs to apply for registration in the Thai market in 
order to be eligible for the procurement stage of implementation [GS01]. According to 
Thai patent law, even during the stage of formulating CL policy, there is an exemption 
allowing generic manufacturers to prepare generic drugs in advance for regulatory 
approval. The registration of CL drugs was accelerated through priority review 
processes (fast-track registration system) [98]. Although this activity aimed to speed up 
the registration system and deliver the drugs to patients in need as soon as possible, the 
accelerating processes firmly maintained the national standard of quality assurance 
[232, 233]. In addition, it was suggested that generic drug suppliers aiming to apply 
through the fast-track registration system had to assure the quality of their products 
from prequalified quality control laboratories [GS01]. These two activities and 
supportive instruments were consistent with the preliminary framework.  
Establishment of evidence base concerning CL policy (A2.4): It’s noteworthy 
that the Thai government establish an evidence base and provide factual information to 
stakeholders. This is an additional activity initiated by the former government that can 
be included in the preliminary framework. MoPH policy makers were concerned that 
information disseminated by policy opponents caused misunderstanding and discredited 
the MoPH [OS01]. Therefore, the government published two official white papers in 
order to clarify facts and evidence on the ten key issues related to the government use of 
patents on ARV, cardiovascular and cancer drugs [81, 83]. It was indicated that the 
papers were a key policy tool aimed to mobilise support from the public “The stake of 
this game is very high [...] we are moving into a very dangerous area. We cannot expect 
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much support from other ministries. Therefore, we have to educate the public; this is 
why the White paper was publicised.” [234]. In addition, research institutes such as 
HITAP played an important role in assessing the potential implications. The HITAP 
study predicted potential health implications and considered economic and social 
aspects, as mentioned in Chapter 2 [70]. In addition, a number of studies were 
conducted prior to and during the period of formulation and implementation of the Thai 
CL policy [68, 70, 71].  
This activity required effective communication channels to deliver policy 
messages concerning historical fact and empirical evidence to stakeholders in the 
society. A series of activities were conducted by the MoPH and its partners, such as: 
publishing formal and informal documents to the public; making a speech at national 
and international meetings; and visiting foreign countries that criticised Thailand’s 
intentions. In addition, empirical evidence studies were presented to a wide range of 
stakeholders, for example, meetings of the Thai cabinet [226], and international 
conferences [235]. This aimed not only to communicate with stakeholder, but also 
educate other ministries and foreign countries. Eventually, the attempts made by the 
MoPH and its partners succeeded its aims to make stakeholders understand the purpose 
of CLs issued by MoPH. This argument was supported by a MOA policy maker that: 
“I’m glad that the representatives from MoPH, MoC, and MFA are agreed that CL itself 
is important […] the negative effect is not as serious as the media mentioned.” (Vitthaya 
Vechachiva the Permanent Secretary for the MFA expressed in [210]; p13). Information 
from policy makers supported that evidence-based information played an important role 
in educating stakeholders and mitigating negative reactions from policy opponents 
[OS01], [OS02].  
 
8.3.2.3 Actors in the policy formulation   
Actors at the policy formulation stage (P2) are similar to the preliminary 
framework. The Thai government established a multidisciplinary committee called 
“Sub-committee for Implementing the Government Use of Patent for Patented Essential 
Drugs”, tasked with developing a CL proposal to exercise the patent rights of the 
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essential medicines in question and with preparing processes for implementing 
government use of patent on these drugs. The committee members were mainly 
affiliated with the Ministry of Public Health (MOPH), including the Food and Drug 
Administration, the Department of Disease Control, the Department of Medical 
Services; Affiliates of the Ministry of Commerce (MOC), including the Department of 
Intellectual Property; representatives from the Office of the Council of State, 
representatives from the consortium of Thai medical schools, representatives from 
patient groups such as the Thai network of people living with HIV/AIDS and cancer 
care network; and other invited views from government offices, NGOs, academics, 
generic drug industries, and individual experts on this issue [236].    
In addition to the transnational drug industries as policy opponents, networks of 
policy supporters played an important role in dealing with pressure from the opponents. 
For example, support was provided in the form of evidence-based information from 
academic sectors such as the Health Intervention and Technology Assessment Program 
(HITAP), International Health Policy Program (IHPP), Knowledge Ecology Institute 
(KEI), and the American University program on information justice and intellectual 
property (Justiceinfo); support in the form of social value such as Médecins Sans 
Frontières (MSF), Third World Network (TWN), Oxfam, the Clinton Foundation, and 
the United Nations Program on HIV/AIDS (UNAIDS) [81]. Therefore, these groups of 
actors were added in Figure 8.1. 
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The framework for policy implementation and monitoring 
Figure 8.2 below summarises key elements for the implementation of CL policy. 
The previous section mentioned the stages of agenda setting and policy formulation as 
the first and second stages of the policy process. This section explains the third and 
fourth stages in the policy process, namely policy implementation and monitoring. It 
was found that most elements of the Thai CLs are in the line with the preliminary 
framework in Chapter 5. The additional elements identified in this chapter are 
highlighted in the framework with underlined and italic texts. Experiences of the former 
government suggest additional contextual elements influencing the policy process.  
The third stage in policy process is the policy implementation. Additional 
elements were identified, including:  
• Three additional contextual elements: unpredictable effects on foreign 
suppliers (C3.2); capacities of local generic drug industries (C3.3); and 
physicians’ perceptions of the quality of generic drugs (C3.4).  
• One additional group of actors: academics (P3).  
The fourth stage in policy process is the policy monitoring. Additional elements 
were identified, including:  
• One additional contextual factor: emerging needs for knowledge about 
policy experiences and implications (C4.2).  
• One additional group of actors: academics (P4). 
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Note: Additional elements identified in this chapter are highlighted by using underlined and italic texts 
Figure 8. 2 The  framework for policy implementation and monitoring of Thailand 
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8.3.3 Key elements of CL implementation in Thailand 
8.3.3.1 Context of the policy implementation 
Capacities of agencies implementing the CL policy (C3.1): Information 
from interviews consistently indicated that capacities of authorised agencies, which 
is consistent with the preliminary framework, had an influence on the achievement 
in the implementation stage. The capacities included personnel qualifications and 
infrastructures of implementing units. According to the revised national drug policy 
2011 (BE 2554), suggested mechanisms are as follows: firstly, strengthening the 
capacity of local pharmaceutical product manufacturers to supply generic drugs 
under the policy; secondly, developing quality assurance system of pre-marketing 
and post-marketing of generic drug products; lastly, reforming the education of 
health care professionals in medical schools [237]. Moreover, experiences of the 
former government also indicated three additional contextual elements as follows. 
Interruptions of drug supply from foreign suppliers (C3.2): The 
availability of good quality generic drugs in the market was the key element for the 
successful implementation of CL policy. As most of the generic drugs procured 
under Thai CLs have been imported from foreign suppliers, long-term availability 
and sustainability of foreign generic drugs is an external factor influencing the 
success of the policy. However, this external factor was not controllable or 
predictable by import country such as Thailand during the implementation period. A 
failure in drug supply means danger to patients due to the high risk of developing 
drug resistance, the high possibility of treatment failure, and the consequent loss of 
health and economic benefits to the country.   
Regarding lessons learnt from experiences of the former government, the 
cases of clopidogrel, letrozole and docetaxel show evidence that there were 
interruptions in supply during the implementation period. It was found that the GPO 
was sometimes unable to find an appropriate generic supplier for the drugs (letrozole 
and docetaxel during 2011 and 2013; and clopidogrel during 2014). Because the 
generic suppliers did not always deliver the drugs on time or the quality of drugs 
supplied failed to meet a proper standard, the GPO had to deal with the unmet need 
by finding and procuring the drugs from other sources. The GPO and public health 
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schemes took risks to manage the unanticipated effects from external suppliers as 
the prices from other sources were higher than the expected procurement plan, and 
the budget plan had to be abruptly reallocated in order to avoid interrupting the 
treatments [GS02]. In addition, in the case of erlotinib, information from a 
government officer indicated that foreign generic manufacturers of erlotinib have 
not invested their time and resources to conduct quality assurance according to the 
requirements of the Thai drug registration system. Consequently, the generic version 
of erlotinib has not yet met the requirements for registration in Thailand [GS05]. 
Therefore, the external factors of foreign generic suppliers were a serious concern 
for the government.  
Capacity of local generic drug industries (C3.3):  The capacity of local 
pharmaceutical industries was an additional key contextual element essential to 
support policy implementation. For example, the four drugs under CL policy, 
namely Efavirenz, Clopidogrel, Letrozole, and Docetaxel, were imported from India 
after a bidding process. However, a pharmaceutical company could win the bidding 
a few times, and the next bidding could be won by another pharmaceutical company, 
which offered different forms of the drug with the same active ingredients [238]. 
Accordingly, generic drugs obtained from bidding came from many companies, 
which were different in trade name, pill forms, and packaging. This resulted in 
problems with drug encoding and recording of patients’ drugs administration 
history, and this was an obstacle to the follow-up of symptoms, therapeutic 
effectiveness, and undesirable symptoms derived from each drug. More importantly, 
doctors found difficulties in explaining the reasons for changing the form and figure 
of drugs, because most patients remembered drugs by their appearance and 
packaging, especially elderly patients, so alterations resulted in confusion about the 
medication they were taking [103] [HS02].  
Fortunately, the combined drugs of lopinavir and ritonavir (LPV/r) have been 
mainly produced by the GPO. In this case, no problem occurred because it is easier 
to manage the locally produced drugs to be produced in the same pill forms and 
packaging. Hospitals could easily put a code on the drugs and record the patients’ 
drugs administration history, which facilitated doctors’ explanations and allowed 
patients to have a clear understanding of what medication they were taking. It also 
eased the follow-up of symptoms, therapeutic effectiveness, as well as adverse 
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symptoms of the drug [103]. This instance could support the argument for 
strengthening local generic drug industries as this would help simplify that issue 
with implementation of the policy given the local conditions of the health care 
system in the country and help avoid the unanticipated effects from foreign drug 
industries (as mentioned in the previous element) [AS01]. 
Physicians’ perceptions of quality of generic drugs (C3.4): The last 
additional contextual element was practitioners’ perceptions of the quality of generic 
drugs. There are different contexts across drug types. Practitioners had high 
confidence in the quality of ARV drugs for treatment of HIV/AIDS because the 
quality was closely monitored, not only by the Thai FDA as the national agency, but 
also at health care facilities. As efavirenz and LPV/r are the first and second line of 
HIV/AIDS treatment, the drugs have commonly been used for all HIV/AIDS 
patients. In this case, in addition to the quality assurance made by national 
authorised agencies, physicians at health care facilities themselves had monitored 
the clinical efficacy and quality of drugs through monitoring CD4 and viral load of 
patients. (Physician from Mongkutklaw hospital expressed in [226]; p56)  This 
statement was supported by a physician from Kampangsan hospital that “the 
negative effects of ARVs have not been found, and the efficacy and safety of the 
drugs have been monitored by the CD4 and viral load in every 6-12 months” [226]. 
As there were no quality problems raised by physicians on the CL ARVs, 
confidence in the quality of generic substitution boosted practitioners’ willingness to 
accept, and dedication to do activities under the policy.  
However, there was less confidence in generic forms of clopidogrel, 
letrozole and docetaxel. Under CL, the price of clopidogrel was 98% lower than 
patented drugs, leading to a constant concern about therapeutic effectiveness. To 
deal with this situation, academic sectors conducted studies to compare the clinical 
outcomes of CL generic drugs with its patented version. The details are explained in 
the section of actors (P3). The empirical academic evidence built trust and 
confidence among health personnel and patients, and adjusted negative perceptions 
of the therapeutic efficiency of generic drugs. In addition, there was literature 
criticising the quality of generic cancer drugs. For example, a study by Vial in 2008 
analysed the quality of generic versions of docetaxel in 14 countries and indicated 
that many generic drugs failed to meet purity standards [239]. The GPO decided to 
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apply for quality assurance for CL cancer drugs at qualified international 
laboratories in order to build the confidence of physician groups. [GS02].  
 
8.3.3.2 Contents in the policy implementation 
Activities to produce or procure generic CL drugs (A3.1):  At the stage of 
policy implementation, there were a number of activities conducted by the former 
government. The GPO assessed local capacity whether it needed for technology 
transfer and investment; availability of technical resources for reverse engineering, 
costs and duration of developing production processes and product formulations 
[GS02]. When the local manufacturers had no capacity, the GPO procured the drugs 
from foreign suppliers. One government officer addressed a lesson learnt from the 
procurement made by GPO. Because there were a large number of generic suppliers 
of efavirenz, high competition led to a sufficient supply to meet the demand and a 
significant decrease in the price of generic products. In the case of LPV/r, the GPO 
produced the generic products locally to satisfy demand, which in turn brought the 
price of Indian generic suppliers down. In contrast, due to the limited number of 
suppliers in the cases of clopidogrel, docetaxel and letrozole, the prices of those 
three drugs had gradually increased. It was also highlighted that if the market is 
dominated by a small number of suppliers (oligopoly), they may collaboratively set 
the price to maximise their profit [GS02]. Therefore, a key success factor was the 
number of suppliers participating in the bidding process. 
Activities to control the quality of generic products (A3.2): On behalf of 
the MOPH, the Thai FDA is responsible for regulating drugs and stipulates that the 
quality, effectiveness, and safety of drug registered by the FDA are closely 
monitored to meet the national standards. Moreover, the Thai FDA developed the 
procedure protocol for control quality of CL drugs. The protocol suggests that the 
GPO had to send samples of produced or imported drugs for quality examination at 
the Department of Medical Sciences (DMSC), affiliated to the MOPH [226]. During 
2007 to 2012, there was no evidence that CL products were sub-standard [240]. At 
the end of 2012, therefore, the DMSC referred its authority for assuring the quality 
of generic drugs to the GPO to do on its own. However, stakeholders criticised that 
it was not a good practice because the drugs’ quality assurance and monitoring 
required double-checking by third parties such as DMSC. After the protocol was 
 
 
185 
 
changed, evidence showed that CL clopidogrel (which was quality-controlled by the 
GPO) failed to comply with the national standard, leading to a recall from the Thai 
market. This point raised serious concerns among physician groups [GS03]. Some 
viewpoints mentioned that physicians are worried about the quality of CL drugs 
because of the evidence of sub-standard of CL drugs. (A physician from Nakorn 
Pathom hospital addressed in [233]; p54).  This statement was consistent with 
physicians from other hospitals that they didn’t use the drug under CL policy 
because of the concern about quality of CL drugs. They had preferred to use other 
alternative drugs until the quality of CL generic drugs was rigorously approved (A 
physician from Ratvithi and Chonburi hospitals addressed in [233]; p54-55). 
Activity to distribute CL drugs to health facilities (A3.3): The GPO is the 
main organisation distributing CL drugs according to the purchase orders from the 
three public health schemes. The public health care schemes have to assess their 
budgets to cover all patients within the target group of CL policy, and respective 
hospitals have to report the number of patients, protocol guidelines, drug dosages, 
and medical care costs to these agencies every month [GS03]. It was highlighted 
from the Thai experiences that, in addition to guidelines for drug distribution, the 
GPO and NHSO established the Vendor Managed Inventory (VMI) system. The 
GPO uses the system for collecting and receiving information about drug purchase 
orders, prescriptions, transportation and distribution of drugs to hospitals. Because 
the Thai government grants CLs for providing generic drugs only to patients under 
public health benefit schemes, the VMI has been used to monitor if the product 
distributes to users beyond the CL policy’s declaration [241]. Based on the VMI 
database, the CL drugs were distributed to health care facilities only under the three 
health benefit schemes and a leak into other users (such as private sectors) was not 
detected. Therefore, the VMI has been used as an effective instrument to monitor the 
performance of CL drug distribution [GS02], and this is an additional instrument 
essential to include in the preliminary framework.  
 
Activities to utilise the drug at health care facilities (A3.4): The last 
activity of policy implementation is the utilisation of generic CL drugs at hospital 
units. The MOPH developed a set of policy guidelines to facilitate health care 
workers who use the CL drugs. The Thai clinical practice guidelines (CPGs) were 
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developed by expert committees from MoPH and health care schemes to promote 
rational drug use including CL drugs [120, 186, 202]. As the prices of CL drugs 
were much lower than the drug used prior to CL implementation, this may lead to 
overutilization of the drugs, especially clopidogrel which has a high proclivity 
toward variation in practice. A physician indicated that “the CL policy significantly 
reduced drug prices and could induce the drug utilisation.” (Physician from 
Chulalongkorn University Hospital expressed in [226]; p36). Moreover, the MoPH 
also published policy notifications, which were used as procedure protocols of CL 
drug utilisation. In general, the procedure protocols for different hospitals are 
similar, as all are based on the MOPH’s Notification. Each of the hospital directors 
applies the protocol guidelines for dispensing drugs for patients.  
In addition, a systematic compliance inspection for the Rational Drug Use 
(RDU) is required at this stage in the form of utilisation review measures, such as a 
formation of contracted provider networks, pre/post authorization for specific 
treatment, and auditing system through inspections of medical records and claim 
audit [242]. This is an additional instrument suggested by experiences of the former 
government. As mentioned in Chapter 3, there are two groups of auditors to monitor 
the drug utilisation: external auditors from the three public health insurance schemes 
and internal auditors from authorised local hospital staff. It was indicated that the 
auditing system was developed to monitor the compliance of practitioners’ 
prescribing performance with the procedure protocols and CPGs, in order to 
promote rational drug use and avoid over-utilizing CL drugs. [GS03], and this is 
also an additional instrument essential to include in the preliminary framework. 
 
8.3.3.3 Actors in the policy implementation   
For the actors at the policy implementation stage (P3), all the way through 
these processes, the government established a multidisciplinary team for 
implementing CL policy. The concerned organizations are affiliates of the Ministry 
of Public Health (MOPH), including the Food and Drug Administration (FDA) who 
regulate and control quality of generic CL drugs, the Government Pharmaceutical 
Organization (GPO) as the drug procurement agency, the Department of Medical 
Sciences (DMSC) playing the role in assuring quality of medicines, the three main 
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public health care scheme (NHSO, SSO, CSMBS), and health care facilities across 
the countries who utilise the drugs.  
In addition to the authorised governmental agencies that implement the CL 
policy, academics who played an important role in promoting stakeholder 
confidence in the quality of generic drug under CL policy were added in figure 8.2. 
An academic network in the social research institute in Chulalongkorn University 
published a series of literature to boost public confidence in the quality of generic 
drugs including those under CL policy.  
There were studies conducted to analyse clinical outcomes of CL clopidogrel 
in nine tertiary hospitals [243]. In addition, another clinical research study from 
Khonkaen University compared the efficacy of generic and patented clopidogrel 
[244]. Both studies concluded that there was no difference in the clinical outcomes 
between the generic and patented clopidogrel. So the CL generics were suggested as 
substitutes for the expensive patented drugs because they offered adequate efficacy 
and value for money. This information was disseminated to health care practitioners 
who had requested empirical evidence about therapeutic effects of CL generics 
compared to patented drugs. This is another strong role of academics in the stage of 
policy implementation, in addition to the authorised governmental agencies under 
the MoPH, to boost and promote public confidence in the quality of generic drugs 
under CL policy.  
 
8.3.4 Key elements of CL monitoring in Thailand 
 
8.3.4.1 Context of policy monitoring 
The main contextual elements in the process of policy monitoring, which is 
consistent with the preliminary framework in Chapter 5, is institutional capacities 
to monitor performance and evaluate implications (C4.1). Information from 
government officers consistently indicated that, in general, the responsible agencies 
by itself were monitored their performance. Responsible agencies had to make plans 
to achieve their objectives, and adjust their behaviours when objectives were not 
achieved [GS02], [GS03]. Moreover, the output of each responsible agency, as a 
piece of jigsaw, had to link together in order to create the overall intended outcomes 
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and impacts [GS03]. The policy was implemented in parallel with monitoring of 
policy performance, and implications were evaluated at the end.   
Emerging needs for knowledge about policy experiences and 
implications (C4.2): As CL policy has been successfully used by a few countries, 
there is value of knowledge and experiences of the former government of Thailand 
in implementing the policy. The information obtained from policy monitoring and 
evaluation not only helps authorised agencies to improve policy performance, but 
also enables other stakeholders to understand and learn from cases of CL policy. 
This is an additional element essential to include in the framework. As this is the 
first use of CL policy in Thailand, in the meeting of the Thai Cabinet (19 January 
2010), the MoPH was assigned to establish systems to monitor and evaluate CL 
policy. The system had to show the progress of policy performance, the achievement 
of policy aims, and problems and obstacles to policy implementation, in order to 
provide feedback to concerned sectors. In addition, as there was a need to enhance 
stakeholder knowledge of CL policy implications at both national and international 
levels, it was suggested that the Thai government should publicly report the policy 
implications on drug access after Thai CLs were granted [233]. A view from 
meeting participants indicated that other countries would like to learn from the 
experiences of Thailand [OS04]. A government office informant supported this 
view, suggesting that the findings of policy monitoring and evaluation could identify 
the problems, obstacles, and defects arising from the policy, as well as offer 
strategies to improve the efficiency and effectiveness of policy. This information 
could help other countries aiming to issue CL to avoid the unanticipated effects 
occurred in the Thai case [GS03]. 
 
8.3.4.2 Contents of the policy monitoring and evaluation 
In this process, activities to monitor performance and evaluate 
implications of CL policy (A4.1) are an important step, which is consistent with the 
preliminary framework, to provide evidence and information to policy makers for 
making a decision to proceed with and improve the policy, or discontinue it. The 
activity required a monitoring system to gather inputs and outputs produced by the 
policy. This system was beneficial not only to monitor policy performance, but also 
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evaluate policy outputs and outcomes [70]. The scope of works for the former 
government contains two sections as follows: 
(1) Compliance with the policy proposal: the aim of this activity was to 
monitor the performance of authorised agencies, whether the policy was performed 
in compliance with the scope defined in the policy proposal, and the achievement of 
policy objectives as committed to the government in the formal notification of CL 
policy. The areas being monitored by responsible agencies were as follows: certain 
product types under the CLs which limit to the CL drugs in all formulations, 
including its derivatives patented in Thailand; certain population groups which limit 
to patients entitled persons under the three public health schemes UC, SSS and 
CSMBS; a certain duration of policy which limits to the defined period of the 
government notifications; and an achievement in increasing the number of patients 
who access CL drugs as the main objective of CL policy [GS03] .   
(2) Implications of policy: the aim of this activity was to evaluate the CL 
policy implications. For the former government’s actions, both positive and negative 
implications were evaluated: negative aspects included reactions from policy 
opponents (withdrawing or delaying registrations of new pharmaceutical products in 
the Thai market, and objections to the Thai government through political retaliation 
and economic sanctions); positive aspects included the health benefits from the 
increase in drug access among patients in need. The benefits for health were 
presented explicitly in terms of short-term and long-term of national health 
expenditures, which have been and are predicted to be reduced by the CL policy. 
The negative implications were evaluated in a previous study in 2013 [71], while 
short and long term positive implications were evaluated in my study.    
 
According to the preliminary framework, activities to develop policy 
feedback to improve policy performance (A4.2) were consistently suggested by 
the former government as the final step, in order to translate the empirical data into 
policy messages for decision makers and other stakeholders in the policy processes. 
Channels to deliver policy messages were an essential instrument to convey policy 
messages to policy makers and stakeholders. This required packaging, 
communication and dissemination of the policy messages in different formats and 
languages, which were accessible to each audience: policy makers, senior‐level 
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government officers (policy elites), junior-level of government officers (operating 
staff), academic sectors, advocacy or NGO groups, practitioners in healthcare 
facilities, patient groups, and the general population [GS03]. It was highlighted that 
there were misunderstandings between central agencies and local health facilities, 
and it was therefore suggested that the MOPH should set up the coordination and 
consultation centre for the CL policy, which was equipped with experts to answer 
questions and provide essential information about this policy in a timely manner. 
This could lessen problems relating the policy implementation and bring about trust 
and confidence among concerned actors in each stage of the policy processes 
[HS01][HS03].  
 
8.3.4.3 Actors in policy monitoring and evaluation   
For the actors in the policy monitoring stage (P4), authorised agencies in the 
implementation process have self-monitored their performance. As mentioned in the 
implementation stage, there are several organizations implementing the policy: the 
Food and Drug Administration (FDA), the Government Pharmaceutical 
Organization (GPO), the Department of Medical Sciences (DMS), the three main 
public health care schemes (NHSO, SSO, CSMBS), and health care facilities across 
the countries. However, information from informants consistently indicated that 
authorised implementation agencies have sufficient capacity to monitor its 
performance, but not to evaluate the policy implications [GS01], [GS03]. A view 
from government officers indicated that this task could be conducted by academic 
sectors, which did not have conflicts of interest with the authorised agencies 
engaged in the policy process. Policy evaluations could identify policy suggestions 
to improve performance of authorized agencies for each stage along the policy 
process: agenda setting, policy formulation and implementation [GS03]. 
In Thailand, the academic sector plays an important role in providing 
evidence-based information to stakeholders including other sectors such as MOC 
affiliates, MFA affiliates, health care professionals, NGOs and patient groups.  
Academic sectors include the Health Intervention and Technology Assessment 
Programme (HITAP), the International Health Policy Program (IHPP), the Health 
System Research Institutes (HSRI), and research institutes in universities, etc. Many 
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policy evaluations were carried out by these institutions. Therefore, the academic 
group was added in Figure  
 
8.4 Discussion and conclusion 
This chapter aims to assess whether the policy elements in the preliminary 
framework (Chapter 5) are applicable to the Thai context. To answer this question, 
three qualitative approaches (document analysis, semi-structured interviews, and 
meeting observations) were employed to analyze the applicability of the identified 
policy elements. Other elements not mentioned in the preliminary framework were 
included in the framework if they influenced the Thai CL process. In this chapter, 
policy elements mentioned in the preliminary framework defined in Chapter 5 were 
consistent with the Thai experience of CL policy. In addition, the experiences of the 
former government suggested additional elements not mentioned in the preliminary 
framework.  
At the agenda setting stage, the common factor is the combination of unmet 
public health needs (due to drug patent barriers) and the availability of TRIPS 
flexibilities. However, while many countries, especially LMICs, have faced the 
problem of unmet needs in their public health system, few countries decided to issue 
CL policy. It is clear that, beside the unmet public health need, there must be other 
essential elements leading to the decision to issue CL. The experiences of the former 
government indicated three additional elements, which are mainly context-specific 
to Thailand: political standpoints of policy makers on health over trade interests, 
strong networks of policy partners, and political commitment to achieve universal 
coverage. These context-specific elements of Thailand significantly influenced the 
decision to issue CL policy in the country. 
At the stage of policy formulation, one of the key contextual elements are the 
common misconceptions of TRIPS flexibilities, resulting in stakeholders attempt to 
interrupt the use of CL policy in Thailand, despite CL implementation complying 
with the TRIPS agreement. Therefore, the availability of TRIPS flexibilities may be 
not sufficient; the correct and consistent interpretation of stakeholders is also 
essential. At this stage, additional contextual elements are relevant to two groups of 
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stakeholders. First, pressure and negative reactions from policy opponent groups 
create an unsupportive environment in order to prevent the government from 
implementing CL policy. In the experience of the former government, these 
opponent reactions were alleviated by strong networks and common social values of 
policy supporters. Therefore, teamwork between government and non-government 
organizations could create a third force to enhance government power to resist 
pressure from policy opponents and help facilitate the implementation of CL policy. 
After the decision is made, the next essential is adequate institutional 
capacity of authorised agencies to implement and monitor the policy performance. 
Experiences from the former Thai government identified additional contextual 
factors. First, interruptions of drug supply from foreign suppliers (which endanger 
patients and the health system) highlight the importance of the government finding 
more sustainable suppliers. The capacity of local drug industries, as the second 
factor, should be strengthened to maintain a continuous national drug supply. When 
the drugs procured and distributed to health care facilities, physicians’ perceptions 
of quality of generic drugs are the third factor that has a significant effect on the 
success of CL implementation. Finally, the last contextual factor is the emerging 
need for knowledge about policy experiences and implications. As CL policy has 
been successfully used by a few countries, there is value in collecting and sharing 
the knowledge and experiences of the former government in implementing CL 
policy. This information could help other countries aiming to issue CL to avoid the 
unanticipated effects occurred in the Thai case. 
In addition, actors who participated in the CL policy process played an 
important role in its success. Policy support included inter-ministerial committees, 
authorized central and local agencies, and also other stakeholders, especially NGOs 
and academics. The NGOs passionately protested against transnational drug 
industries, while academics provided concrete evidence to support the policy. The 
experiences of the former government highlighted that academics played a 
significant role throughout the CL policy process. Academics established the 
evidence base about problems related to patentability to encourage concerned 
sectors to develop a rigorous system of drug patentability as an alternative measure 
to avoid using CL policy. Academics conducted a study to estimate the potential 
implications of CL policy to help the government in making decisions based on 
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evidence. Academics also conducted clinical studies to assure the quality of CL 
generic drugs in order to boost practitioners’ confidence in the quality of generic 
drugs procured under the policy. Finally, the policy performance and implications 
were evaluated by academics in order to inform stakeholders and educate the public. 
The approach had several limitations. First, as the CL policy was introduced 
in Thailand eight years ago, although the policy is still active, it was impossible to 
directly observe the policy areas of agenda setting and policy formulation. Second, 
many interviewees were unable to recall all of the events that occurred in the past. 
This limitation leads to some difficulties in identifying policy elements in the 
process of policy-making and implementation. Third, the policy is politically 
sensitive. Crucially this suggests that some interviewees may tend to conceal 
particular issues, such as failure, mismanagement, or poor practices concerning the 
policy. Fourth, given the norms of Thai culture, subordinates might hesitate to 
criticise senior staff, or policy partners might be reluctant to criticise each other. To 
mitigate these limitations, sources of information were retrieved from several data 
sources and different groups of informants in order to verify findings as far as 
possible.  
In addition, one of the key limitations of my study is the small number of 
interviewees. The framework developed in this study was based on information from 
policy makers, government officers and partners of the government including: 
NGOs and academics, who supported the policy; the generic drug industries, who 
provided the CL generic drugs; and the health care professionals, who used the CL 
drugs in hospitals. These groups of stakeholders were set as the priority group from 
whom the information was collected. Although I was unable to interview the 
patented drug industries, inter-governmental organizations, and other relevant 
ministries such as the Ministry of Foreign Affairs (MFA) and the Ministry of 
Commerce (MOC), due to the time limitation, I collected the views of these groups 
from literature.  
As the CL policy was introduced in Thailand eight years ago, I found that 
some of the interviewees were unable to recall all of the events that occurred in the 
past. Therefore, I believed that the best reliable information for developing the 
framework were mainly obtained from literature, such as official letters, meeting 
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minutes, conference reports, which documented at the time of events. In my field 
work, I found abundant literature, which documented information from and opinions 
of various stakeholders including MoPH, MOC, MFA, NGOs, inter-governmental 
organization, and patented industries. These data sources sufficiently triangulated 
information among different groups of stakeholders.  
In conclusion, although most of the important elements were already 
mentioned in Chapter 5, elements from experiences of the former government 
helped strengthen the framework with respect to the processes of decision-making 
and implementation of drug policy, focusing on CL policy.   
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Chapter 9: Discussion and conclusions of the thesis  
   
9.1 Introduction 
Patent protection for pharmaceutical products can create incentives for 
research and development of new medicines. However, it is acknowledged that the 
global patent regime does not necessarily address the needs of the developing world, 
instead creating barriers to access to essential drugs through pharmaceutical patent 
protection. Therefore, a series of remedial flexibilities have been included in the 
TRIPS agreement in order to allow countries to use the flexibilities of TRIPS to 
protect public health and promote access to essential medicines for their citizens. 
One of the flexibilities is the compulsory licensing (CL) policy; however, only few 
LMICs have made use of CL. Possible explanations for the low uptake of CL is that 
most countries are worried about the potential political and economic retaliations, 
and they are uncertain about which implementation strategies might help optimise 
benefits and avoid negative consequences. In the case of Thailand, the former 
government issued and implemented CL policy through learning by doing, and there 
were a number of unanticipated events. The knowledge acquired and lessons learnt 
from experiences of the former government are of value for developing a 
framework. Therefore, the framework developed under this study suggests key 
elements to be considered for decision-making and implementation of drug policy, 
focusing on CL policy.  
The aim of this chapter is to provide a discussion and synthesis of all 
findings by clarifying roles of each policy element in the framework and the 
interactions between them. In addition, key findings for each policy process: agenda 
setting, policy formulation, implementation and monitoring are provided. Other 
issues around CL implementation, such as improving policy efficiency, and 
encouraging strategic roles of actors at each stage, are also addressed. 
Complementary information was included, such as other countries’ experiences of 
the policy, in order to strengthen and validate the study findings. Finally, this 
chapter closes with policy recommendations for the Thai government about the 
current and future use of CL policy to improve its performance, and for other 
countries having the similar context to learn from the Thai experiences. 
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In this study, CL is suggested to be one of the policies to promote drug 
access in Thailand. The inclusion of CL as an institutional component in the Thai 
drug policy helps offer an additional measure beside the available measures, such as 
patent opposition and price negotiation, to policy makers. After the failure from 
these measures, the CL policy can be applied in case of public non-commercial use, 
in order to achieve the aims of the Thai universal coverage policy. In addition, the 
CL policy can be used to solve public health problems in the management of 
national emergencies. Therefore, the Thai government should keep the CL policy as 
an institutional element that can safeguard public health benefits of the country. This 
is completely compatible with TRIPs. The findings of this study could be beneficial, 
if the Thai government needs to use CL again in the future. 
To develop the framework, my study contained four objectives as follows. In 
objective 1, an intensive review was conducted to identify policy elements affecting 
the decision-making and implementation of the policy from literature published by 
intergovernmental organisations. The contents of the preliminary framework were 
assessed by qualitative approaches in objective 4. Any additional elements derived 
from experiences and insights of CL implementation by the former government of 
Thailand were used to strengthen the framework. Moreover, there are 
implementation strategies identified in this study. In objective 2, potential 
implications across different drug types were analysed to identify key elements that 
should be incorporated in the drug selection criteria, and the performance of the Thai 
government in implementing the policy was evaluated in objective 3 to develop 
strategies to improve the government’s performance. The findings of each objective 
are shown in figure 9.1. 
According to the findings in objective 1 and 4, key elements were identified 
for inclusion in the framework. In the framework, policy elements include: policy 
contents in terms of activities and instruments required to implement the policy; 
contextual factors required to support policy implementation; actors required to 
participate in the policy process; and policy processes containing four stages: agenda 
setting, policy formulation, implementation, and monitoring. The details are as 
follows. 
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At the agenda setting stage, there are four main activities: (i) identification of 
unaffordable drugs, (ii) consideration for patent opposition, (iii) consideration for 
price negotiations, and (iv) consideration for using TRIPS flexibilities. In this stage, 
the combination of an unmet public health need and the availability of TRIPS 
flexibilities is an important contextual factor leading to the decision to put CL policy 
onto the national agenda. Experiences from the Thai government indicated that there 
are three additional contextual factors at this stage: (i) political standpoints of policy 
makers, (ii) strong networks of policy elites and partners, and (iii) political 
commitment to universal coverage. The key actors influentially participating in the 
process of agenda setting are multi-ministerial committees and patented drug 
industries; other additional actors include academics, NGOs, and patient groups. 
In the stage of policy formulation, there are four main activities: (i) 
development of a CL policy proposal, (ii) identification of generic drug sources, (iii) 
development of streamlined procedures; and (iv) establishment of evidence base of 
CL to support the policy decision. The last activity is suggested by the experiences 
of the former government. The main contextual factor in this stage is the common 
misconception of TRIPs flexibilities. In addition, the experiences of the Thai 
government indicate three additional contextual factors influencing the policy 
formulation: (i) pressure from policy opponents, (ii) strong networks of policy elites 
and partners, and (iii) social values of policy supporters. The key actors in this stage 
are similar to the previous stage, but include two additional groups: (i) policy 
supporting groups, including international NGO and international academic groups; 
and (ii) policy opponent groups, including transnational-patented drug companies, 
and countries representing the patented drug firms. 
There are six main activities for policy implementation and monitoring: (i) 
procurement of CL drugs, (ii) quality assurance of CL drugs, (iii) distribution of CL 
drugs to health facilities, (iv) utilization of CL drugs by health practitioners, (v) 
monitoring and evaluation of CL performance, and (iv) development of policy 
feedback. The key actors in this stage are authorised agencies responsible for the 
policy implementation, and academics are essential to adding in the framework. The 
main contextual factors to consider at this stage are institutional capacities 
(infrastructure and staff expertise) to implement the policy and to monitor and 
evaluate the policy performance. In addition, the experience of the former 
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government identified four additional contextual factors: (i) interruptions of drug 
supply from foreign suppliers, (ii) capacity of local generic drug industries, (iii) 
physicians’ attitudes to the quality of generic drugs, and (iv) emerging need for 
knowledge of CL implementation. 
Moreover, the findings in objective 2 suggest key factors, which should be 
included in the CL drug selection criteria. The key elements are: (i) drugs for 
treatment of diseases that are the leading causes of public health burden; (ii) drugs 
with the highest potential difference in treatment cost; and (iii) drugs that are 
required for diseases with no alternative treatments. The criteria could promote the 
transparency of policy decision process, and help policy makers to select the drugs, 
which potentially create the highest benefits to the society. 
Furthermore, findings in objective 3 suggest implementation areas, which 
merit more government attention in order to improve performance. The 
implementation areas are prioritised as follows: (i) most vitally, improving 
physicians’ attitudes to the quality of CL drugs; (ii) managing the risk of 
interruptions of drug supply from foreign suppliers, which significantly affected the 
implications of CL policy; (iii) strengthening the capacities of local drug industries 
to maintain drug supply in the long run; and (iv) Encouraging feedback from local 
facilities in order to improve CL performance and implications.  
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Figure 9. 1 Summary of findings from this study 
 
 
 
200 
 
 
The PhD findings contain strategies to optimise the positive consequences 
and minimise the negative consequences. According to the systematic review in 
chapter 2, there are three positive consequences: (i) increase in public health 
benefits, (ii) increase in consumer welfare, and (iii) decrease in market prices of 
pharmaceutical products. My findings suggest that the positive consequences can be 
optimised by improving the performance in implementing the policy. The 
government should improve its performance through three contextual elements: 
preparing a supportive system to prevent interruptions of foreign drug supply, 
strengthening capacity of local generic drug industries, and strengthening 
physicians’ confidence on the quality of generic drugs. Moreover, the findings 
suggest key indicators that should be incorporated in the criteria of drug selection, in 
order to achieve the highest benefits of the policy on certain drugs. These 
suggestions could help the Thai government optimize the positive consequences of 
CL policy. 
In addition, three negative consequences were found in the literature review: 
(i) disincentive for drug innovations, (ii) delay of new drug launches, and (iii) 
deterioration of the national economy. Strategies to lessen or mitigate the negative 
consequences were identified. As most negative consequences result from pressure 
of policy opponents, my study suggested three approaches to prevent the negative 
reactions of stakeholders. First, the government should clearly declare the aim and 
scope of CL implementation to avoid misinterpretation among stakeholders. 
Secondly, the use of CL policy under the ideological aim of universal access to 
essential drugs could be an appropriate ground for the CL justification. Thirdly, if 
any negative reactions from policy opponents still occur, strong networks of policy 
elites and partners could create a third force to support the use of CL and resist the 
opponents’ pressure. Furthermore, my findings suggest to avoid the potential 
negative consequences of CL that Thai government should also consider other 
alternatives, including patent opposition, price regulation and negotiation, parallel 
import, and voluntary licensing, in order to avoid using CL policy and subsequently 
avoid the potential negative consequences of CL.  
 
 
 
201 
 
9.2 Key findings in the stage of agenda setting 
  
9.2.1 Essential elements leading to a decision to issue CL policy 
According to the study findings, an unmet public health need caused by 
unaffordable patented medicines prompted policymakers and elites to find a policy 
solution. The former Thai government was faced with budget burdens in health care 
treatment for three life-threatening diseases: HIV/AIDS, cerebrovascular disease, 
and cancer, and these burdens led to the CL decisions [81] [83]. However, the 
government had never used this policy before, despite having the problem for a long 
time. It is clear that, beside the unmet public health needs, there must be other 
essential elements leading to the decision to issue CL. Examining the experiences of 
the former government highlights that three additional contextual elements influence 
the setting of CL policy.   
- Political standpoints of policy makers on health over trade interests: 
Among several alternative measures to promote drug access, CL policy highlights 
conflicts between trade and health interests. As most countries issuing CL policy 
were confronted with strong negative reactions from patent owners, many LMICs 
have been reluctant to grant the policy [19, 20]. However, Thailand is a leader in 
many aspects of public health policy, including the areas of drug access, and the 
leadership of policy makers and politicians is a key factor leading to the decision to 
implement CL despite conflicts with other stakeholders [20, 229]. This point is 
consistent with CL in Ecuador. For example, the Ecuadorian President expressed his 
political viewpoint that “This is our vision of intellectual property. It's not a 
mechanism to enrich the pharmaceutical or agrochemical companies.  It's a 
mechanism for development for the people” [64]. Consequently, in Ecuador CL was 
chosen and pursued to achieve drug access. 
- Strong networks of policy elites and partners: A policy analysis study 
refers to the model of "the triangle that moves the mountain" to explain key factors 
influencing successful decisions when issuing CL policy [20]. It highlights that, in 
addition to the political standpoint of policy makers mentioned earlier, other two 
angles in the model were (i) the knowledge generated by academic groups and (ii) 
the movement of civil society [20, 229]. The findings in Chapter 8 highlight that 
strong institutional networks and stakeholder participation (especially health 
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professionals, academics, health NGO networks and patient groups) played an 
important role in successfully developing the policy and placing the problem of drug 
access and CL policy on the national agenda. In addition, the former government 
established an inter-ministerial committee, consisting of public health, trade, 
industry and foreign affairs, to participate in policy decision-making process. This 
point is supported by the fact that ministerial collaboration is often necessary to 
develop a partnership between ministries, and also to promote policy coherence 
across issues concerning the interaction of trade and health. [245].  
- Political commitment to achieving universal health care coverage: 
According to the findings in Chapter 8, the former government argued that the 
decision of CL policy was made to support the universal health care coverage by 
improving access to essential medicines for all patients in need [81, 83]. The 
universal access program has also been implemented in Brazil and CL policy is one 
of the essential measures used to sustain universal access to ARV drugs [246]. The 
ideological aims of universal access to medicines, as the duty of the government to 
promote the right of its citizens in access to essential drugs, can help to justify the 
use of CL policy to serve public health interests. Therefore, any license used to 
support the national public health program could be an appropriate ground for the 
CL justification. It is consistently mentioned by Pogge et al. that the national 
program of universal access to essential medicines may become an important 
context, which justifies issuing CL policy [247].    
 
9.2.2 Criteria for selecting drugs to issue CL policy 
According to the literature review in Chapter 2, an interesting case of CL in 
LMICs is Egypt, which used CL on Viagra®. Stakeholders raised doubts about 
whether increasing access to the drug was essential to public health interest [33]. 
This suggests that a transparent process is required when selecting drugs to be issued 
under CL policy, a point consistently mentioned in Chapter 5 and 8.   
Clear criteria for selecting drugs to serve unmet public health needs could 
help promote the transparency and effectiveness of the CL decision on a particular 
drug. A previous study provided explicit drug selection criteria for CL policy as 
follows: (i) the number of patients in need of the drugs, which could be estimated by 
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using epidemiological data of disease prevalence and incidence; (ii) the difference in 
prices between currently available patented drugs and the proposed generic drugs; 
(iii) the safety and efficacy of the drugs of interest by comparing with alternatives 
currently available on the market; (iv) the remaining duration of term of patent 
protection of the original drug in question; (v) variations in prescription practices of 
health professionals and the potential for irrational use of particular drugs; and (vi) 
the preparedness of streamlined procedures for registration, importation and 
distribution of generic drugs under CL policy [70].  
The findings from my study are consistent with the previous suggestions, but 
add some important factors to the first three points. The findings in Chapter 6 
suggest that the drug selection criteria should be adjusted as follows: (i) it should 
target not only diseases affecting a high number of patients, but also diseases 
causing a high burden to the country. The leading causes of public health burden 
(such as diseases listed in the national burden of disease, which takes mortality and 
morbidity into account), should be employed; (ii) it should not only look at the 
difference in prices between patented and generic drugs, but rather analyse the 
difference in total treatment cost, between potential CL drugs and current practices; 
(iii) it should not only select the drug with the highest safety and efficacy records, 
but also drugs required to use for diseases with “no alternative treatments”. The 
revisions of drug selection criteria suggested above could help policy makers and 
elites to cautiously consider the drugs, which potentially create the highest benefits 
to the society.   
 
9.2.3 Alternatives to CL policy 
It has been argued that the decision to apply CL should be made only when 
necessary, after failures in properly trying other alternatives [148]. However, there 
are two areas, in which the government needs to improve its performance when 
engaging in alternatives to CL. First, the government should develop the quality and 
usability of the patent information system. The key problem for Thai 
implementation of CL is the lack of a high-quality domestic information system for 
pharmaceutical patents. As mentioned in Chapter 8, the government issued an 
unnecessary CL for letrozole because no effective and comprehensive database 
 
 
204 
 
system is available for the patent investigation. The patent database in Thailand is 
unstable, very complex and time-consuming to use, effecting the certainty for 
making a decision. Concerns over the pharmaceutical patent database are supported 
by Yamabhai et al., who argue that the drug patent information system in Thailand 
should be strengthened to be more effectively used for public health interests [219]. 
 Second, the government should develop effective mechanisms to control or 
manage the price of drugs. Regarding the issue of drug price, price negotiations of 
the former government with patent owners failed to obtain price reductions for most 
of the drugs in question. Imatinib is the only successful case: the patent owner, 
Novartis, agreed to provide imatinib for all patients under the Glivec® International 
Patient Assistance Program (GIPAP). As such, price negotiation enabled the 
government to avoid using CL for Imatinib. In addition, evidence suggests that CL 
seems to be an effective threat in price negotiations to patent firms. For example, the 
Brazilian government successfully used the threat of issuing CL policy to obtain 
significant price reductions from the patent industries [73]. Another point of concern 
is that Thailand seems to have ineffective measures to control medicine prices, 
leading to high drug prices which are sometimes unaffordable for the government 
and patients [90]. Therefore, to overcome the problem in long-term, the Thai 
government should develop rigorous national legislation to control the price of 
essential drugs, especially the patented pharmaceutical products. 
 
9.3 Key findings for the policy formulation stage 
  
9.3.1 Common misconceptions of CL provisions  
Misconceptions of CL policy provision is the main contextual element 
identified in Chapter 5. For example, according to the TRIPS article 31, the use of 
CL is not restricted to situations of national emergency and in the case of other 
circumstances of extreme urgency, but rather “in cases of public non-commercial 
use”. In addition, the public health crises, including “but not restricted to” those 
concerning HIV/AIDS, tuberculosis, malaria, and other epidemics, can represent a 
national emergency or other circumstances of extreme urgency [24]. The findings in 
Chapter 8 highlighted that, although the Thai government issued the CL policy for 
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public non-commercial use (compliant with the TRIPS agreement), the government 
was still faced with negative reactions from policy opponents [234]. Therefore, the 
availability of the TRIPS agreement may be not sufficient, but the correct 
conception and consistent interpretation of stakeholders is also essential in order to 
avoid improper interruption of CL implementation.  
The findings from Chapter 8 also addressed effective strategies used by the 
Thai government to adjust stakeholder misconceptions of the Thai CLs. The 
government published two official white papers in order to clarify facts and 
evidence on the key issues related to the government use of patents on ARV, 
cardiovascular and cancer drugs. The Thai government clarified in its white paper 
that the rationale behind the use of CL policy complied with the provision of TRIPS 
[81, 83]. In addition, a series of activities was conducted by the former government 
and its partners, such as: publishing formal and informal documents and 
disseminating them to the public, making speeches at national and international 
meetings, visiting foreign countries that criticized Thailand, and inviting inter-
governmental organizations to investigate the implementation of CL policy in 
Thailand. These strategies succeeded in adjusting the misconceptions of concerned 
stakeholders, and developing policy support from sectors outside public health [88]. 
These effective strategies should be recorded as key policy elements for any future 
CL use in Thailand and other countries.     
 
9.3.2 Common threats to be aware of when issuing CL policy  
Policy opponents commonly put political and economic pressures on the 
countries issuing CL policy. The results from the systematic review of CL 
implications in Chapter 2 and the findings from the Thai experiences in Chapter 8 
consistently indicated that transnational patented drug companies and countries 
representing such companies commonly try to put pressure on countries issuing the 
CL. An effective strategy to deal with the threats and negative reactions is a strong 
network of policy partners. The findings from Chapter 8 indicated that negative 
reactions from policy opponents were mitigated through support from the policy 
networks. The concerned supporters were local organisations, such as local NGOs, 
patient groups and academics as well as international organisations. This is 
consistent with the CL case in Brazil, where the Brazilian government gained 
 
 
206 
 
support for its decision from several sectors [248]. Collaboration between policy 
supporters played an important role in the success of CL implementation: while 
NGOs strongly protested against transnational drug industries, academics provided 
evidence to support the policy [20, 229]. Therefore, teamwork between government 
and non-government organisations could create a third force to enhance CL-
implementing countries’ power to resist such pressure.  
 
9.4 Key findings for the policy implementation stage 
 
9.4.1 The quality of generic drugs under CL policy 
 One key element influencing the success or failure of CL implementation is 
practitioner confidence in the quality of generic substitutes. A number of studies 
have criticised the quality of generic drugs from India and China, both major 
international suppliers of generic drugs. For example, Feldman argued that concerns 
about low-quality drugs arose from the fact that quality-control inspections are 
rarely conducted by the Food and Drug Administrations in India or China, meaning 
these generic drugs are potentially unsafe and/or ineffective [249].  Uncertainty 
about the quality of generic drugs makes physicians hesitant to prescribe the generic 
CL drugs, and this may produce significant problems in the public health system. 
Evidence from findings in Chapter 7 indicated that the lack of confidence in the 
quality of CL generic drugs to substitute its patented version among Thai prescribers 
created the highest monetary loss (approximately 119 million US$ during 2012 to 
2014) in Thailand. The confidence of practitioners in the quality of generic 
substitution affects the practitioners’ acceptance of, and dedication to activities 
undertaken under the policy [250]. Such significant costs suggest that resolving the 
issue should be a priority for the government.  
  Based on findings from Chapters 5 and 8, several strategies might build 
confidence in the quality of CL generic drugs, For example, the drugs could be 
selected from the WHO list of prequalified medicinal products; any drug not 
obtained from the list could be quality assured by a laboratory, itself prequalified by 
the WHO. This practice is consistent with CL in Brazil, which implemented CL 
policy by using generic versions prequalified by the WHO [246]. However, because 
even the best quality assurance systems may not prevent occasional production 
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failures, the drug production process must adhere to the Good Manufacturing 
Practices (GMP) standard and comply with requirements for quality specifications. 
In addition, random representative sampling and testing should be done to verify 
compliance with standards and references given. Another issue is the lack of 
regulation in drug promotion and advertisement, which can also cause serious 
problems for CL implementation. It has been reported that aggressive and 
misleading advertising of brands has influenced patients against generic drugs 
[157].  Advertising regulation is essential to avoid the misleading advertisements for 
drugs. The series of mechanisms mentioned above should build up confidence and 
create positive perceptions of the quality of CL generic drugs. 
  
 
9.4.2 Interruptions in drug supply under CL policy  
Another key issue in the implementation stage is interruptions in drug 
supply. The Chapter 7 performance evaluation for drug procurement showed that 
clopidogrel, letrozole and docetaxel were directly imported from a limited number 
of foreign generic manufacturers. The government was faced with a problem of 
supply interruptions of the drugs several times, which itself has serious 
consequences. For example, the interruptions in supply of the three CL drugs created 
monetary loss (approximately 5.9 million US$ during 2010 to 2014). The Thai 
government took a high risk when the foreign generic suppliers did not deliver the 
drugs on time or the quality of supplied drugs failed to meet an acceptable national 
standard. In addition, interruptions in supply mean danger to patients because of the 
risk of treatment failure, and the possibility of developing drug resistance leading to 
lost health, social, and economic benefits to the country. This seems to be a strong 
argument for increased government focus on securing a range of drug suppliers. The 
argument is also supported by the case of efavirenz. As efavirenz has five generic 
drug suppliers cooperating with the GPO to supply the product under CL policy, 
there are no unanticipated effects from an interruption in supply during the CL 
period. Therefore, this is a key issue that authorised agencies should be concerned 
about when the CL drugs are mainly procured from foreign suppliers. This is 
supported by Bate et al., who argue that there are difficulties in controlling or 
predicting the external factors of foreign generic manufacturers for delivering 
qualified generic drugs to meet local context-specific demands [251]. 
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In addition to the reliance on foreign drug industries, domestic industries 
should be strengthened in order to play an important role in maintaining a 
continuous CL drug supply. Through knowledge and technology transfer, CL policy 
can play a crucial role in developing and fostering local generic drug industries 
[252]. The findings from Chapter 7 supported this point. LPV/r has been locally 
produced by the GPO itself through technology transfer and never faced with any 
interruption in supply because the drug has been managed as a national priority. The 
GPO took complete responsibility for meeting the national demand for LPV/r, (this 
commitment also brought the price of Indian generic suppliers down in an attempt to 
compete). It can be seen that the capacity of local drug industries is another element 
contributing to ensuring steady long-term drug supply. This statement is supported 
by WHO, which comments that local drug industries should be strengthened to 
continuously maintain national drug supply, and establishing a network of drug 
suppliers for the country is also essential [253]. The strong network could overcome 
the unanticipated effects posed by foreign generic drug suppliers in terms of 
interruptions or long lead times in drug supply. 
 There is, however, an important precaution concerning the price of drugs 
produced by local industries. Where medicines are produced locally there tends to be 
an expectation that their prices will be more in line with the purchasing parity of the 
local population; however, this may not always be the case. For example, it was 
shown in Chapter 7 that the GPO aimed to produce efavirenz locally, through 
technology transfer, but the decision was reversed because purchasing generic 
efavirenz from India was cheaper than local production. It can be seen that locally 
produced generic medicines may not be cheaper than their imported equivalents, 
unless a combination of efficiencies in production and economies of scale can be 
achieved [253]. Therefore, policy makers should be wary of assuming that local 
drug production is always the cheapest or most efficient mechanism. 
 
9.5 Key findings in the stage of policy monitoring 
 
9.5.1 Supportive system for monitoring CL performance  
According to the TRIPS agreement and Thai patent law, the legal validity of 
any CL decision can be subject to judicial review by authorised agencies. Therefore, 
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at the policy monitoring stage, the policy implementation is monitored and evaluated 
by authorised agencies to analyse whether the performance meets expectations and 
complies with the policy proposal.  In response to the policy review, the former 
government used two instruments to support the process. First, the Vendor Managed 
Inventory (VMI) system to control the distribution of CL drugs was used to 
monitors whether the drugs were distributed only to patients eligible under the CL 
protocol. Second, the Rational Drug Use (RDU) system was used to monitor 
whether CL drugs were utilised in compliance with the defined treatment indications 
within the scope of the policy proposal. 
9.5.2 Channels to communicate with stakeholders and public  
Problems, obstacles, and defects arising from the policy were identified to 
develop policy feedback to improve efficiency and effectiveness. The information is 
beneficial not only to policy makers and authorised agencies, but also helps other 
stakeholders to understand the situation. The former government used two main 
approaches: vertical and horizontal communication. First, the experiences of the 
former government indicate that a purely top-down policy is not sufficient. When 
the policy was transformed into work plans, feedback from local staff is essential 
because there was a need to engage with local staff to achieve their acceptance of, 
trust in, and compliance with the policy. Therefore, the government should allow 
operating units in health care facilities to feed back their experiences through 
bottom-up suggestions. This argument is consistently mentioned in Chapter 7 and 8. 
Second, horizontal communication is required to communicate with stakeholders 
and the public. Mass media can be used to attract politician and public interest, and 
to harness reactions from other stakeholders. Evidence suggests that an NGO-
supported mass media campaign successfully pressured a patented drug firm to 
change their behaviour in order to maintain their positive social image [254]. In 
addition, Chapter 8 found that the former government also effectively used 
international meetings and conferences to disseminate information to the public and 
exchange experiences with other countries.  
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9.6 Strategies to improve efficiency of the CL process  
In this study, the policy processes were simplified by using heuristic stages, 
which assume a linearity to the public policy process: agenda setting, formulation, 
implementation and monitoring. However, policy analysts have argued that the idea 
of a linear process may not reflect reality [136]. The findings from the CL cases of 
Thailand support this argument: the former policy makers worked on different 
policy processes simultaneously, in order to improve policy efficiency.  
The simultaneous approach was employed in the process of decision-making 
and implementation. According to the findings from Chapter 8, patent owners 
tended to extend the negotiation period in order to delay the implementation of CL 
policy.  As a result, the government negotiated with patented drug firms alongside 
the formulation of CL policy. In addition, the legal validity of any CL decision is 
subject to judicial review by courts or other authorised agencies as mentioned 
earlier. The use of CL may be delayed if the patent owners appeal the validity of the 
license used or the kind and level of remuneration granted under the policy. 
Therefore, the parallel work also occurred in the process of policy implementation 
and monitoring. This point is consistent with the Indian case, in which applications 
for CL policy could be delayed by CL oppositions, thus limiting the effectiveness of 
this policy [255]. It is, therefore, suggested that, once the decision is made, the 
government should fully implement the policy even while appeal procedures are 
being operated by other parties, as these approaches can avoid the delay in 
implementing the policy. 
 
9.7 Strategic roles of actors in each stage of policy process 
 Multi ministries and multi-disciplinary stakeholders are essential. This 
statement is consistent in the case of Thailand and India.  Key actors include 
Ministry of Public Health, Industry, Commerce, Foreign Affairs, and other 
authorised agencies in central sectors and local health care facilities, played a 
significant role in the policy processes [221, 256]. In addition, other stakeholders 
such as the NGOs and academics are regularly invited, in order to enhance policy 
partnership [221, 256]. Especially, academic groups play a significant role in the CL 
policy process. According to experiences of the former government, the finding in 
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Chapter 8 indicated that in agenda setting, academics established empirical evidence 
to encourage the government to develop a rigorous system of patentability for 
pharmaceuticals. In the formulation stage, academics and NGO groups played a 
significant and positive role in supporting CL policy against the policy opponents. In 
the implementation stage, academics conducted clinical studies to confirm the 
equivalent quality of CL generic drugs compared to its patented version to boost 
practitioner confidence in CL drug quality. In the policy monitoring stage, empirical 
studies from Thai academics were presented in many important meetings and to a 
wide range of stakeholders, in order not only to communicate with stakeholders, but 
also to educate other ministries and foreign countries. It can be seen that there are 
several actors in the CL policy processes, with academics playing a key role. This is 
consistent with Almeida et al. addressed that research results are seen as having a 
significant impact on the public policy process. Integration between researchers and 
decision makers seems to condition the ways in which research results are used in 
policies [257]. 
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9.8 Policy recommendations 
 
For the Thai government for the current use of CL policy  
Based on the evaluation of the Thai government’s performance in 
implementing CL policy, there are several suggestions for ways in which the Thai 
government could improve its performance. (1) Improving physicians’ confidence 
on the quality of CL drugs is the priority as it created the highest costs in CL 
implementation. (2) The issue of supply interruption effects from foreign suppliers, 
which sometimes provide generic drugs of unacceptable quality or late delivery, 
significantly affected the implementation of CL policy; and the capacities of local 
drug industries should be strengthened to maintain a consistent long-term drug 
supply. (3) The implementation step required performance monitoring and feedback 
from local operating units such as health care facilities to improve CL policy 
implementation performance. 
1. To boost physician confidence in the quality of CL drugs, several 
strategies should be applied, such as: selecting drugs from the WHO list of 
prequalified medicine products; drugs not obtained from that list should be quality-
assured by a laboratory prequalified by the WHO. Testing should be done 
periodically to verify compliance with standards and references given, and evidence 
of quality assurance should be accessible to drug prescribers. In addition, advertising 
regulation should be strengthened to avoid misleading advertisement, which 
encourages people to become averse to generics. 
2. To mitigate the risk of supply interruptions effects from foreign suppliers, 
procurement agencies should consider the number of qualified suppliers available in 
the market. Where there is a limited number of drug suppliers, local production 
through technology transfer should also be managed as a priority. Therefore, local 
capacity in terms of infrastructure and personal expertise has to be strengthened in 
order to choose and replicate new transferred technologies wisely. The government 
should establish local research and manufacturing capacity to meet public health 
needs and ensure sustainability of the long-term drug supply system.    
3. To improve policy implementation, it is essential that central agencies and 
peripheral health facilities collaborate in the monitoring of policy performance. 
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Effective communication approaches through regular meetings among policy 
networks and public hearing approaches to obtain feedback of stakeholders should 
be maintained, as it plays a crucial role in identifying the problems and solutions to 
improve the CL policy performance. 
 
For the Thai government for future use of CL policy  
1. To achieve maximum benefits, the key parameters that should be 
incorporated in the drug selection criteria are: (i) Drugs for treatment of diseases 
which are the leading causes of the public health burden, (ii) Drugs which offer the 
highest difference in treatment cost saving compared to current practices, (iii) Drugs 
which are required for diseases with no alternative treatments, and (iv) The 
remaining duration of patent protection for the relevant drug. These criteria should 
be applied in order to determine which drugs to select if CL is required in the future.  
2. There are alternative measures to be considered prior to the use of CL such 
as patent oppositions and price negotiations. However, the Thai government should 
pay more attention to: (i) strengthening the use of rigorous criteria for patentability 
and implementing guidelines for patent examination; (ii) strengthening the patent 
information system so it can be effectively used for public health interests; (iii) 
strengthening national legislation to control the price of essential drugs under patent 
protection. CL policy may be applied when necessary after failures in trying other 
alternative measures. In addition, the Thai government has never used parallel 
imports. Therefore, the government should design a comprehensive procedure and 
assign a responsible agency to perform the parallel import policy.    
3. The issues to be considered in formulating a proposal to issue CL policy 
include: (i) scope of product which should include all subject elements covered by 
the patent in question, (ii) duration which should last until the patent expiration or 
there is no more essential need for the drug, (iii) remuneration rate which should 
comply with international standard guidelines, and (iv) target population of drug 
users which should not be limited to patients entitled under the three schemes (UC, 
SSS and CSMBS), since this may deprive some patient groups, especially stateless 
people, an ignored group of patients by the current CL policy in Thailand.  
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4. Any decision concerning the grant of CL policy can be subject to judicial 
review by courts or other authorised agencies, key supportive instruments, including 
Vendor Managed Inventory (VMI) and Rational Drug Use (RDU), to monitor the 
performance of CL policy implementation should be maintained if CL is required in 
the future. (i) The VMI system can be used to check that the drugs are distributed 
only to patients under the scope of CL protocol and are not leaked to other users 
(such as private sectors), which would contradict the declared notifications. (ii) The 
RDU system can be used to monitor the utilisation of CL drugs. As the prices of CL 
drugs are substantially lower than the drugs used prior to the granting of the policy; 
this may lead to overutilization of drugs. Protocol guidelines of CL drug utilisation 
and clinical practice should be established to promote the rational use of the drugs. 
The information on both systems is essential for any judicial review.  
5. It was highlighted that there were misunderstandings between central 
agencies and local health facilities because there are no coordinators to provide 
essential information. Therefore, the Thai government should establish a 
coordination and consultation unit equipped with experts to answer questions about 
the policy promptly. This unit should deal with both policy partners and the public 
in order to create trust and confidence in the MOPH’s operation and lessen problems 
relating the policy implementation. 
 
For other countries with similar contexts 
1. Other countries could learn from the Thai CL experience. The Thai 
experience highlighted that, in addition to the problems of unmet needs in the public 
health system, there were three additional contextual elements, which influenced the 
agenda: (i) Political standpoints of policy makers on health over trade interests, (ii) 
Strong networks of policymakers and partners, and (iii) Political commitment to 
achieving universal health care coverage (one ground for CL justification).  
2. Any government aiming to use CL policy should be aware of negative 
consequences in terms of political and economic retaliation from policy opponents. 
According to the Thai CL experience, key strategies, which should be considered 
prior to implementation of CL policy, are as follows. (i) The grounds for CL 
implementation for a particular drug should be clearly justified on case by case 
basis, in order to avoid negative reactions from stakeholders based on 
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misconceptions. (ii) If opponent reactions result from a certain interest of 
stakeholders against the use of a particular patent, strong networks of policy partners 
and social value of policy supporters could create a third force to enhance power for 
CL countries to resist such pressure.  
3. A strength of CL implementation in Thailand is the participation of a range 
of stakeholders throughout the policy process. It is suggested that an inter-
ministerial committee should be established at the agenda setting and policy 
formulation stages, in order to allow decision makers from concerned ministries, 
such as trade, industry and foreign affairs, to engage from the beginning of policy 
process. In addition, other stakeholders, such as NGOs and academics, should also 
be invited to participate. Both groups play an important role in CL policy process.  
4. Finally, lessons learnt from Thailand indicated that countries aiming to use 
CL should conduct price negotiations in parallel with CL formulation in order to 
improve the efficiency of the policy process. In addition, parallel work may be 
conducted between policy implementation and monitoring, in order to prevent 
specious delays from appearing the patent validation to CL implementation. This 
approach was used effectively by the former Thai government and may be applied to 
other countries.  
 
For further studies  
1. This study focused mainly on insights derived from the Thai government 
experiences to develop the framework to aid decision-making and implementation of 
drug policy, focusing on CL policy.  Since activities related to the policy processes 
were mainly carried out by the Ministry of Public Health (MoPH), the main 
weakness of this study is that the picture of policy process in non-MoPH and the 
private sectors may not be focused. To extend knowledge, there is value in analysing 
the views of other sectors, such as the government sectors in trade, industry, and 
foreign affairs; non-governmental organisation sectors from civil society and not-
for-profit groups, as well as for-profit groups, such as patented and generic drug 
firms. The knowledge gained from the views of other concerned sectors may 
complement the findings of this study.  
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2. As only the case of Thailand was studied, the findings may not represent 
other LMIC contexts. However, some of the findings may be useful to apply in other 
countries where most elements of the health system are similar to the Thai context. 
Even in places with a different environment, this thesis may usefully contribute 
some aspects of lessons learnt on CL policy process, especially in resource-limited 
settings. However, further studies should be conducted in other contexts, and the 
findings should be compared with the Thai cases. Sharing experiences across 
different countries with different contexts are essential to complement and 
strengthen information and to gain more knowledge about the generalizability of the 
framework of CL policy.  
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Appendix 1: Ethical approval 
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Appendix 2: Information sheet 
 
Research title: Compulsory licensing of pharmaceuticals in Thailand: Development of a 
framework for decision making and implementation of compulsory licensing 
 
This research is being led by the Health Intervention and Technology Assessment 
Programe (HITAP) in Thailand and the London School of Hygiene and Tropical 
Medicine (LSHTM).   
Study objectives 
Thailand has implemented Compulsory Licensing (CL) since 2006 to increase 
access to seven essential drugs for treatment of HIV/AIDS, cardiovascular disease 
and cancer. This study aims to develop a framework for decision making and 
implementation of CL policy. The framework will be applied for further decision to 
issue CL in Thailand, and may be applicable to other countries. 
The project is funded by the Health Insurance System Research Office (HISRO) and 
takes place during August 2014 - December 2015.  
Methods 
The methods used will be interviews with key informants from the Thai government, 
academia, non-profit organizations, and the private sector.  
Participation 
 I request your participation in this interview because I believe you may be able to 
contribute to my understanding about past experiences, the current situation and 
future requirements of CL policy in Thailand.  
Taking part in the study is entirely voluntary and withdrawal is possible at any time 
without any penalty to you and without having to give a reason.  
If you agree to take part in this research I would like to ask you some questions for 
between 30 - 60 minutes.  
The research will in no way inconvenience you apart from the time it will take you 
to participate in this interview.  
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Confidentiality 
 
The information that I gather from you and others will assist me in understanding 
the history and challenges of CL policy decision and implementation in Thailand. I 
will write reports and other outputs based on this information. I will maintain strict 
confidentiality throughout this study. Your name will not be linked to any quotes or 
other results of this study or included in any reports, even anonymously. 
Your interview will be recorded with your permission. A researcher will be taking 
notes, which will be stored in secured rooms and computer files with access codes 
and will only be shared among study team members. 
 I appreciate your participation in this study.  Thank you for your time and your 
effort.  Again, if you have any questions or concerns about the study, please do not 
hesitate to contact the investigator at the detail below. 
 
Mr. Adun Mohara 
Health Intervention and Technology Assessment Programe (HITAP)  
6th Floor, 6th Building, Department of Health, Ministry of Public Health, 
Tiwanon Rd., Muang, Nonthaburi 11000, Thailand 
Tel: +662-590-4549, +662-590-4374-5 
Fax: +662-590-4369 
Mobile: +6689-457-1892 
Email: adun.m@hitap.net 
 
The Institute for Development of Human Research Protection (IHRP) ethics panel 
approved this study on: …………………………….. 
The London School of Hygiene and Tropical Medicine Ethical Committee approved 
this study on: …………………………….. 
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Appendix 3: Research participant consent form 
 
Research Title: Compulsory licensing of pharmaceuticals in Thailand: Development of         
a framework for decision making and implementation of compulsory licensing 
 
Contact information of local research institute: Health Intervention and 
Technology Assessment Programe (HITAP), Ministry of Public Health,  
Tiwanon Road Nonthaburi 11000. 
 Please 
initial box 
1. I confirm that I have read and understand the participant information 
sheet for the above study.  I have had the opportunity to consider the 
information, ask questions and have had these answered fully. 
 
2. I give consent for my quotes to be used in the research.  
3. I understand that data collected during the study will be analysed by 
responsible individuals from the Health Intervention and Technology 
Assessment Programe (HITAP) and the London School of Hygiene & 
Tropical Medicine (LSHTM). 
 
4. I agree to take part in the above study.  
 
 
Name of Participant  
(printed) 
 
 Signature  Date 
Name of Person taking consent 
 
 
 Signature  Date 
1 copy for participant; 1 copy for study researcher  
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Appendix 4: Interview schedule 
  
As there are very few actors in the area of CL policy in Thailand, their 
affiliations can be linked to the informants. Therefore, only codes and interview 
dates were provided in the interview schedule. 
 
 
 
 
  
No.[Code] Interview date 
1.[GS01] 11 September 2014 
2.[GS02] 13 October 2014 
3.[AS01] 17 October 2014 
4.[PS01] 17 October 2014 
5.[NS01] 29 October 2014 
6.[AS02] 5 November 2014 
7.[GS03] 6 November 2014 
8.[NS02] 12 November 2014 
9. [GS04] 26 November 2014 
10.[GS05] 3 December 2014 
11.[HS01]  8 December 2014 
12.[HS02] 17 December 2014 
13.[HS03] 19 December 2014 
14.[GS02] 11 February 2015  (Follow-up interview) 
15.[GS03] 26 February 2015 (Follow-up interview) 
 
 
246 
 
Appendix 5: Data collection tools 
 
There are two data collection tools. First, the list of semi-structured interview 
topic questions includes introductory and specific questions as follows: the questions 
about background information of informants, and their knowledge or opinion about 
policy activities, supportive instruments, contextual factors, and actors that 
influenced the Thai CL policy process. The policy process is classified into four 
stages: agenda setting, policy formulation, implementation, and monitoring. These 
questions were used to ask for all groups of informants.  
 
1) Introductory questions: 
1. What was your position at the time of decision-making and implementation 
of CL policy? 
2. What were the responsibilities in your job relevant to decision-making and 
implementation of CL policy? 
 
2) Specific questions: 
1. From your view, what were the policy elements essential in the stage of 
agenda setting, and why they were essential: 
1.1 Contextual elements required to support the agenda setting for improving 
drug access.  
1.2 Activities required to set a national policy agenda to improve drug 
access. 
1.3 Supportive instruments required to support each of the activity. 
1.4 Actors required to participate in the stage of agenda setting and the 
actors’ role 
 
2. What were policy elements essential in the stage of policy formulation, and 
why they were essential:  
2.1 Contextual elements required to support the policy formulation of CL 
policy. 
2.2 Activities required to formulate the CL policy.  
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2.3 Supportive instruments required to support each of the activity. 
2.4 Actors required to participate in the stage of policy formulation and the 
actors’ role 
 
3. What were policy elements in the policy implementation, and why they were 
essential: 
3.1 Contextual elements required to support the implementation of CL 
policy. 
3.2 Activities required to implement the CL policy. 
3.3 Supportive instruments required to support each of the activity. 
3.4 Actors required to participate in the stage of policy implementation and 
the actors’ role.  
 
4. What were policy elements in the policy monitoring, and why they were 
essential: 
4.1 Contextual elements required to support the monitoring and evaluation of 
CL policy. 
4.2 Activities required to monitor the CL policy performance and evaluate its 
implications. 
4.3 Supportive instruments required to support each of the activity. 
4.4 Actors required to participate in the stage of policy monitoring and 
evaluation and the actors’ role. 
5. Additional issues of concerns: Would you like to add other issues of 
concerns?  
 
 
  
 
 
248 
 
Second, in the stakeholder meeting, I used observational guides as the table 
below. I made matrix, which includes the same contents as the interview topic 
questions mentioned above, in order to facilitate in data collection. 
 
Observation 
category 
Contents 
Settings  Describe the whole context/meetings, layout on seating 
plan of people present  
Participants and 
their relationship 
Who are in the settings? What are their roles?  
 
Participants’ 
information  
What do they mention about the policy elements relevant to 
the CL policy according to the matrix below 
Key elements Agenda 
setting 
Formulation Implementation Monitoring 
Contextual elements     
Participant No.1.     
Participant No.2     
Participant …     
Activities     
Participant No.1.     
Participant …     
Supportive 
instruments 
    
Participant No.1.     
Participant …     
Actors     
Participant No.1.     
Participant …     
Additional issues of 
concerns 
    
Participant No.1.     
Participant …     
 
